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Abstract 
To what extent genetic variability influences gene expression in human 
primary tissues is a critical question in molecular genetics. Work investigating 
this phenomenon is not only interesting biologically, but also has the potential 
to provide mechanistic insight into traits, including disease. The past decade 
has seen tremendous progress in this field, and this thesis includes a 
description of work that spanned from the relatively early stages of this type of 
work, to current, more refined efforts.  
This work sought to ask three questions: first, are eQTL detectable in brain 
tissues using whole genome methods; second, are eQTL measurably different 
in different parts of the brain; and third, does the investigation of eQTL in a 
particular neuronal cell type offer significant advantages over similar studies in 
tissue with a mixed cellular composition. 
In the first part of this work, I present a pilot study aimed at assessing the 
feasibility of eQTL detection in brain tissue. This study showed that the use of 
genome wide genotyping and expression arrays revealed a number of 
significant eQTL, and that in general, when genetic variability was associated 
with expression, the genetic locus and the expressed transcript were 
physically close. This work was then expanded to assess eQTL in multiple 
brain regions, with an attempt to assess whether eQTL were measurably 
different between distinct brain regions. In this work, tissue from cerebral 
frontal cortex, cerebral temporal cortex, caudal pons, and cerebellum was 
used. The analysis showed that there are region-specific eQTL, but that many 
of the strongest eQTL were present in multiple tissues. Lastly, I show using 
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data from laser capture microdissected Purkinje cells that additional cell-type 
specific eQTL may be found that are not revealed when performing eQTL in 
heterogeneous tissue containing this cell type.  
In summary this work initially revealed the feasibility of eQTL work in human 
brain, showed that eQTL were measurably different, but generally similar 
across varied brain tissues, and showed that there are likely several 
advantages in pursuing single cell type work in tandem with whole tissue 
efforts.  
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1:  Introduction 
An essential challenge in the post-genome era is to understand the effects of 
genetic variation found within the genome. With the widespread application of 
highly parallel SNP (single nucleotide polymorphism) genotyping arrays much 
of the recent effort in human genetics has focused on defining the role of 
genetic variation in disease and physical traits. A smaller subset of work, 
however, has attempted to examine the more proximal effects of genetic 
variation, particularly their effects on mRNA (messenger ribonucleic acid) and 
protein levels. This has the potential to inform on several levels: first, it is a 
critical step toward understanding the pathobiological consequences of 
genetic variants linked to clinical phenotypes; second, it affords the 
opportunity to form inferences regarding relationships between genes based 
on patterns of co-regulation; and third, it provides a more complete view of 
multiple levels of regulation of gene expression than that provided by the 
traditional reductionist method. 
 
The genetic code is largely fixed across human populations and, with rare 
exceptions, absolutely fixed within an individual. However, there is substantial 
variability in gene expression between individuals and across tissues. Much of 
the inter-individual differences will be embedded in genetic variation at the 
sequence level. However, changes in expression at the individual and tissue 
level will also reflect responses to external stimuli and this is likely to be 
mediated in part through epigenetic variation. Previously the relationship 
between genetic and epigenetic influences on gene expression is one that 
has been largely and necessarily confined to observations at single loci and 
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transcripts in individual cell systems or tissues. The advent of genome-scale 
technologies provides unprecedented opportunities to expand upon these 
experiments. The integration of genetic and expression data promises to 
provide general observations regarding the relationship between genetic 
variation and expression. Beyond these observations, these data can be 
readily mined to unravel the network of effects associated with genomic 
variants. This may reveal some of the rather cryptic intermediate events that 
occur between DNA (deoxyribonucleic acid) variant and phenotype. 
 
1.1: Research Aims 
With the arrival of high-density SNP chips combined with the maturation of 
expression microarray platforms it is now feasible to capture most of the 
known common genetic variation as well as the expression profiles for well-
known mRNA transcripts in the human genome for a large number of 
individuals. The mapping of these effects where genetic variation in a 
particular region of the genome is linked or associated with a change in the 
expression of a particular mRNA transcript is commonly referred to as an 
expression quantitative trait locus or eQTL. The study of expression 
quantitative traits is very similar to other quantitative traits, such as clinical 
measures, but here the trait or phenotype of interest is the expression of 
mRNA transcripts. These expression traits may also be referred to as 
molecular, intermediate, or endo-phenotypes as they are internal phenotypes 
that may lead to an external phenotype. The study of eQTL is the integration 
of genetic variation and gene expression variation by correlation, where the 
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abundance of an mRNA transcript increases or decreases in relation to 
genotype (Figure 1.1). 
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Figure 1.1: Example plot of the linear relationship between genotype and gene 
expression for an eQTL. The plot depicts this linear relationship, where the abundance 
of an mRNA transcript increases with the dosage of the B allele. In this example, the 
correlation is positive, but a negative correlation is also possible where mRNA’s 
transcript abundance decreases with the dosage of the B allele. 
 
The expectation of identifying eQTL is that we can begin to provide an 
additional layer of functional information onto genetic variation within the 
human genome as well as to understand the general characteristics of eQTL. 
The utility of such a resource is that many of the expression quantitative trait 
loci may overlap with regions of the genome associated with clinical traits or 
disease phenotypes. In recent years, hundreds (and now thousands) of 
genome wide association studies have been published many with robust and 
replicated findings (Hindorff et al. 2009). What is apparent from these many 
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genome wide association studies is that large effect disease loci that tag 
protein-coding changes such as complement factor H for age related macular 
degeneration (Klein et al. 2005) and APOE for Alzheimer's disease (Rogaeva 
2002) will not be the norm. Many of these disease-associated loci may confer 
moderate to small risk through changes in gene expression. 
 
Towards this end, my thesis focuses on eQTL studies within brain tissues 
using whole-genome SNP genotyping and mRNA expression microarray data. 
The first study was conceptually a ‘pilot’ project for the detection of eQTL 
within a mix of cortical tissues from elderly neurologically normal individuals. 
The second study expands upon the ‘pilot‘ study, again using neurologically 
normal individuals but with improved analysis techniques and multiple brain 
tissues from each individual. The third study describes eQTL in a single 
neuronal cell type from human brain, using a subset of the second study’s 
subject cohort and makes use of additionally refined analysis methods. My 
thesis also includes a chapter describing the integration of eQTL and disease 
risk loci identified by genome-wide association studies (GWAS). The bulk of 
my thesis and central project is within the second cohort focusing on 
identifying eQTL within distinct human brain regions. However, the first ‘pilot’ 
cohort is seminal in my understanding of how to do this kind of work in a 
primary human tissue and was the first study, using whole genome and 
transcriptome data, to show that it is possible to see such effects in human 
brain tissue. The third study, of eQTL in a single neuronal cell type, is critical 
to beginning to understand eQTL in the context of a specific cell type and 
within heterogeneous tissues. 
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1.2: Human Genome  
1.2.1: Human Genome and Genetic Variation 
After the completion of the Human Genome Project, much research has 
focused on understanding variation within the human genome, among 
individuals, and among populations. A primary goal of this work is to 
understand how the patterns of variation can be applied towards localizing loci 
associated with complex traits, such as disease, within humans. The work to 
begin to achieve this understanding has accelerated rapidly since the draft 
human genome was sequenced. This effort requires not only cataloguing 
variation within the human genome but also the development of methods to 
assay and analyse this catalogue in order to better understand patterns within 
the variation. Of course, much of this work has also centred on how to 
maximize the efficiency and effectiveness of the data for generation and 
analysis.  
 
Early studies of genetic variation between individuals and populations had 
shown that much of this variation is between individuals and to a lesser extent 
between populations. One of these very early studies was based on allele 
frequencies at 15 protein loci and found that 85% of genetic diversity is 
between subjects from within the same population (R C Lewontin 1972). This 
estimate was re-affirmed more than twenty years later in a much larger cohort 
using DNA markers. In this later study, 1,109 subjects were genotyped at 109 
DNA markers, where the markers included microsatellites and restriction 
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fragment length polymorphisms (RFLP). Microsatellites are short tandem 
repeats, containing two to six base pairs of repeating sequence. RFLPs are 
genetic markers captured by segmenting DNA using restriction enzymes and 
then separated according to their length by gel electrophoresis. The results 
showed that the within population differences accounted for 84.4% of the 
genetic variation and approximately 10% of the variation is accounted for by 
continental population differences (Barbujani et al. 1997). Additionally, when 
studying a larger more diverse set of populations the majority of genetic 
variation was again found to be primarily between individuals and not between 
populations (Rosenberg et al. 2002). In the Rosenberg study, which was 
based on microsatellites genotyped in 52 populations, it was found that ~94% 
of the genetic variation is among individuals within a population and ~4% of 
the variation is between major population groups. 
 
The rate of introduction and the change in frequency of new combinations of 
alleles in a genome is determined by recombination. Recombination results in 
the selection for or against new haplotypes and this in turn may also lead to 
the selection of alleles that modify recombination rates (Otto and Lenormand 
2002; Coop and Przeworski 2007). Two roles of recombination in mammals 
and other organisms are that it helps in homology recognition resulting in 
synapsis early in meiosis and then later provides the tension required for the 
correct chromatids to be pulled together binding through crossing over of the 
non-sister chromatids (Roeder 1997; Coop and Przeworski 2007). Synapsis is 
the pairing of two homologous chromosomes. A chromatid is a new copy of a 
replicated chromosome. Meiotic pairing, synapsis, and recombination occur 
during prophase I of meiosis. In prophase I, sister chromatids are brought into 
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close reach with one another and sister chromatid cohesion is imparted by a 
meiosis-specific cohesion complex (Zickler and Kleckner 1999; Petronczki, 
Siomos and Nasmyth 2003). Double-strand breaks initiate meiotic 
recombination and Holliday junctions are formed during repair. These 
junctions are resolved as a gene conversion with or without a crossover. 
Where in non-crossover conversions the resolution does not include the 
exchange of flanking variants as opposed to a crossover conversion where 
flanking variants are exchanged (Allers and Lichten 2001; de Massy 2003; 
Coop and Przeworski 2007). Large crossover rates increase the genetic 
diversity within humans and divergence with other species (Hellmann et al. 
2003, 2005). Recombination rates vary within in humans and there are 
differences between humans and other species (Lynn, Ashley and Hassold 
2004). Recombination ensures the proper segregation of chromosomes 
during meiosis and breaks up genetic linkage between loci resulting in 
increased diversity. 
 
Recombination can be measured indirectly using genotypes within families to 
create maps inferring the recombination events from the parents. These 
recombination maps are referred to as genetic maps, which consider the 
polymorphic loci in a linear fashion along a chromosome and their interlocus 
interval lengths. Previously, restriction fragment length polymorphisms 
(RFLPs) were used as the genomic variants for construction of these genetic 
maps (Botstein et al. 1980) and later microsatellites (Litt and Luty 1989; 
Weber and May 1989). A Morgan is a unit of length used to denote the linear 
distance in genomic maps of recombination fractions and measures the 
relationship between pairs of “marker” loci or variants in the genome. These 
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genetic maps estimate the segregation of the alleles for a pair of markers 
determining if the pair is linked together forming a linkage group. For mapping 
purposes, Morgans are typically denoted as centiMorgans. The closer 
together two loci are the more unlikely it is that a double recombination event 
exists between them so the loci are linked. As the distance between loci 
increases, the possibility of a recombination event occurring between them 
increases as well. The Centre d’Etude du Polymorphisme humain (CEPH) 
was established to maintain a collection of a common set of pedigrees 
containing enough families to help facilitate the construction of linkage maps. 
This collection of samples allowed laboratories developing genotyping 
markers to work with the same samples and return this information to a public 
repository so that genome-wide linkage maps could be constructed (Dausset 
et al. 1990).  
 
The larger chromosomes have more meiotic exchange and thus more 
recombination events. Variation in recombination can be driven by specific 
factors for specific chromosomes (Laurie and Hultén 1985; Lynn, Ashley and 
Hassold 2004). Recombination rates have also been found to be significantly 
correlated with GC content in the human genome (Kong et al. 2002; Lynn, 
Ashley and Hassold 2004). Recombination hotspots occur in small regions 
typically less than 1 to 2 Kb (kilobases) and separate long regions of cold 
spots typically 200 Kb; recombination hotspots are not randomly distributed in 
the genome (Jeffreys, Kauppi and Neumann 2001; May et al. 2002; Lynn, 
Ashley and Hassold 2004). There is an inverse relationship between linkage 
disequilibrium (LD) and recombination rates (Nordborg and Tavaré 2002). In 
2004, McVean et al. published a study estimating recombination rates based 
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on genotypes. They used European and African population genotypes and 
found variation in local recombination rates. They found that 50% of 
recombination events occur in less than 10% of the genome and occur on 
average every 200 Kb or less. These results suggested that recombination 
hotspots are a common feature of the human genome and typically occur 
outside of genes (McVean et al. 2004). In a similar study using LD patterns 
based on genome-wide genotyping, it was suggested that there are likely 
more the 25,000 hotspots in the human genome. The use of genome-wide 
genotyping allowed for fine-scale estimates of recombination. Additionally, it 
was found that these hotspots occur approximately every 50 Kb and that 80% 
of crossover events happen in 10 to 20% of the human genome (Myers et al. 
2005). In 2005, Hellman et al. published a study examining diversity in the 
human genome and divergence with chimpanzees under the hypothesis that 
variation has two main drivers, mutation rates and natural selection. This 
study was undertaken based on previous observations that both within 
species diversity and between species divergence increase with 
recombination rates. The observation that both diversity and divergence 
increases with recombination rate suggests that there is a link with 
recombination and mutation directly or through another factor. By studying the 
human and chimpanzee genomes, they found that GC and CpG content, 
simple-repeats, and chromosomal distance from centromeres and telomeres 
also predict diversity and divergence. They suggest that changes in 
recombination rates since the split with our common chimpanzee ancestor are 
a better explanation for diversity within species. Their basis for this conclusion 
was the observation that recombination rates appear to have rapidly changed 
during human evolution (Hellmann et al. 2005). An earlier study of diversity 
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and divergence in humans, also from Hellmann et al., was undertaken to 
examine previous findings that regions with low recombination often have 
lower diversity within species but not lower divergence between species. They 
regenerated maps of recombination within related species and found that, 
between chimpanzees and baboons, regions with low recombination have 
less divergence and diversity for the two non-human primates (Hellmann et al. 
2003). In 2011, Wegmann et al. published a study based on admixed human 
subjects to generate a recombination map of relative rates, which allowed for 
observing ancestry switch points. They used genotypes from African-
American and African-Caribbean subjects, and found several thousand 
recombination events when compared to maps from non-admixed 
populations. Their results showed a fine-scale difference in recombination 
between populations suggesting that admixture does not have a large effect 
on recombination rates in humans (Wegmann et al. 2011). 
 
The Hill-Robertson (H-R) effect suggests that in finite populations for two 
linked loci that selection at one locus reduces the effectiveness of selection at 
the other one (Hill and Robertson 1966; Felsenstein 1974). Intragenic H-R 
effects may be reduced advantageously by introns and may predict selection 
effectiveness differences between genes with different exon-intron structures 
(Comeron, Williford and Kliman 2008). Populations without recombination will 
accumulate deleterious mutations more rapidly, this is known as Mueller’s 
Ratchet (Muller 1964). Both the H-R effect and Mueller’s Ratchet suggest that 
the advantage of recombination is that it increases the rate of adaptation in a 
species by breaking up negative linkage disequilibrium (LD) that may result 
from selection and genetic drift (Felsenstein 1974; Barton and Otto 2005; 
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Keightley and Otto 2006; Comeron, Williford and Kliman 2008). Negative 
linkage disequilibrium is the association between beneficial and deleterious 
alleles at different loci occurring more often than expected by chance 
(Keightley and Otto 2006). In 2011, Udeba and Wilkins put forth a model to 
account for observed recombination mechanisms. Their model results 
suggested a Red Queen dynamic based on an intragenomic conflict model. 
The Red Queen hypothesis, put forth by van Valen in 1973, suggested that 
organisms must constantly adapt, evolve, and proliferate not just for 
reproductive advantage but also to survive against other evolving organism in 
environments that are also changing. The Udeba and Wilkins model accounts 
for evolutionary dynamics of hotspot turnover and the non-random targeting of 
recombination mechanisms. Chromosomal regions where crossover events 
occur more often are recombination hotspots and these regions are often 
small. Double-strand breaks (DSB) initiate recombination and requires 
involvement of the DSB repair mechanism, which may result in homologous 
chromosome exchange (crossover). This exchange would then result in a 
biased gene conversion. However, a biased gene conversion results in a 
transmission advantage preventing recombination and therefore the hotspot 
becomes transient. The persistence of hotspots over time when they should 
be self-destructive is known as the recombination hotspot paradox. They 
suggest that their intragenomic conflict model accounts for this. In their model 
fertility selection drives trans (distal) modifiers to maintain crossover rates 
which is in conflict with cis-acting (proximal) targets promoting their own 
transmission, thus the intragenomic conflict, leading to the Red Queen 
dynamics (Ubeda and Wilkins 2011). More recently, Lesecque et al. published 
a study of the evolution of human recombination hotspots and PR domain 
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containing 9 (PRDM9) DNA-binding domain target motifs in the human 
genome. The PRDM9 protein is a zinc finger protein with a sequence-specific 
DNA binding domain that determines the location of recombination hotspots in 
humans (Baudat et al. 2010; Myers et al. 2010). The Lesecque et al. study 
examined the evolution of hotspots and PRDM9 target motifs by comparing 
the genomes of modern human and Denisovan to identify hotspot turnover in 
recent human evolution. This study found that even though Denisovans and 
modern humans share similar PRDM9 target motifs their recombination 
hotspots did not overlap. They also found that modern human hotspots are 
young, becoming active shortly before the split with Denisovans but long after 
divergence from chimpanzee ancestor. Their findings suggest that the loss of 
existing human hotspots, through biased gene conversion, should occur in the 
next three million years and this depletion would decrease fitness thereby 
favouring new PRDM9 alleles binding different motifs which supports the Red 
Queen hypothesis of recombination hotspot evolution (Lesecque et al. 2014). 
 
As technologies and understanding continually improved, it became possible 
to start increasing the density of variation being genotyped, and to better 
comprehend the characteristics and patterns of variation in the human 
genome. Single Nucleotide Polymorphisms (SNPs) are the most common 
form of sequence variation in the human genome and thus it was a necessity 
to densely map these genetic variants. At the time, it was infeasible to whole 
genome sequence large cohorts of subjects in multiple populations, which 
would allow direct identification of most of the genetic variation within and 
across populations. Consequently, an alternative was pursued to catalogue 
common variants in the genome. This set of common genome variants could 
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then be genotyped in any cohort of interest with the benefit of knowledge of 
population allele frequency and linkage disequilibrium. The underlying 
hypothesis behind this work was that based on the genotypes of common 
variants it should be possible to detect trait association signal at a genome-
wide level and then proceed to search for causative variants within the 
localized region (Collins, Guyer and Charkravarti 1997). This approach also 
allows for a genome-wide search space so that researchers do not have to 
know putative functional information of all variants beforehand. Thus, 
candidate gene or region selections were not required a priori. This type of 
resource would provide a haplotype map of the human genome. Two of the 
key and related characteristics of genomic variation making this type of map 
possible are linkage disequilibrium (LD) and haplotypes. LD is the non-
random association between markers of genetic variation in a genome and a 
haplotype is a set of co-segregating alleles on a chromosome. By contrast, 
when markers of genetic variation are independent of each other, such that no 
association exists between their alleles (i.e. no LD), these markers are 
considered to be in linkage equilibrium. Recombination, as discussed earlier, 
is the pairing of homologous chromosomes during meiosis where by sections 
of genetic material are copied from one chromosome to the other by breakage 
and re-joining; LD arises because of a lack of recombination between sites. 
Basing the catalogue on common SNPs the patterns of LD within this map 
should primarily reflect historical recombination and demographic events 
because the common SNPs will typically be older than rare SNPs 
(Chakravarti 1999). In 1999, Kruglyak published a study describing population 
simulations involving LD to guide the design of dense genotyping platforms. 
The designs of these platforms were based on using whole-genome LD to 
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map common disease loci. In this study, LD between common variants was 
considered based on simulations of both general and isolated human 
populations. The results showed that the useful LD for mapping is not likely to 
extend beyond 3 Kb in the general population. These simulations suggested 
that approximately 500,000 SNPs would be required. This finding also held for 
isolated populations unless there was a significant founder bottleneck or the 
disease risk variant was not common (minor allele frequency less than 5%) 
(Kruglyak 1999). Another study was performed to find empirical evidence 
about the extent of LD in the human genome and whether it fits with the 
theory that was driving the design of possible whole-genome association 
studies based and SNP genotyping. This analysis was based on 38 variants 
with an allele frequency greater than 10%, under the assumption that these 
should be comparable to disease risk variants. These variants were from 
three regions on three different chromosomes, where previous variant 
mapping had already been performed. They genotyped these 38 variants in 
1,600 subjects from four European populations. They found that the LD and 
allele frequencies among these populations were very similar and that there 
was an inverse relationship between LD and distance in general. Based on 
these finding they suggested that whole-genome genotyping scans for 
association studies would need variants spaced less than or equal to 5 Kb 
apart (Dunning et al. 2000). 
 
Early cataloguing of common variation resulted in a map of 1.42 million single 
nucleotide polymorphisms released from multiple consortia, representing the 
most comprehensive map of human genome sequence variation at the time. 
The average density was one SNP every 1.9 kilobases (Kb) and 85% of 
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exons were within 5 Kb of a SNP. This map was based on ethnically diverse 
populations (Sachidanandam et al. 2001). Using these denser maps of SNPs, 
a study was performed by Reich et al., to further characterize the size of LD 
blocks in three diverse populations. This study found that LD for Northern 
Europeans, around common SNPs, typically extended to 60 Kb but within an 
African population the typical size was reduced to 5 Kb. The authors 
suggested that these results may reflect a demographic event that occurred 
between 27-53 thousand years ago (Reich et al. 2001). LD is the correlation 
among proximal variants reflecting haplotypes descended from single, 
ancestral chromosomes. LD between genetic variants emerges as a result of 
selection or population history (population size, genetic drift, and population 
mixture), and decays because of recombination breaking up the ancestral 
haplotypes. Decay in LD is proportional to the number of generations since 
the ancestral haplotype formed. The presumed and simplest reason for the 
existence of long-range LD in a population is that a population under went a 
bottleneck, severe founder effect, or because of a lack of recombination. Such 
an effect can occur if a population is reduced so drastically in size that only a 
few ancestral haplotypes remained from which today’s haplotype originated. 
LD in Europeans typically extends 60 Kb from common alleles whereas the 
Yoruban blocks are much smaller but primarily a subset of the blocks seen in 
Europeans. The smaller Yoruban haplotypes are within the longer European 
ones with very few specific to the Yorubans. This large difference in LD sizes 
while still being a subset suggests a population history event that occurred in 
Europeans after the divergence from ancestral Africans, likely a bottleneck or 
founder effect (Reich et al. 2001). Several other early studies demonstrated 
how LD and haplotypes confirm the feasibility of these cataloguing efforts 
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based on variation from isolated regions of the human genome. Based on 
genotypes from a European population at 103 SNPs within 500 Kb on 
chromosome 5 it was observed that discrete haplotype blocks with limited 
diversity could be identified. These haplotype blocks were up to 100 Kb in size 
and typically contained between 2 and 4 haplotypes representing more than 
90% of the genetic variation within the block, each block was flanked by sites 
of apparent recombination (Daly et al. 2001). In a similar study, based on 
common genetic variation from chromosome 21, it was also shown that 
haplotypes have a block like structure of limited diversity and suggested that 
80% of the global human population can be characterized by three common 
haplotypes (Patil et al. 2001). It was also shown in another study that it was 
practical and possible to identify these common haplotypes based on fewer 
representative SNPs. These representative SNPs capture the pattern of LD 
for the adjacent markers in the haplotype, thereby tagging the haplotype 
(Figure 1.2). Thus, these representative SNPs were termed haplotype tag 
SNPs, ‘tag’ SNPs or htSNPs. This study of tag SNPs was based on 122 SNPs 
from nine genes covering 135 Kb of the genome in 384 European subjects. In 
identifying the htSNPs that capture the common haplotypes, it was found that 
the number of SNPs required to provide fine mapping in regions of high LD 
could be greatly reduced. Within this study the 122 SNPs could be reduced to 
34 informative htSNPs (Johnson et al. 2001).  
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Figure 1.2: Schematic of the relationship between SNPs, haplotypes, and haplotype 
tagging SNPs. a) SNPs present in DNA from four versions of the same small 
chromosomal region from different individuals. The majority of the DNA sequence in 
the region is identical; however, single nucleotide polymorphisms are present at three 
of the bases. Each of these SNPs is biallelic, where the first SNP’s alleles are C and T 
and the 2nd and 3rd SNPs have G and A alleles. b) A haplotype is a set of co-segregating 
alleles in a chromosomal region. The three SNPs are within a larger region of variation, 
in this example the region has 20 SNPs, and four haplotypes are present in the 
population for this region. c) From the SNPs present, it is possible to identify a subset 
of three SNPs that tag (identify) these four haplotypes. In this example, for the three 
tag SNPs identified, if the combination A-T-C is present on a particular chromosome 
this pattern would match haplotype 1. This figure is reproduced from (International 
HapMap Consortium 2003). 
Similar characteristics of haplotypes were also observed in another study over 
a larger portion of the genome and including subjects from different 
populations (Gabriel et al. 2002). This study also found that these regions 
could be parsed into haplotype blocks over large regions and containing only 
a few common haplotypes. This study was based on an analysis of 13 
megabases (Mb) from 51 autosomal regions of the human genome and 
included subjects from Europe, Asia, and Africa that were successfully 
genotyped at 3,738 SNPs. These haplotypes also show some evidence of 
historical recombination events, with recombination events more frequent in 
African populations than in the European or Asian populations. There was 
also evidence that recombination rises more rapidly over a shorter genomic 
interval in African populations than European and Asian populations. The 
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African haplotype blocks averaged 9 Kb in size whereas European and Asian 
blocks were 18 Kb in size. The range of block sizes was also different 
between the populations, 1 - 94 Kb in the African population and 1 - 173 Kb 
for European and Asian populations. As seen in the previous studies, low 
haplotype diversity was observed with typically 3 to 5 common haplotypes that 
capture the majority of haplotypes in any region. These haplotypes could be 
identified based on 6 to 8 randomly chosen markers and additional common 
markers did not increase the identification of common haplotypes in regions 
with a low rate of historical recombination. The African population also had 
higher haplotype diversity averaging five haplotypes whereas the European 
and Asian populations averaged 4.2 and 3.5 respectively. Like the previous 
studies, these few common haplotypes still captured more than 90% of the 
diversity (Gabriel et al. 2002). The Gabriel et al. study found large regions 
containing both low and high rates of variation, as long as 100 Kb. They 
suggest that this arrangement is primarily driven by genealogical history with 
less than 25% being due to local mutation rate. This study provided a 
genome-wide estimate on the average correlation of variants (LD) as well as 
providing evidence that recombination hotspots are a general feature of the 
human genome and have a role in shaping genetic variation. Chromosomal 
regions inherited from shared ancestry and without recombination locks 
specific allele combinations in the population forming a haplotype. SNPs 
within a region of low recombination will track together in the population 
(Gabriel et al. 2002). In 2002, Dawson et al. published a study of LD patterns 
based on Centre d'Etude du Polymorphisme Humain (CEPH) families with 
replication in unrelated individuals from the United Kingdom. They found that 
the patterns of LD are highly variable across the genome. This study, based 
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on 1,504 SNPs spaced on average every 15 Kb along chromosome 22 found 
large regions of almost complete LD interspersed with regions containing little 
to no LD. It was also observed that while LD decays with distance there is 
considerable variation in the size of each block. Some regions in almost 
complete LD spanned over 800 Kb while others regions smaller than 5 Kb 
contained almost no discernable LD.  This study also observed a strong 
correlation between high LD and low recombination suggesting that 
recombination in humans is not random, that there are recombination 
hotspots, and that historical and contemporary recombination rates are similar 
(Dawson et al. 2002). In some rare instances LD can be quite strong over 
very large regions such as the ~2 megabase region on chromosome 17 
flanking MAPT (Pittman et al. 2004). The MAPT region appears to completely 
lack recombination between the two major haplotypes present in the region. 
This large block of LD and considerable divergence between the haplotypes is 
apparently the result of a large inversion, ~900 Kb in size. The inversion 
impedes recombination between the haplotypes, with the inversion haplotype 
(H2) and the non-inversion haplotype (H1) showing no evidence for 
recombination within their study (Stefansson et al. 2005). This region is of 
particular interest as it is associated with several neurodegenerative diseases 
and is investigated throughout this thesis. 
 
To formalize and facilitate the cataloguing of common genetic variation in the 
human genome the HapMap Project was formed. This created a public 
resource that characterizes common sequence variants (initially more than a 
million), their allele frequencies and the associations between them (i.e. their 
LD structure) based on four populations from Europe, Asia, and Africa 
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(International HapMap Consortium 2003, 2005). This resource has had three 
primary releases termed Phase 1, 2 and 3 since inception. Phase 1 was the 
initial release based on subjects from four populations and included 1.1 million 
common SNPs. The Phase 2 release expanded the density of genetic 
variants to 3.1 million SNPs common within the four HapMap Project 
populations (International HapMap Consortium et al. 2007). The Phase 3 
release of the HapMap project expanded the number of populations surveyed 
from four populations to 11 global populations (Altshuler et al. 2010). In 
addition to expanding the number of populations genotyped for common 
SNPs, the Phase 3 release included copy number polymorphisms as well as 
rare variants identified by sequencing in select regions of the human genome. 
Copy number polymorphisms, more commonly referred to as copy number 
variants (CNVs), are structural variants where the number of copies of a 
portion of the genome is aberrant. The regions selected for sequencing are 
from the ENCyclopedia Of DNA Elements (ENCODE) regions. The ENCODE 
project was established to identify the functional elements within the human 
genome. The pilot phase of the ENCODE project focused on ~1% (30 
megabases) of the human genome to specifically target functional elements 
including; genes, promoters, enhancers, transcription factor binding sites, 
DNase I hypersensitive sites, methylation sites, chromatin modifications, and 
multi-species conserved sequences (ENCODE Project Consortium 2004). 
The public release of these resources allowed for the rapid and continually 
improved design of assays which could genotype hundreds of thousands of 
informative tag SNPs allowing for effective genotyping in genome-wide 
association studies (GWAS) to be performed. 
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Inferring membership in a population based on genetic variability, resulting 
from the ability to densely genotype large sample cohorts, has allowed the 
study of populations based on genetics to move from theory to empirically 
driven findings (Pool et al. 2010). The method most commonly used to study 
population genetics is principal component analysis (PCA), which was 
proposed decades ago (Menozzi, Piazza and Cavalli-Sforza 1978) and 
renewed for use with studies based on high-density genotyping (Patterson, 
Price and Reich 2006; Price et al. 2006). The study from Monizzi et al. used 
multi-dimensional scaling (MDS) and PCA to spatially condense and show 
population structure based on genetic variation. They did so using 38 alleles 
from 10 loci in Europeans and Asian populations and found that the results 
map matched expectations from the hypothesis that early farming in Europe 
was a result of new migration rather than a technology diffusion into the 
population (Menozzi, Piazza and Cavalli-Sforza 1978). MDS is a method for 
information visualization, particularly for distance metrics, which aims to place 
each item in N-dimensional space such that the between-object distances are 
preserved as well as possible. PCA is a transformation that converts possibly 
correlated variables into linearly uncorrelated components, where the 1st 
component accounts for largest variance, 2nd the second most, etc. In a later 
study of spatial variation using PCA, it was found that the use of PCA with 
spatial data results in gradients that are a general sinusoidal mathematical 
artefact and therefore may not necessarily reflect specific migrations. 
However, the authors did find that using PCA does help correct for population 
structure in association studies (Novembre and Stephens 2008). Studies have 
also shown that beyond recent migration that linkage patterns can show 
additional historic information (Davison, Pritchard and Coop 2009), such as 
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haplotype frequency and haplotype number with changes in population sizes 
(Lohmueller, Bustamante and Clark 2009). Additionally, it has been shown 
that using clusters of linked mutations can detect archaic population 
structures (Plagnol and Wall 2006). These studies suggested that in addition 
to haplotype patterns reflecting recent migration that small haplotype patterns 
reveal older gene flow and demographic events (Pool et al. 2010). Dense 
whole-genome genotyping also allows for further analysis of natural selection 
both negative and positive. Negative selection reduces genomic variation by 
removing variants, maintaining low frequencies for variants or by removing 
variants linked to damaging alleles (background selection) (Charlesworth, 
Morgan and Charlesworth 1993). Positive selection results in local reductions 
in diversity by “genetic hitchhiking”. Hitchhiking is when an advantageous 
variant’s frequency increases in population and neutral variants linked to the 
positive variant will be lost or become fixed along with the variant in the 
population, known as a “selective sweep”. The size of the selective sweep is 
affected by recombination rate and selection strength (Smith and Haigh 1974; 
Hudson and Kaplan 1988; Stephan, Song and Langley 2006). Spatial patterns 
of LD are produced by selective sweeps and represent hitchhiking signals that 
differ from stochastic patterns resulting from bottlenecks (Stephan, Song and 
Langley 2006; Jensen et al. 2007). These specific LD patterns may also 
reveal partial selective sweeps detected by the imbalance of haplotype 
homozygosity. Comparing haplotype homozygosity can also be used to detect 
selective sweeps that are population-specific (Sabeti et al. 2002, 2007; Voight 
et al. 2006). 
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The study of genetic variation in world populations has continued to increase 
in the number of populations considered and the amount of genetic variation 
that is assayable with expanding throughput and types of assays. Such a 
study of genetic variation in world populations was performed by Jakobsson et 
al., and examined SNP, haplotype, and copy-number variation (CNV). This 
study was based on the genotyping of ~500,000 SNPs in 29 world 
populations. The analysis found that dense SNP genotypes allow for fine-
scale inferences of population structure and that using haplotype analysis 
methods also revealed these same fine-scale inferences. The analysis of 
CNVs showed that they could also be used for detecting population structure 
but to a lesser degree. The results from the SNP, haplotype, and CNV 
analyses showed that increased LD patterns matched increases in 
geographic distance from Africa. The authors suggest that this LD increase 
may be expected based on serial founder effects of the out of Africa spread of 
human populations (Jakobsson et al. 2008). Another study, based on the 
dense genotyping of a large number of samples from multiple European 
populations, found that patterns of genetic variation also exist within spatially 
close populations. In this study, the authors considered variation from 3,000 
Europeans based on genotypes at ~500,000 variants. They found that even 
though there are low levels of differentiation, within European populations, 
they did find correlation between genetic and geographic distances. These 
genetic correlations within European populations also aligned geographically 
to reveal a picture of European genetic diversity that matches European 
geographic maps when projected as a two dimension summary plot. Their 
results reinforce the idea that fine-scale population structure, based on 
genetic distances, needs to be accounted for when doing analysis for disease 
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traits even within a population determined by genetic ancestry. Their results 
revealed a south-east to north-west axis within European populations based 
on genetic distance where haplotype diversity decreases from south to north 
(Novembre et al. 2008). 
 
More recently it has become possible and feasible to directly sequence large 
cohorts of subjects using high-throughput short-read sequencing. It is now 
feasible to directly identify most of the genetic variation in a large number of 
subjects and this has been done in large public consortia such as the 1000 
Genomes projects (1000 Genomes Project Consortium et al. 2010, 2012). 
These denser maps of genetic variation, in multiple populations, have also 
greatly improved our ability to impute genotypes, using the refined population 
haplotypes generated from these data. The ability to determine which 
haplotype an individual belongs to over short intervals, using a reference 
population(s) haplotypes, also makes it is possible to predict the genotypes 
within the interval, with a given probability, for variants that were not directly 
genotyped in the individual. This statistical inference of variants not originally 
genotyped from variants that were genotyped is an imputation of those 
unobserved genotypes through estimating the individual’s haplotype and 
using LD to predict these genotypes. A study based on a cohort of ~72,000 
parent-offspring pairs from Iceland (using imputation from whole-genome 
sequencing of 2,200 subjects), was undertaken to identify variants associated 
with recombination rate. Meiotic recombination yields new combinations of 
alleles contributing to genetic diversity and an individual’s recombination 
counts vary in their gametes. They found 13 variants from eight regions 
associated with genome-wide recombination rate. Eight of 13 variants were 
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previously unknown; three of these variants were male only, seven were 
female only, and three were for both. Two of these variants are low-frequency 
with large effects on recombination rates, with one of these increasing the 
male genetic map by 111 cM and the female map by 416 cM and is located in 
an intron (Kong et al. 2014). Another recent paper estimated the ages of rare 
variants, based on whole-genome sequencing of subjects in the 1000 
Genomes Project. They found that the ages of rare variants are related to 
population histories and can be estimated by haplotype sharing patterns. 
Their analysis allows for estimating the age of each haplotype. Notably in 
considering haplotypes shared within and between populations, the ages of 
these haplotypes are consistent with known historical relationships among the 
populations. Their findings suggest that the age of haplotypes carrying 
variants that occur twice in populations, based on the populations represented 
in the 1000 Genomes Project, is 50 to 160 generations in Europe and Asia 
and 170 to 320 generations in Africa. They also note that haplotypes shared 
between continents (Europe and Asia) are much older, from 320 to 670 
generations. When they considered the distribution of haplotypes containing 
these twice-occurring variants they suggest this pattern shows demography, 
recent bottlenecks, ancient splits, and modern mixture of populations. They 
also found that functional variants are younger than non-functional variants of 
the same frequency suggesting this is an effect of selection (Mathieson and 
McVean 2014). 
 
A recent study of human population size and separation of populations was 
performed based on human genome sequences. The authors developed a 
method to analyse population separations that occurred less than 20,000 
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years ago. Their results suggested that genetic separation between non-
African and African populations started long before 50,000 years ago. The 
analysis was also informative for more recent events including: population 
separations within Africa, Asia, and Europe; and bottlenecks in the early 
Americas (Schiffels and Durbin 2014). Another recent study considered 
whether selection is less effective at removing damaging mutations in 
Europeans than in Africans. They undertook the study to examine the 
hypothesis that since European populations have undergone size reductions 
since the split from West Africans that the removal of weakly deleterious 
mutations by natural selection would be less effective. Based on per-genome 
accumulations of nonsynonymous variants they found no evidence of higher 
amount in non-Africans. However, looking at more divergent populations they 
found that Denisovans did accumulate nonsynonymous mutations faster than 
both Neanderthals and modern humans (Do et al. 2015). Another study was 
recently performed considering recombination and its effects on the 
accumulation of damaging and disease associated mutations in humans. In 
non-recombining species, damaging mutations can accumulate potentially 
leading to the extinction of many asexual species. This study examined the 
accumulation of damaging mutations within chromosomes that have variable 
crossovers rates, based on 1,400 subjects. They found that recombination 
rates affect the distribution of damaging variants across the genome. Their 
results showed that exons in regions with low recombination rates are 
enriched for damaging variants, but this varies across populations with 
different demographic histories. Their results also suggest that new damaging 
mutations occurring in regions with higher recombination rates will more 
efficiently be removed by natural selection than mutations in regions with 
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lower recombination rates. Regions of the human genome with lower 
recombination rates are enriched for conserved genes with essential functions 
such as cell cycle progression, mRNA processing, and DNA repair. The 
authors conclude that this co-enrichment of damaging variants and conserved 
genes with essential function likely affect human disease susceptibility 
(Hussin et al. 2015). 
 
1.2.2: Gene Expression 
The expressed human genome is also variable and this variation is likely to 
contribute to health related phenotypes, where variation of expression is likely 
to be an intermediate phenotype. With the ability to profile the relative mRNA 
transcript abundance (i.e. gene expression) for most of the known and 
predicted transcriptome in parallel, in a high throughput manner, we can begin 
to understand the patterns of expression variation. Understanding gene 
expression variation in multiple contexts is of importance and relevant to our 
understanding of molecular biology in general, and as it relates to health. The 
context of the variation is also important; gene expression varies not only in 
whether or not a gene is expressed in a particular cell or tissue type, but how 
much is expressed, how variable is this level of expression temporally and in 
relation to stimuli as well as to which particular transcripts and alternate splice 
forms are expressed. The last two decades have seen a great maturation in 
the technologies, assays, and methods that allow for the reproducible 
measurements of mRNA transcripts. These developments have allowed the 
field to begin to catalogue and better understand gene expression.  
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1.2.2.1: Regulation of Gene Expression 
In eukaryotes, the basal or core promoter is required for transcription but by 
itself cannot result in high levels of expression (Wray et al. 2003). The core 
promoter is the genomic region near the transcription start site (TSS), typically 
+/- 40 base pairs, and is the site where the transcription machinery assembles 
(Figure 1.3A) (Yáñez-Cuna, Kvon and Stark 2013). This assembly includes 
transcription factors that are bound to sites they have affinity for in the 
promoter region, which may affect the specificity and frequency of 
transcription (Kuras and Struhl 1999; Lee and Young 2000; Lemon and Tjian 
2000; Wray et al. 2003). The rate of transcription initiation is considered to be 
the primary point of control for regulation of gene expression in eukaryotes but 
other important mechanisms are also involved including: chromatin 
accessibility, DNA methylation, pre-mRNA splicing, mRNA stability, 
translation, post-translation modification, and degradation (Lemon and Tjian 
2000; Wray et al. 2003). As transcription initiation is the primary control point 
of gene expression I will focus almost exclusively on transcription within my 
thesis. The assembly that initiates transcription is the RNA polymerase II 
holoenzyme complex (RNA Pol II). This complex is made up of approximately 
12 proteins and is responsible for the transcription of genes in eukaryotes 
(Orphanides, Lagrange and Reinberg 1996; Lee and Young 2000; Wray et al. 
2003). The RNA Pol II complex assembles at the core promoter, which is a 
sequence region in close proximity (5’) to the transcription start site (TSS). 
While core promoter sequences differ for genes, common DNA elements that 
can be found in human core promoters include: CpG islands, the initiator 
element (Inr), the TATA-box, the TFIIB recognition element (BRE), and the 
downstream promoter element (DPE) (Sandelin et al. 2007; Yang et al. 2007). 
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CpG (5’-cytosine-phosphodiester bond-guanine-3’) islands are genomic 
regions enriched with CG dinucleotide content compared to the rest of the 
genome. CpG island promoters are most often associated with ubiquitously 
expressed genes, although they are also associated with tissue-specific 
genes including brain-specific genes (Schug et al. 2005; Gustincich et al. 
2006). Promoters with CpG islands are the most common in the human 
genome, it is estimated that 72% to 76% of human promoters contain CpG 
islands (Saxonov, Berg and Brutlag 2006; Yang et al. 2007). Promoters with a 
TATA-box sequence motif are bound by the TATA-binding protein (TBP), 
which in combination with other TBP-associated factors brings the RNA Pol II 
complex to the DNA (Figure 1.3B) (Reinberg et al. 1998; Lee and Young 
2000; Wray et al. 2003). TATA-box promoters are typically associated with 
genes that have tissue- or context-specific expression and only represent 
~10% of human promoters, although ~24% of human promoters have TATA-
like elements (Carninci et al. 2006; Ponjavic et al. 2006; Yang et al. 2007). 
Promoters with an initiator element (Inr) contain a consensus sequence motif 
that is distinct from the TATA-box motif, but both the Inr and TATA-box 
elements can be found together in some promoters and work together to 
recruit the transcription intiation complex. It has been estimated that ~46% of 
human promoters contain the mammalian consesus sequence Inr and that 
~30% of promoters with an Inr element are TATA-less (Yang et al. 2007). The 
BRE (Transcription Factor II B) is a consensus sequence motif located 
upstream of the TATA-box and is present in 12% to 25% of human promoters 
and typically acts to increase or decrease transcription rates (Lagrange et al. 
1998; Yang et al. 2007). The DPE is a consensus sequence motif found 
downstream of the TSS (typically 30 bases) in promoters that also have an Inr 
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and are present in 12% to 25% of human promoters (Yang et al. 2007). 
Genes may have multiple core promoters and each of these promoters may 
initiate transcription at a different TSS. CpG islands are associated with 
promoters that have a broader distribution of TSSs while TATA-box promoters 
are associated with only one or a few consecutive nucleotides as TSSs 
(Carninci et al. 2005; Sandelin et al. 2007). The TSS does not have a specific 
sequence motif, as the translation start site does, but instead is determined by 
the second DNA contact point for the RNA Pol II complex and is 
approximately 30 bp downstream of the first RNA Pol II contact point (Wray et 
al. 2003). Many of the proteins that bind into the core promoter are 
ubiquitously expressed and known as general transcription factors; while 
others are known to have isoforms that are tissue-specific (Holstege et al. 
1998; Wray et al. 2003). TATA-box promoters are bound by the TATA-binding 
protein (TBP) transcription factor while CpG island promoters are enriched for 
transcription factor or transcription factor family binding motifs including: E 
twenty-six (ETS), E2F, nuclear respiratory factor 1 (NRF-1), specificity protein 
1 (SP1), cAMP response elements (CRE), and E-box (Rozenberg et al. 2008; 
Landolin et al. 2010). 
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Figure 1.3: Simplified general schematic of the cis-regulatory region of a gene and a 
cartoon of this region at transcription initiation. A) General linear organization of a 
gene and its promoter region. The cis-regulatory region is located proximal (region of 
the left in this simplified schematic) to the transcription start site (TSS; black arrow in 
the centre) and the transcriptional unit is on the right. The core promoter is located 
near the TSS and transcript factor binding sites are interspersed within the regulatory 
region (indicated by vertical bars) and typically found in modular units (enhancers), 
which can be located both up and downstream of the TSS. B) Cartoon of a gene’s 
promoter region during transcript initiation, for a gene with a TATA-box in the 
promoter. The chromatin is open so that the promoter region is available for 
interaction with regulatory proteins. RNA Pol II has assembled at the core promoter. 
Transcription factors are bound to binding sites and looping factors have brought 
some of these factors into proximity of the core promoter so they may interact with 
other regulatory factors. This figure is reproduced from (Wray et al. 2003). 
 
Achieving increased levels of transcription beyond the low level possible with 
the complex forming at the core promoter typically requires other transcription 
factors bound to sites outside the core promoter. The presence of these other 
transcription factors and other cofactors in the nucleus can be temporal and 
differ among cell types (Lemon and Tjian 2000; Wray et al. 2003). For 
example, paired box 6 (PAX6) is a regulatory protein with temporal and 
abundance variation and is important during the development of neural 
tissues and the eye (Kammandel et al. 1999; Wray et al. 2003). Regulatory 
proteins affect transcription by influencing how often the RNA Pol II complex 
assembles onto the core promoter. This influence can be through protein-
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protein interactions, where a transcription factor may interact to increase or 
decrease transcription rates by activation and repression domains (Torchia, 
Glass and Rosenfeld 1998; Wray et al. 2003). Studies of eukaryotic promoters 
suggest that there may typically be 10 to 50 binding sites for 5 to 15 different 
transcription factors in a typical promoter (Arnone and Davidson 1997; Wray 
et al. 2003). Most binding sites for transcription factors are 5 to 8 base pairs in 
length, but the “footprint” of the bound transcription factor on a segment of 
DNA is typically 10 to 20 base pairs. The 5 to 8 base pair binding motif may 
tolerate some polymorphic changes without losing functionality but the binding 
site motifs that a transcription factor binds can change in the presence of 
different binding partners (Wray et al. 2003). Transcription factors can also 
affect the binding of other factors by binding to sites such that they block the 
binding of another transcription factor at an adjacent site. The binding of other 
transcript factors at proximal sites can modulate the process, which allows 
gene regulation to be a dynamic and tuneable process (Jackson-Fisher et al. 
1999; Kuras and Struhl 1999; Lee and Young 2000; Lemon and Tjian 2000; 
Wray et al. 2003). Transcription factors typically contain several functional 
domains including: DNA-binding, protein-protein interaction, intracellular 
trafficking, and ligand-binding domains (Abu-Shaar, Ryoo and Mann 1999; 
Carrión et al. 1999; Wray et al. 2003). The DNA-binding domains for most 
transcription factors are short motifs, typically five bp, and transcription factors 
may contain multiple DNA-binding domains. For these short motifs, a single 
amino acid change in the domain can alter its binding specificity (Treisman et 
al. 1989; Wray et al. 2003). The small size of these binding motifs also means 
the binding target motifs can occur often in the genome resulting in a lack of 
sequence specificity and many potential target sites. Because transcription 
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factors may bind to multiple motifs and these sites may occur often in the 
genome, this means that many copies of the factor must be present in the 
nucleus for binding to occur at specific sites (Wray et al. 2003). Additionally, a 
transcription factor’s specificity can be strongly modulated through cofactors 
or by post-translational modifications such as phosphorylation (Knoepfler and 
Kamps 1995; Berthelsen et al. 1998; Dröge and Müller-Hill 2001; Wray et al. 
2003). Regulation of transcription can also be influenced by bound 
transcription factor(s) altering the chromatin structure through DNA 
methylation and histone modifications such as acetylation, where this 
remodelling can take place in a small timescales and in small regions such as 
a promoter or even within a promoter (Kadosh and Struhl 1998; Jones and 
Takai 2001; Richards and Elgin 2002; Wray et al. 2003). Before transcription 
the chromatin surrounding the core promoter and some of the transcript must 
be decondensed so that transcription factors can bind and recruit RNA Pol II 
to the core promoter (Reinberg et al. 1998; Wray et al. 2003). There are 
regulatory proteins, referred to as pioneer transcription factors that can initiate 
regulatory events in chromatin. These factors may bind cooperatively or 
sequentially, and open up local chromatin so that other factors can bind (Zaret 
and Carroll 2011). The forkhead box (FOX) proteins are an example of 
pioneer transcript factors. The FOX proteins mediate fine-tuning of spatial and 
temporal expression of genes during development and in adult tissue (Lam et 
al. 2013).  
 
The size of cis-regulatory regions may vary from a few hundred bases to more 
than 100 kilobases (Kb). In some instances, the cis-regulatory region can be 
much further from the TSS. Such is the case for Shh locus in humans and 
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mice where the cis-regulatory region is ~800 Kb from the TSS (Lettice et al. 
2002; Wray et al. 2003). The position of cis-regulatory transcription factor 
binding sites may also vary relative to the TSS. These binding sites are 
typically within a few Kb upstream (5’) of the core promoter, but they can also 
be found much further upstream as well, or in other instances within the 5’ 
untranslated region (UTR), in introns, or downstream (3’) of the gene and in 
rare instances in exons (Wray et al. 2003). A promoter’s transcriptional yield is 
not simply based on which binding sites are present but also involves the 
sequence, relative position and orientation of the binding site as well as the 
expression of other transcription factors and cofactors. Thus interactions are 
complex and context dependent. Groups of transcription factor binding sites 
can operate as a unit or a functional module to yield a distinct aspect of a 
transcript’s expression profile (Dynan 1989; Arnone & Davidson 1997; Wray 
et al. 2003). These functional modules may initiate transcription, increase 
transcription, mediate transcription signals, repress transcription, or modulate 
other functional modules; these modules are referred to as enhancers 
(Atchison 1988; Wray et al. 2003). These enhancers can be functionally 
related to the regulation of a transcript by way of DNA looping (Figure 1.3B). 
Regulatory proteins bound to DNA can affect the bending or looping of DNA, 
allowing other factors bound distally to be near each other for interaction, and 
this function may be necessary for the transcription factor to act as an 
activator or repressor (Fry and Farnham 1999; Scaffidi and Bianchi 2001; 
Wray et al. 2003). The looping of DNA allows for the interaction of these 
binding proteins even at distal sites (Simon et al. 1990; Neznanov, Umezawa 
and Oshima 1997; DiLeone, Russell and Kingsley 1998; Nielsen et al. 1998; 
Kammandel et al. 1999; Bamshad et al. 2002; Calhoun, Stathopoulos and 
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Levine 2002; Yuh et al. 2002; Wray et al. 2003). Binding sites that are not 
near the core promoter may interact with the preinitiation complex at the 
promoter through DNA looping or bending and as a result their distance and 
orientation is relatively independent of the target TSS (Wray et al. 2003; 
Yáñez-Cuna, Kvon and Stark 2013; Core et al. 2014; Shlyueva, Stampfel and 
Stark 2014). In general regulatory cis-architecture, the promoter is in the 
immediate proximity of the TSS and binds the preinitiation complex. 
Enhancers are typically less constrained in their genomic context and may act 
in a more cell-specific manner and help to bring specific transcription factors 
to the preinitiation complex at the promoter (Yáñez-Cuna, Kvon and Stark 
2013; Shlyueva, Stampfel and Stark 2014). The interaction of transcription 
factors bound at distant sites through looping potentially allows for 
transcription at multiple genes to be affected. These distal interactions can be 
spatially restricted through insulators or bound elements likely involving 
chromatin modifications (Wolffe 1994; Bell and Felsenfeld 1999; Dillon and 
Sabbattini 2000; Wray et al. 2003). Typically, binding sites effect the 
expression of one gene, but instances of shared regulation also occur. 
Additionally, there are instances where genetic variation in shared regulatory 
regions affect the expression of multiple genes, for example: beta and 
gamma-globin (Metherall, Gillespie and Forget 1988; Grosveld et al. 1993); 
insulin and insulin-like growth factor 2 (IGF2) (Paquette et al. 1998); and 
apolipoprotein A-I (APOA1) and apolipoprotein C-III (APOCIII). In APOA1 and 
APOCII the effect of variation in the shared regulatory region is tissue-
specific; down-regulation of APOA1 in colon and up-regulation of APOCIII in 
liver (Li et al. 1995; Naganawa et al. 1997; Wray et al. 2003).  
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Enhancers and repressors may be in introns and cis-regulatory elements may 
extend long distances both up and downstream of the transcribed sequence. 
Some evidence for this is that many noncoding regions show strong 
conservation and functional studies of these regions suggest they are 
regulatory elements generally containing sites for tissue-specific DNA-binding 
proteins (Kleinjan and van Heyningen 2005). In 2003, Nobrega et al. 
published a study where gene deserts were searched for conserved 
enhancers that modulate expression. In this study, the authors found 
conserved elements for human dachshund family transcription factor (DACH), 
which is flanked by two large gene deserts. They considered a 2.6 megabase 
(Mb) region where they found and validated enhancer elements for DACH in a 
1.5 Mb region. These conserved elements were estimated be to 
approximately 1 billion years old. Based on mouse reporter assays they 
showed that these conserved elements were long-range enhancers driving 
expression. DACH is expressed in many tissues and involved in development 
of brain, limbs and sensory organs (Nobrega et al. 2003). Conversely, in a 
recent study, by Jacques et al., considering the possible origins of primate-
specific regulatory elements, it was found that transposable elements (TEs) 
appear to have contributed to many primate-specific regulatory elements. 
Transposable elements are DNA sequences that are mobile within a genome, 
where the location of the sequence can change or be duplicated to another 
location in a genome. This study used ENCODE DNase I hypersensitivity site 
(DHS) data from multiple cell types and found that 44% of these TEs were in 
open chromatin and this number increased to 63% when considering TEs in 
primate-specific regions. They also found that 80% of endogenous 
retroviruses (ERV), a specific subfamily of TEs, were also in open chromatin 
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and that their derived sequences were activated in a cell-specific manner and 
were associated with nearby genes (Jacques, Jeyakani and Bourque 2013). 
In a recent study, from Heidari et al., interaction maps of regulatory elements 
were constructed based on ENCODE data from human cells for 80% of 
DHSs, which included 99.7% of TSSs and 98% of enhancers. They found that 
cohesin, CCCTC-binding factor (CTCF), and zinc finger protein 143  
(ZNF143) are proteins that are key contributors to the three-dimensional (3D) 
structure of chromatin and how distal chromatin state can affect transcription. 
When analysing these structural interactions, between cell types, they found 
that many enhancer-promoter interactions were cell-type specific. Additionally, 
they found that housekeeping genes are enriched for proximal events 
whereas distal events included genes involved in dynamic biological 
processes (Heidari et al. 2014). The 3D structure of chromatin that organizes 
the genome into functional regulatory compartments at a megabase scale, 
where regulatory elements such as promoters and enhancers can interact, 
are referred to as topologically associating domains (TADs). In 2012, Dixon et 
al. published a study of 3D genome organization and chromatin interaction. 
This study examined the 3D organization of genomes in human and mouse 
embryonic stem cells and differentiated cell types. They found that these 
megabase-sized local chromatin interacting domains were a pervasive 
structural feature of genome organization stable across different cell types 
and conserved across species. Additionally, they found that the boundaries of 
these domains were enriched for insulator binding protein CTCF, 
housekeeping genes, transfer RNAs and short interspersed element (SINE) 
retrotransposons (Dixon et al. 2012). In another recent study, from Vierstra et 
al., considering more than 1.3 million DHSs from 45 mouse tissue and cell 
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lines, a comparison to human orthologous DHSs was performed. The authors 
found extensive cis-regulatory changes that appear to be mediated by 
turnover of transcription factor recognition elements during evolution. 
However, despite these pervasive changes to individual cis-regulatory regions 
within DHSs shared between mouse and human, 58.7% of transcription factor 
binding sites were conserved (Vierstra et al. 2014). In 2013, Sheffield et al. 
published a study considering how regulatory elements and transcription 
factors affect gene expression across cell types. The authors were able to 
develop a classifier based on 43 DHSs that could predict cell-type lineage. 
This study was based on 112 human samples for 72 cell types to analyse 
DHSs, promoters, CpG islands, and transcription factor motifs (Sheffield et al. 
2013). In 2013, Xie et al. published a study of DNA methylation of TEs in 
human embryonic and adult tissues. TEs comprise a very large portion of the 
human genome and it is assumed that many of them are hypermethylated 
and inactive. They found that ~ 10% of TE families are hypomethylated in a 
tissue-specific manner. The regions containing hypomethylated TEs were 
proximal to genes that shared function important to the tissue and many 
showed enhancer activity. These findings suggest that TEs are responsible 
for setting up tissue-specific regulation and have tissue-specific epigenetic 
regulation (Xie et al. 2013).  
 
The genetic basis of many adaptations are likely a result of variation in cis-
regulatory sequences, cis-regulatory variants are more likely to affect certain 
kinds of traits than coding variants (Wray 2007). That cis-regulatory variation 
may intrinsically be able to affect certain traits centres on the flexibility that 
regulation is afforded as a dynamic process (Wray 2007). This flexibility 
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allows for more context-dependent effects, whereas a coding variant would 
likely have a more static effect without context (Jacob and Monod 1961; Stern 
2000; Wray 2007). It has been proposed that natural selection may be more 
efficient for cis-regulatory variants than coding variants (Stern 2000; Wray et 
al. 2003). The basis of this hypothesis has two parts: cis-regulatory variants 
are often co-dominant and cis-regulatory regions are modular (Wray 2007). In 
diploid organisms each allele is transcribed independently, based on allele-
specific measures of transcript abundance (Ruvkun et al. 1991; Pastinen et al. 
2004; Wittkopp, Haerum and Clark 2004; Ronald et al. 2005; Wray 2007). The 
independence of allele transcription allows for cis-regulatory variants to be co-
dominant. Under co-dominance, heterozygote variants have fitness costs 
making these variants visible to selection before the allele frequencies reach a 
point were homozygotes emerge in the population. Therefore, if cis-regulatory 
variants are more co-dominant than coding variants, then natural selection will 
be more efficient in functional non-coding regions than coding regions 
(Ruvkun et al. 1991; Wray 2007). Additionally the modular nature that is often 
present in cis-regulatory regions suggests that a variant can occur in a portion 
of the region and possibly have some effect on a certain aspect of a 
transcript’s expression profile but not likely a total effect on overall expression 
(Force et al. 1999; Stern 2000; Wray 2007). Conversely a nonsynonymous 
coding variant would very likely have an affect on protein function regardless 
of its expression context. This allows selection to operate more efficiently 
through a reduction in functional trade-offs especially in the context of gene 
expression in different tissues and cell types (Force et al. 1999; Stern 2000; 
Wray 2007). Sequence comparisons studies have shown that the number of 
conserved intergenic and coding nucleotides is similar. This similarity may 
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suggest that the number of functional noncoding and protein-coding 
nucleotides is roughly equal, and much of this noncoding sequence may be 
phenotypically penetrant (Onyango et al. 2000; Frazer et al. 2001; Shabalina 
et al. 2001; Wray 2007). Conservation of promoter sequence would suggest 
that gene expression is modulated through stabilizing selection (Cavener 
1992; Stone and Wray 2001; Wray 2007). It is also known that promoter 
sequences can rapidly diverge. For instance in a study of 20 regulatory 
regions between humans and rodents, it was found that a third of the binding 
sites that are functional in humans are probably not functional in rodents 
(Dermitzakis and Clark 2002; Wray 2007). Known cis-regulatory variants 
contribute to phenotypes that differ between closely related species such as 
the ability of human adults to digest lactose (lactose persistence), which is not 
present in other great apes. This human dietary adaption is thought to have 
evolved in the past 2,000 to 20,000 years (Swallow 2003; Bersaglieri et al. 
2004; Wray 2007). Lactose persistence is linked to cis-regulatory genetic 
variation that increases the transcription of lactase (LCT). This cis-regulatory 
genetic variation for LCT is different between European and East African 
populations, but confers lactose persistence in both through the same 
regulatory landscape, which is located in an intron of maintenance deficient 6 
homologue (MCM6) just upstream of LCT (Olds and Sibley 2003; Bersaglieri 
et al. 2004; Tishkoff et al. 2007; Wray 2007). A recent study of transcription 
factor binding in human and chimpanzees suggest that natural selection 
through regulatory genetic variation greatly affected transcription factor (TF) 
binding sites between the species 4 to 6 million years ago. This study found 
that on average transcription factor binding sites show weaker selection than 
protein coding nucleotides, but binding sites of several transcription factors 
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show evidence of adaptation (Arbiza et al. 2013). In 2010, Kasowski et al. 
published a study of speciation and phenotypic diversity based on gene 
expression. This study considered transcription factor binding in humans and 
chimpanzees based on LCLs. They specifically looked at RNA Pol II and 
nuclear factor kappa B (NFkB) based on ChIP-seq data. ChIP-seq is a 
method that combines chromatin immunoprecipitation (ChIP) with DNA 
sequencing to identify binding sites of protein-DNA interactions. They found 
that within humans between 7% and 25% of binding regions for NFkB and 
RNA Pol II differed, and these differences were associated with SNPs or 
structural variants that were often correlated with changes in gene expression. 
Additionally, when comparing RNA Pol II binding they found extensive 
divergence in transcription factor binding between humans and chimpanzees 
for 32% of the binding regions (Kasowski et al. 2010). An example of a gene 
that shows expression differences between humans and chimpanzees as a 
result of regulatory variation is prodynorphin (PDYN). This gene is involved in 
the release of a neuropeptide linked with memory, emotional status, and pain 
perceptions. For PDYN there are functional cis-regulatory variants present in 
humans that are not present in chimpanzees that are linked to changes in 
gene expression (Wray 2007). Additionally, PDYN has been linked through 
expression analysis and genetic association to schizophrenia, bipolar 
disorder, and temporal lobe epilepsy; and show signs of positive selection in 
human evolution and balancing selection between populations (Peckys and 
Hurd 2001; Hurd 2002; Stögmann et al. 2002; Ventriglia et al. 2002; Rockman 
et al. 2005; Wray 2007). Other human behavioural and cognitive  traits have 
also been linked to cis-regulatory variants, for the genes encoding: arginine 
vasopressin receptor 1A (AVPR1A) (Bachner-Melman et al. 2005; Hammock 
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and Young 2005), 5-hydroxytryptamine (serotonin) receptor 2A, G protein-
coupled (HTR2A) (Enoch et al. 1998), monoamine oxidase A (MAOA) (Caspi 
et al. 2002; Kim-Cohen et al. 2006), and solute carrier family 6 
(neurotransmitter transporter), member 4 (SLC6A4) (Trefilov et al. 2000; Hariri 
et al. 2002; Bachner-Melman et al. 2005). 
 
Genetic variants can affect regulatory binding sites in multiple ways; by 
creating or eliminating the site, modifying the site such that it becomes the 
target of a different transcription factor, or changing the spacing between sites 
(Belting, Shashikant and Ruddle 1998; Segal, Barnett and Crawford 1999; 
Trefilov et al. 2000; Rockman and Wray 2002; Wray 2007). Additionally, 
variants may have a trans effect. Trans effects could be through a cis effect 
on a transcription factor’s expression levels. A trans variant may affect the 
DNA-binding domain of a transcription factor. A trans variant may also affect a 
protein-protein interaction domain of the transcription factor. These trans 
effects may impact the expression of many genes in many tissues (Dawson, 
Morris and Latchman 1996; Manzanares et al. 2000; Brickman et al. 2001; 
D’Elia et al. 2001; Wray 2007). Variants in cis-regulatory regions may alter 
transcription, but this alteration may not be carried through to the protein 
abundance as the regulation of gene and protein expression is a network of 
interacting genes and this network can modulate protein abundance typically 
through feedback loops (von Dassow et al. 2000; Milo et al. 2002; Wray 
2007). In a study of translational control of messenger RNA (mRNA) by 
microRNAs (miRNA), it was shown that a single miRNA can repress the levels 
of hundreds of proteins. The repression effect is typically mild, and in addition 
to down regulation of mRNA may also affect its translation. Regulation of 
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mRNAs by miRNAs may inhibit translation by inducing degradation. This 
study measured protein synthesis (pulsed stable isotope labelling with amino 
acids in cell culture, pSILAC) and mRNA expression (microarray) changes in 
response to transfecting in miRNA or lowering levels of endogenous miRNAs 
(Selbach et al. 2008). Another study of the impact of miRNA on expression 
was performed using quantitative mass spectrometry for protein measures. 
MicroRNA are an endogenous species of RNA typically 23 nucleotides in 
length that bind to target sites in mRNA and down regulate these targeted 
mRNAs. The authors perturbed their systems by adding miRNAs to cultured 
cells after deleting mir-223 in mouse neutrophils. Their data suggested that 
targeted binding sites are typically located in 3’ UTRs and that hundreds of 
genes are repressed by individual miRNAs but to a relatively mild level. The 
down-regulated genes with the highest translational repression also displayed 
increased destabilization. They suggest miRNAs confer mild adjustments and 
act as a tuning of protein synthesis (Baek et al. 2008). In a study considering 
expression activity including: transcription, translation, and turnover, the 
authors used mRNA and protein levels from mammalian cells to study the 
correlations within these. They found better mRNA and protein level 
correlation than expected but the half-lives of the molecules were not 
correlated. Their findings may suggest that protein abundance is controlled 
during translation (Schwanhäusser et al. 2011). In a follow up to the above 
study, of the correlation of mRNA and protein abundance, it was found that 
systematic errors may underlie a substantial underestimate in the abundance 
of protein present per cell which suggested that 10% to 40% of protein 
variation is from mRNA expression. A re-analysis of the study estimated 10 
fold more protein molecules per cell. Based on the corrected protein 
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abundance levels mRNA expression accounted for 56% of the protein levels 
and that translation is 12% lower than previously estimated. This new study 
suggested that mRNA expression explained ~84% of protein level variation. 
These results suggest that transcription is the main driver in protein level 
variation and that translation, RNA degradation, and protein degradation are 
smaller contributors of the variation (Li, Bickel and Biggin 2014). In another 
recent study of protein levels, the regulation of protein expression during 
cellular differentiation was considered. Protein levels depend on transcription, 
translation, and degradation to determine steady-state level but less is known 
about how system-level perturbations impact on these levels. This study 
found that during differentiation that synthesis rate was the main determinant 
and that degradation rates were constant. They also found that synthesis and 
degradation rates are the reason that transcript and protein expression levels 
typically have poor correlation (Kristensen, Gsponer and Foster 2013). It has 
previously been shown that the average rate of transcription in mammalian 
cells is between 1.3 Kb and 4.3 Kb per minute and that the largest gene in the 
human genome, dystrophin (DMD; Duchenne muscular dystrophy), takes 16 
hours for transcription (Tennyson, Klamut and Worton 1995; Ben-Ari et al. 
2010; Maiuri et al. 2011). The median estimated half-life of mRNA is between 
7 and 9 hours while the median half-life of proteins is estimated to be between 
22 and 46 hours but can be as short as 45 minutes (Sharova et al. 2009; 
Eden et al. 2011; Schwanhäusser et al. 2011). In a study of orthologous 
protein and mRNA expression correlations across seven different species, it 
was found that even across diverse taxa protein abundances show higher 
correlation than the corresponding mRNAs. This study included mRNA and 
protein measures from: two bacteria, yeast, nematode, fly, human, and rice. 
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The authors were interested in this because while nematode and fly 
orthologous proteins were well correlated the corresponding mRNA was not. 
So while it is thought that mRNA transcription primarily determines protein 
levels and that post-transcription, translation and degradation play a lesser 
role these data suggest, there is likely strong selective pressure to maintain 
protein abundances even when mRNA abundances diverge (Laurent et al. 
2010). 
 
Regulatory adaptations are a significant part of phenotypic evolution (Wray 
2007). There are phenotypic consequences to changes in the regulation of 
transcription. Sequence variants that result in a protein coding change may 
have multiple phenotypic effects (pleiotropy). For example a protein coding 
change in a transcription factor may alter its function or expression affecting 
its interaction with other regulatory proteins or binding site specificity and may 
have a regulatory effect on many genes. The modular organization of 
enhancers and promoters in cis-regulatory regions allows for discrete effects 
on expression that restricts the pleiotropy and permits these discrete effects to 
be modified by selection. Selection has increased efficiency in cis-regulatory 
regions allowing beneficial alleles to be fixed and eliminating deleterious ones 
because alleles in the cis-regulatory regions are likely to be codominant and 
visible to selection immediately as these variants may have fitness 
consequences as heterozygotes (Arnone and Davidson 1997; Stern 2000; 
Wray 2007). Altering the gene expression of functionally conserved proteins 
may largely account for evolution of form and these alterations in gene 
expression occur through cis-regulatory variation (Carroll 2008). Selection is 
active in promoter sequences, like it is for coding sequences, through 
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negative or purifying selection, positive selection, overdominant selection, 
balancing selection, stabilizing selection, and compensatory selection 
(Guardiola et al. 1996; Cowell et al. 1998; Crawford, Segal and Barnett 1999; 
Romey et al. 1999, 2000; Hamblin and Di Rienzo 2000; Trefilov et al. 2000; 
Bamshad et al. 2002; Wray 2007). An example of compensatory selection in a 
promoter with an effect on expression and relevant to disease is at the cystic 
fibrosis transmembrane conductance regulator (CFTR) locus. A hypomorphic 
allele in the CFTR coding sequence causes cystic fibrosis but there are 
haplotypes where a second cis-variant modulates disease prognosis. This 
second cis-variant adds an additional binding site for the Sp1 transcription 
factor resulting in increased transcription and improved disease prognosis. 
The non-disease causing haplotypes never carry this second variant and 
therefore do not have the additional Sp1 binding site, suggesting a 
compensatory effect under positive selection (Romey et al. 1999, 2000; Wray 
2007). 
 
1.2.2.2: Variation in Gene Expression 
Many early studies using parallel gene expression profiling arrays focused on 
the task of identifying which genes were expressed in which tissue. In 2000, 
Warrington et al. published a study looking at gene expression in 11 different 
human tissues (Warrington et al. 2000). These different tissues included both 
adult and fetal tissues assayed to capture expression levels for ~7,000 mRNA 
transcripts. In this study, they identified which transcripts are expressed in 
which tissue. To minimize individual variation, and presumably reduce costs, 
they used a pooling strategy. One of their research aims was to identify genes 
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that are expressed in all tissues, as these would be likely candidates as 
‘housekeeping’ genes. Their basis for this being that since these genes are 
expressed in all tested tissues from early fetal development through to 
adulthood these are likely required for cellular maintenance or ‘housekeeping’. 
The tissues included in this study were: adult and fetal brain, adult and fetal 
kidney, adult and fetal lung, fetal liver, adult heart, adult pancreas, adult 
uterus, and adult testis. They identified 535 genes that are expressed in all 11 
tissues, which they suggest are candidate housekeeping genes. Additionally, 
they found 400 genes that were expressed in fetal tissues but were absent 
from any adult tissue; 767 genes that were expressed in all four fetal tissues; 
and 695 that were expressed in all 7 adult tissues (Warrington et al. 2000). In 
a similar study of gene expression in multiple human tissues, Hsiao et al. 
surveyed 19 distinct tissue types from 59 samples. In addition to detecting 
which transcripts were expressed in which tissues they also considered the 
variation in expression levels between the tissues. They found 451 genes that 
were detected in all tissues. However, the variation in the expression levels of 
these genes between the tissues was such that they were able to detect 
tissue-specific signatures. Of the 451 ubiquitously expressed genes, which 
they also labelled ‘housekeeping’, 358 overlapped with the previous study. 
Here the tissue-specific signature of expression was based on statistical tests 
to identify highly expressed genes within a specific tissue. They identified 
genes that showed a tissue-specific signature: 618 in brain, 91 in kidney, 277 
in liver, 75 in lung, 317 in muscle, 46 in prostate, and 101 in vulva. They also 
attempted to identify which genes were most variable within a tissue between 
individual subjects. There were some limitations based on their cohort and 
tissue sampling but the investigators were able to identify a small set of genes 
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that appear variable within specific tissues. Their results suggest that kidney 
contained the highest variation in expression, but that brain, liver, lung, 
muscle, and, vulva also showed considerable gene expression variation 
between individuals (Hsiao et al. 2001). The recent functional annotation of 
the mammalian genome 5 (FANTOM5) study which mapped transcription 
start sites in 975 human and 399 mouse tissue and cell lines found that 
‘housekeeping’ genes may be fewer than previously believed. Their findings 
suggest that many mammalian promoters include multiple TSSs with cell-type 
specific expression patterns. These cell-specific TSSs appear to have evolved 
at different rates, where as the promoters of broadly expressed genes show 
the most conservation (FANTOM Consortium and the RIKEN PMI and CLST 
(DGT) et al. 2014). 
 
 Additional studies continued surveying expression in human tissues. In 2002, 
Saito-Hisaminato et al. analysed gene expression in 25 adult and four fetal 
tissues. They found that many genes were highly expressed in only one or a 
few tissues and very few are exclusively expressed in a single tissue. They 
also found, based on gene profiles, that the tissues not only cluster well by 
distinct tissue but also by general tissue category such as: nerve, lymphoid, 
muscle, and adipose (Saito-Hisaminato et al. 2002). In 2003, Evans et al. 
investigated differences in distinct regions of the brain and similar brain 
tissues based on 13 normal human subjects in three regions. The cerebellar 
cortex and the cerebral cortex were highly divergent, and the anterior 
cingulate cortex and the dorsolateral prefrontal cortex were highly similar. This 
group found ~1,000 genes differentially expressed between cerebellum and 
cerebral cortex but very few between neocortical regions. Clustering revealed 
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a 1st order branch between cerebellum and the neocortical regions, a 2nd 
order branch was between the replicating labs (3 total labs), and the 3rd order 
branch between individual subjects. The authors were unable to separate 
neocortical tissues based on their clustering approach. These data also 
revealed an important confound to consider when analysing microarray 
expression data, namely experimental batch and site effects. Of the reliably 
detected probes, 30% were detected in the cerebral cortices and 22% in 
cerebellum. They were unable to identify any differences in genes that were 
expressed in the cerebral cortices but 74 transcripts were specific to the 
cerebral cortical regions and 15 transcripts were specific to cerebellum (Evans 
et al. 2003).  
 
As technology improved and costs began to decline, the feasibility of running 
more samples per tissue was reflected in a couple of the published studies. In 
2005, Son et al. published a survey of human expression based on 30 
subjects in 19 organs (158 total tissue samples). One particularly interesting 
aspect of this study from a methodological point of view was the inclusion 
within the analysis of their known covariates. They found that the covariate 
effects for age, sex, ethnicity, and post-mortem interval were smaller than that 
of tissue type. They also found that randomly sub-setting with as few as 100 
genes can reproduce distinct tissue clustering: suggesting that differential 
expression of more than 90% of the genes is of biological origin. This study 
observed that tissues of a similar cellular composition and function cluster 
more closely together, but still clearly separate. They also observed a great 
deal of variation in transcript abundance levels in different tissues. Based on 
this heterogeneity of transcript expression they were able to identify a subset 
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of tissues that were distinctive based on a set of characteristics. These 
characteristics included: higher expression variation, cluster categorization 
when considering the Gene Ontology term for high level energy consumption, 
and the number of tissue-specific genes expressed. The two brain tissues 
included in the study, cerebellum and cerebrum, were present in this subset of 
distinctive tissues based on these categories (Son et al. 2005). In addition, in 
2005, Shyamsundar et al. published what at the time was a very large 
expression series surveying normal human tissue from 115 subjects in 35 
different tissue types. This study again reaffirmed previous results showing 
tissue-specific gene expression and transcript abundance. This work 
reaffirmed that tissues cluster separately but also cluster in large part based 
on anatomical location, cellular composition and physiological function 
(Shyamsundar et al. 2005).  
 
There were also some critical early studies that made use of highly parallel 
gene expression assays to survey gene expression variation using model 
organisms. In 2001, Jin et al. published a study in Drosophila melanogaster. 
Within this fly model, they found that gene expression was strongly affected 
by gender and very little by age. They also found that interactions between 
gender and genotype were present and affected up to 10% of the fly’s 
expressed genome. This work concluded that there are genotypic 
contributions to transcriptional variation (Jin et al. 2001). In 2002, Oleksiak 
and colleagues surveyed population differences in teleost fish. In this study 
they found expression variation between populations of teleost fish but also 
variation in 18% of expressed genes between fish from the same population 
(Oleksiak, Churchill and Crawford 2002). A study of four natural population 
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isolates in wine Yeast also identified that the genetic variation in these natural 
populations affected variation in gene expression on a genomic scale 
(Townsend, Cavalieri and Hartl 2003). 
 
Early surveys of gene expression were also performed in mammalian model 
organisms and compared to gene expression in humans. In 2002, Su et al. 
published a study comparing gene expression in human and mouse tissues. 
This study used 46 human and 45 mouse tissues. Similar to the Warrington 
study of 2000 and the Hsiao work of 2001 they found that 6% of genes were 
expressed across all tissues again re-enforcing the possibility that these 
genes are housekeeping genes (Warrington et al. 2000; Hsiao et al. 2001; Su 
et al. 2002). Each individual tissue expressed 30-40% of the assayed genes, 
and 90% were expressed in at least one tissue. Based on an analysis of 
variance (ANOVA) they found that 78% of genes are differentially expressed 
in mice and 82% are differentially expressed in humans (Su et al. 2002). A 
study, in 2002, by Enard et al. compared the differences between human and 
non-human primates for gene and protein expression, as well as three mouse 
species (Enard et al. 2002). In primates they looked at both gene and protein 
expression in blood, liver, and brain from humans, chimpanzees, orangutans, 
and macaques. They found substantial variation between subjects of the 
same species and showed that for blood and liver that human and 
chimpanzee were more similar than chimpanzee and macaque. However, the 
chimpanzee brain cortex was more similar to that of the macaque than the 
human brain samples. Their data suggest an accelerated rate of change in 
gene expression in brain presumably associated with human evolution. This 
result was also supported in their protein work where they identified many 
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species-specific expression patterns in both gene and protein expression, with 
this pattern being particularly pronounced in human brain (Enard et al. 2002). 
Additional studies have also compared gene expression of cell populations for 
human and other primates and found greater divergence in brain than in liver 
suggesting that approximately 10% of genes differed in expression. These 
studies also suggested the differential expression they detected is likely an 
underestimate based on the regions studied, assays used, and analysis 
methodologies that were based on large differences in expression (Enard et 
al. 2002; Cáceres et al. 2003; Khaitovich et al. 2004, 2005). In 2011, Cain et 
al. published a study of histone modifications, specifically H3K4me3, and 
gene expression between human and non-human primates in LCLs. They 
found that many H3K4me3 localizations are conserved in primates and 
enriched near transcript start sites. H3K4me3 is an epigenetic mark thought to 
promote expression. As expected, highly expressed genes are more likely to 
have histone modifications near TSSs than genes with lower expression 
levels. They also found that genes that are differentially expressed between 
primates also had differences in H3K4me3 marks near the TSS. Their 
estimates suggest that up to 7% of expression differences between primates 
are in some part related to H3K4me3 histone modifications (Cain et al. 2011). 
In a study of DNA methylation and gene expression between humans and 
chimpanzees in liver, heart, and kidney tissues it was found that methylation 
patterns between tissues are often conserved between these species. 
However, the authors also found a large number of gene expression 
differences between humans and chimpanzees that had corresponding 
differences in DNA methylation at the promoters of these genes. Based on 
their findings they estimate that 12-18% of gene expression differences 
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between human and chimpanzees may be because of differences in DNA 
methylations in gene promoters (Pai et al. 2011).  
 
In a study published, in 2007, by Storey et al. it was shown that variation in 
gene expression, like genetic variation, is also primarily between individuals 
within a population, and to a smaller degree between populations. Their study 
included individuals of European and African ancestry and analysed 5,194 
genes expressed in lymphoblastoid cell lines (LCL). This study’s results 
suggest that 83% of genes are differentially expressed between individuals 
and 17% between human populations (Storey et al. 2007). A recent study was 
undertaken to consider if local adaptations between human populations are 
driven by gene expression changes and not protein-coding changes. This 
study found that these local adaptations are 10 fold more likely to affect gene 
expression than amino acid changes. Additionally, they found that polygenic 
local adaptations show recent positive selection for (ultra-violet) UV radiation 
response, immune cell proliferation, and diabetes pathways. These results 
support the idea that gene expression changes have driven human adaptation 
(Fraser 2013). 
 
Beyond which genes are expressed in which tissues and at what abundance, 
there are characteristics of these tissue-specific patterns that have also been 
identified. In 2004, Plotkin et al. reported a study considering synonymous 
codon usage in genes that are selectively expressed by tissue. For genes that 
have tissue-specific expression in humans, the authors determined how much 
these genes differ in their encoding of amino acids. The authors describe this 
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difference as the distance between synonymous codon usage. They 
calculated this distance by computing the codon frequency per gene and 
using the frequencies for synonymous codons to compute how the genes 
differ in the encoding of each amino acid. They hypothesize that tissue-
specific codon usage may be a mechanism of protein regulation and tissue 
differentiation through translation rate, modulation based on relative tRNA 
abundance, mRNA folding, and RNA transport. The investigators found that 
the codon usage distinguishes genes expressed in a tissue from those in 
another tissue, and that this codon usage in brains is selectively preserved 
throughout mammalian evolution based on human and mouse data (Plotkin, 
Robins and Levine 2004). In 2004, Yeo et al. published a study that examined 
splicing events in different human tissues. They found that splicing events 
were more prevalent in certain tissues than in others. These alternative 
splicing events were identified in human tissues based on the mining of cDNA 
sequences from Genbank and expressed sequence tags from dbEST from 16 
human tissues. The largest splicing differences found were in brain, testis, 
and liver (Figure 1.4). The brain and testis had the highest level of exon 
skipping, while liver had the highest alternate 3’ and 5’ splice site usage (Yeo 
et al. 2004). In 2012, Barbosa-Morais et al. published a study comparing the 
transcriptomes of vertebrates, spanning 350 million years, considering 
splicing between vertebrate lineages. They found significant differences in 
splicing complexity with the highest complexity found within primates. The 
splicing profiles were more strongly related to species than to organ type, and 
that separation in the profiles occurred within the last six million years. They 
state that species-specific splicing in vertebrates is cis directed; although, 
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there is a subset of pronounced splicing predicted to occur in trans (Barbosa-
Morais et al. 2012). 
 
 
Figure 1.4: These plots show the proportion of alternative splicing (AS) present in 16 
human tissues. The horizontal bars show the proportion of alternatively spliced genes 
(with estimated standard deviation) based on a random sampling of 20 expressed 
sequence tags (EST) from each gene, derived from a human tissue. The four plots 
represent different alternative splice type categories, with the splice types 
schematically represented in the plots. (a) Proportion of AS genes with skipped exons, 
alternative 3’ exon splice sites, or alternative 5’ exon splice sites. (b) Proportion of AS 
genes with skipped exons. (c) Proportion of AS genes with alternative 3’ exon splice 
sites. (d) Proportion of AS genes with alternative 3’ exon splice sites. This figure is 
reproduced from (Yeo et al. 2004). 
 
In 2008, Wang et al. published a RNA-sequencing (RNAseq) based study on 
15 human tissues examining mRNA isoform expression. The authors found 
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that 92-94% of human genes undergo alternative splicing. Their analysis 
found that isoform variation of alternative splicing, cleavage, and 
polyadenylation occurred more often between tissues rather than between 
individuals. They also found that the more tissue-specific isoforms are 
correlated with conserved regulatory regions (Wang et al. 2008). In 2008, Pan 
et al. also published an RNAseq based study examining alternative splicing in 
human tissues. They identified novel splice junctions for 20% of genes, that 
have multiple exons, and that 95% of multi-exon genes have alternative 
splicing events in human tissues. Based on their results and previous studies 
results they estimate that between 6,000 and 10,000 genes are expressed in 
most tissues. Their results also found, as previously reported by Yeo et al., 
that both brain and liver show the highest levels of alternative splicing (Pan et 
al. 2008). Based on the previous findings that splicing appears to be more 
prevalent in brain and testis, de la Grange et al. performed a study of splicing 
in 11 human tissues. They found that cerebellum, testis, and spleen showed 
the largest amount of differentially expressed alternative exons among the 
tissues tested. They also found that this variation was correlated with a larger 
number of splicing factors expressed at higher levels in these three tissues. 
For these three tissues they also found that a larger number of genes had 
higher expression as well (de la Grange et al. 2010). In 2014, Braunschwig et 
al. published a study exploring intron retention as a specific form of alternative 
splicing in mammals. While intron retention is thought to be less prevalent in 
mammals, it is the most common form of alternative splicing in plants and 
unicellular eukaryotes. This study found that intron retention is more frequent 
than previously thought, and serves as a mechanism for the suppression of 
inappropriately expressed transcripts as a form of transcriptome tuning. They 
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formed this conclusion based on finding that as many as 75% of multi-exon 
genes show evidence of intron retention. This retention is correlated to cis 
features, but the retained intron leads to a reduction in expression of the 
transcript through nonsense-mediated decay, nuclear sequestration, turnover, 
local stalling of RNA Pol II, and reduced splicesomal components 
(Braunschweig et al. 2014). 
 
These studies highlight that mRNA expression is often tissue-specific and 
variable across species, populations, and individuals. This variability includes 
not only where genes are expressed but at what abundance and in what form. 
In many of these studies, which considered the variability of expression within 
the same tissue and species, variation between individuals was consistently 
well supported. It is also important to note that even with very similar species 
and tissues of a similar cellular composition there is substantial variation. The 
expressed splice forms, mRNA transcripts, of genes also vary substantially 
between tissues in the same species. Several of the studies that included 
human brain tissues typically found that these tissues often stood out or are in 
the subset of outlier tissues when examining profiling metrics and 
characteristics. The divergence of expression in human brain tissues from that 
of other tissues may be a result of the complexity of the organ and the 
heterogeneity of its cellular composition, but this also likely reflects the biology 
underlying the evolution of the human brain and that gene expression may 
have driven many of the adaptations in this organ. 
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1.3:  Foundations of Expression Quantitative Loci (eQTL) 
Similar to the study of clinical traits and disease phenotypes prior to the 
HapMap Project (International HapMap Consortium 2005), and the arrival of 
high-density SNP chips, the study of eQTL was typically executed by linkage 
based studies in families and then afterwards using association studies in 
populations. Large-scale assessments of the role of genetic variability in the 
control of gene expression have also undergone rapid growth during the last 
decade. The bulk of this earlier work included: linkage based analysis of gene 
expression in CEPH (Centre d'Etude du Polymorphisme Humain; Utah 
residents with ancestry from northern and western Europe) lymphoblastoid 
cell lines and multiple tissues from rat and mouse crosses, and association 
based expression analyses in human lymphoblastoid cell lines (LCLs).  
 
An initial proposal for combining genetic markers and gene expression data 
was from the field of plant biology and termed ‘genetical genomics’ (Jansen 
and Nap 2001). However, much earlier work already existed in understanding 
gene expression difference linked to genetic variants in complex organisms 
and resulting in a morphological phenotype. In fruit flies, it has been show that 
cis-regulatory variation can result in morphological phenotypes such as those 
related to abdominal pigmentation (Simpson, Woehl and Usui 1999; Wittkopp, 
True and Carroll 2002), wing pigmentation (Gompel et al. 2005; Prud’homme 
et al. 2006), the distribution of bristles (Simpson, Woehl and Usui 1999; Skaer 
and Simpson 2000; Sucena and Stern 2000), and larval denticle bands 
(Sucena and Stern 2000; Sucena et al. 2003). While specific phenotypes 
have shown strong association to genetic variation in gene expression, LD 
often confounds the ability to determine the precise region of sequence 
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variation for these specific phenotypes (Karp et al. 2000; Beldade, Brakefield 
and Long 2002). More recently, Bickel et al. undertook a study in fly to identify 
causative genetic variants for cuticular pigmentation in flies. The fly genome 
contains high sequence variation and low LD, which lends itself to finding 
causative variants within a QTL. The authors focused on alleles segregating 
within the bric-a-brac locus, which has a large effect on cuticular 
pigmentation. They found that cis-regulation modulates transcription at the 
locus and that the variation has a cumulative effect through three functional 
regions: promoter, tissue-specific enhancer, and polycomb response element 
(Bickel, Kopp and Nuzhdin 2011). In stickleback fish, changes in skeletal 
morphology result from cis-regulatory variation. These genetic variations 
result in changes to the dorsal spines and pelvic girdle resulting in a loss or 
reduction in skeletal armour between different species of sticklebacks (Shang, 
Luo and Clayton 1997; Marcil et al. 2003; Cresko et al. 2004; Shapiro et al. 
2004; Shapiro, Bell and Kingsley 2006). 
 
Human phenotypic traits had also previously been linked to genetic variation 
in cis-regulation as well. Resistance to malaria results from cell-specific 
expression linked to cis-regulatory variants near Duffy blood group chemokine 
receptor (DARC), which is a receptor that binds interleukin 8 (IL8) (Horuk et 
al. 1993; Chaudhuri et al. 1994; Tournamille et al. 2004). DARC is expressed 
in multiple cell and tissue types. The expression of DARC in erythrocytes is 
the entry point of the malarial parasite Plasmodium vivax (Pogo and 
Chaudhuri 2000). However, there are DARC haplotypes that segregate 
between human populations that are resistant to infection from this parasite. 
This resistance results from the Duffy protein not being expressed in 
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erythrocytes while still being expressed in other tissues. The cell-specific lack 
of expression in erythrocytes, for the infection-resistant haplotype, is the result 
of disrupting of a binding site for the transcription factor GATA binding protein 
1 (GATA1) (Miller et al. 1976; Chaudhuri et al. 1995; Peiper et al. 1995; 
Tournamille et al. 1995; Iwamoto et al. 1996; Hadley and Peiper 1997). This 
example shows how a single cis-regulatory variant results in a phenotype with 
restricted pleiotropy and a significant fitness gain. It has also been shown in a 
studies of variation near DARC that this locus shows strong positive selection 
in geographic populations where malaria is prevalent (Hamblin and Di Rienzo 
2000; Hamblin, Thompson and Di Rienzo 2002).  
 
An early application of integrating genetics and gene expression in humans 
was published by Rockman and Wray in 2002. In this study, they published a 
survey of experimentally validated functional cis-regulatory variants. They 
carried out the study to understand if cis-regulatory variants may represent 
evolutionary changes in phenotypes. They authors looked at 140 
polymorphisms possibly involved in the regulation of 107 genes in humans.  
They suggested that genetic variation contributes to variation in transcription 
rates and therefore to phenotypic variation. This conclusion was based on the 
observation that variation in functional cis-regulatory regions is widespread, 
can lead to large gene expression difference for 63% of the genes they 
assayed, and that on average humans are more heterozygous at cis-
regulatory sites than at protein coding bases. This difference in heterozygosity 
suggests that cis-regulatory regions may store more heritable phenotypic 
variation and have higher substitution rates (Rockman and Wray 2002). A 
similar study, by Yan et al., also found evidence of variation in gene 
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expression in humans. In this study, it was observed that the difference in the 
expression of alleles from heterozygous individuals was more than 20%. This 
study examined allelic expression in 13 genes using 96 individuals from 
CEPH families. Allelic variation in mRNA expression was observed in 6 of the 
13 genes. Three of the families, which were informative in displaying allelic 
variation, were fully consistent with Mendelian inheritance. Thus they 
concluded that cis-acting variation in gene expression is relatively common 
among normal individuals (Yan et al. 2002). In 2003, Bray et al. published a 
similar study of allele-specific expression. This study was based on 
expression in brain tissue from 60 subjects. The alleles selected for study 
were from common heterozygotes in 15 genes expressed in human brain. 
The brain tissues were frontal, parietal, and temporal cortex. Allele-specific 
expression differences were detected in 7 of the 15 genes examined. The 
detection of allele-specific expression was based on a difference of at least 
20% in allele representation in at least one individual. The gene DTNBP1, 
encoding dystrobrevin binding protein 1, showed allele expression differences 
in multiple individuals, which exceeded 50% on average (Bray et al. 2003).  
 
An early implementation of an eQTL study, on a genome-wide scale, was 
published by Schadt et al. in 2003. This study was performed with small 
sample sizes but for multiple species using microsatellite markers and 
expression data to perform linkage based analysis to identify eQTL in maize, 
murine, and human samples. Additionally, the authors were able to show, in 
the murine samples, an example of a clinical quantitative trait locus (cQTL) for 
obesity localizing together with an eQTL (Schadt et al. 2003). A 2003 study, 
from Cheung et al., using human LCLs, was a key step in determining that 
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genetics contributes to variation in gene expression in humans. This study 
used early arrays with pooled samples from 35 CEPH subjects to identify 
genes expressed with high variation. To validate their results they ran RT-
PCR on five of the genes, with the highest variation, in 49 unrelated CEPH 
subjects; children from 5 CEPH families, and 10 pairs of monozygotic twins. 
These authors found that expression variation was higher in unrelated 
individuals than in siblings and that the expression variation was lowest in the 
monozygotic twins. Expression variation in the unrelated subjects was 3 to 11 
times higher than in twins, while in siblings this variation was 2 to 5 times 
higher than in twins. This suggested that a component of expression variation 
is genetic and provided critical evidence for heritability in gene expression 
(Cheung et al. 2003). Linkage-based studies in additional CEPH families 
continued, making use of SNPs instead of microsatellite marker panels to 
capture genetic variation, and using regression methods to associate genetic 
variation with gene expression in addition to linkage analysis methods (Monks 
et al. 2004; Morley et al. 2004). The Monks et al. study, from 2004, showed 
expression heritability results in a cohort of 167 CEPH subjects. They found 
that 31% of genes were heritable (Figure 1.5). They also found that for genes 
with a linkage-based eQTL, that 75% of these had high heritability. 
Additionally, later studies suggest that the heritability of gene expression 
appears to affect 40-90% of genes, with median estimates of 15-35% (Monks 
et al. 2004; Dixon et al. 2007; Göring et al. 2007; Emilsson et al. 2008; Price 
et al. 2011; Grundberg et al. 2012).  
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Figure 1.5: Histogram of heritability estimates for genes that are differentially 
expression and significantly heritable, based on a false-discovery rate of 5%. This 
figure is reproduced from (Monks et al. 2004). 
 
After the early eQTL studies, which were typically family based, more 
population-oriented studies of eQTL began to be performed. In 2005, Stranger 
et al. published a seminal eQTL study based on expression in LCLs from 60 
unrelated CEPH individuals from HapMap. Three hundred and seventy four of 
the 630 genes assayed, from ENCODE regions on chromosomes 20 and 21, 
were reliably detected and used for eQTL analysis. They ran cis- and trans-
eQTL analysis making use of multiple association methods for comparison 
purposes. For this study, the authors considered a cis region as all variants 
that are 1 Mb proximal to the gene being tested, and trans as all variants 
outside (distal) of the cis region. This study also performed comparisons of 
different methods of multiple test correction techniques for their cis and trans 
results. In cis, they found between 10 and 40 significant eQTL depending on 
the test and correction method used, and very little evidence for reliable trans-
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eQTL. This study also showed early methods for correcting for polymorphisms 
within the expression probe (Stranger et al. 2005). The polymorphism within 
expression probe is a critical assay artefact to correct for when performing 
eQTL analysis, when the expression levels are measured using a microarray. 
The artefact arises based on how the typical microarray chip works, and how 
the probes on the chips are designed. Typically, the probes are designed 
based on an N-mer sequence such that the unique transcript to be measured 
by the probe will hybridize to the matching unique transcript’s sequence, when 
the transcript is present in the sample. The expression abundance, for the 
transcripts hybridized to the chip, can then be quantitatively measured based 
on the probe’s relative intensity. However, the N-mer probe is typically 
designed from a transcript’s sequence based on a reference genome and 
therefore variation from the reference sequence is not accounted for. This 
polymorphism within the probe can affect the hybridization of the transcript 
fragment to the chip resulting in a biased measurement of the transcript’s 
abundance, usually a decrease in expression. This artefact can bias cis-eQTL 
analysis, as the variant within the assay probe may be in LD with the variant 
being tested against the transcript’s expression level resulting in a false 
positive result. Cheung et al. also published a regional and genome-wide 
population based eQTL study in 2005. This study was performed using 57 
unrelated CEU (CEPH; Utah residents with ancestry from northern and 
western Europe) individuals from the HapMap Project. The study used a 
regression based method and a dense SNP marker set, composed of 770,000 
SNPs, to associate genetic variation with variation in gene expression for 
genes that had previously been found to have an eQTL in their earlier study 
using a linkage based analysis method (Cheung et al. 2005). 
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These early studies leveraged new technologies, and a growing base of 
reference genetic information to build the foundation for eQTL work. In 
combination, they showed the feasibility of this approach, and revealed critical 
insights into the genetic regulation of gene expression.  
 
1.4: Rapid Expansion of the eQTL field of study 
Continuing with a population-based association approach to eQTL, a study 
was conducted in all unrelated HapMap individuals, totalling 210 individuals 
from the four Phase II HapMap populations: CEU, YRI (Yoruba in Ibadan, 
Nigeria), JPT (Japanese in Tokyo, Japan) and CHB (Han Chinese in Beijing, 
China). Within this study, the genetic variation included both SNPs as well as 
CNVs (copy number variants) and the expression phenotypes of 
approximately 14,000 mRNA transcripts, from LCLs, were analysed. Based 
on an analysis of cis-eQTL, the authors identified 1061 genes with an eQTL 
where 86.3% were correlated with SNPs, 17.7% with CNVs, and 1.3% with 
both variant types (Stranger et al. 2007). Moffet et al. published a disease 
relevant study of eQTL in a genomic region associated with childhood 
asthma. A genome-wide association study (GWAS) was performed using the 
SNPs and transcripts within this region resulting in the finding that an eQTL 
for ORMDL3 may contribute to the risk of childhood asthma (Moffatt et al. 
2007). In a large linkage-based eQTL study, which included lymphocyte 
samples from 1240 subjects, the authors found that 85% of detected 
autosomal transcripts were heritable. Heritability is an estimate how much 
variation in a phenotype or trait is due to genetic variation between individuals 
in a population. The subjects included in this study were recruited as part of a 
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heart study, which allowed the authors to integrate their eQTL results with 
linkage based QTL analysis of high-density lipoprotein cholesterol levels, in 
these subjects. Based on the integrated results they found that cis-regulatory 
variants for vanin 1 (VNN1) affect high-density lipoprotein cholesterol 
concentrations (Göring et al. 2007). In 2007, Libioulle et al. published a 
GWAS study for Crohn’s disease, with replication, and identified two 
previously known loci and a novel locus associated with the disease. The 
novel locus was located within a 1.25 Mb gene desert on chromosome 5. 
They found that the Crohn’s disease associated variants within this locus 
were also part of an eQTL for prostaglandin E receptor 4 (PTGER4), the gene 
most proximal to the GWAS locus (Libioulle et al. 2007). These studies and 
approaches have all demonstrated that genetic variability can be correlated 
with changes in gene expression (Gilad, Rifkin and Pritchard 2008; Cookson 
et al. 2009). However, most of these studies thus far have primarily used 
human LCL (lymphoblastoid cell lines) as the tissue to assay for gene 
expression phenotypes or have used non-human mammalian tissue (Hovatta 
et al. 2005, 2007; McClurg et al. 2007).  
 
It is in the context of this described work that I began my doctoral research. 
During the period of time I have been working on my thesis, investigating 
eQTL in human brain tissues, the eQTL field has progressed a great deal, 
moving from an area of relatively sparse activity, to one that is central to our 
understanding of the biologic consequences of genetic variability and the 
interpretation of non-coding genetic variability associated with disease. This 
thesis describes the contributions I have made to the study of eQTL during 
this time and reflects the progress of this growing field, describing maturing 
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methodological and analytical approaches. These contributions focus on the 
study of eQTL in human brain tissues following the progression from using a 
mix of brain tissues, four distinct brain tissue regions, and finally to a specific 
neuronal cell type in the brain, as well as a progression in the methods used 
to identify eQTL. 
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2: Identifying eQTL in Human Cortical Tissue  
(Myers, Gibbs et al. 2007a) 
Statement of Contribution to this Research: 
I was involved in the conception and design of this study, including choice of 
expression platform, and selection of tissue. I performed data quality control, 
data analysis, and data interpretation. I co-drafted and edited the manuscript. 
Myers AJ and Hardy J were also involved in the conception, design, choice of 
platform, and tissue selection. Myers AJ, Hardy J, Webster JA and Holmans P 
and I drafted and edited the manuscript. Webster JA and Holmans P were 
also involved in the multiple test correction portion of the data analysis. I was 
not involved in the collection of the tissue samples or the generation of the 
genotype and mRNA expression data. Coordination of tissue collection was 
performed by Myers AJ and Hardy J. Genotyping of the samples was 
coordinated or performed by; Webster JA, Craig DW, Pearson JV, Zismann 
VL, Joshipura K, Huentelman MJ, Hu-Lince D, and Coon KD. Generation of 
mRNA expression data was coordinated or performed by; Myers AJ, Rohrer 
K, Zhao A, Marlowe L, Kaleem M, Leung D, Bryden L, and Nath P. 
 
2.1:  Introduction 
We initiated an eQTL analysis in human cortical tissue using whole-genome 
genotyping and gene expression data. This study was one of the first whole-
genome eQTL studies performed in human neurological tissues and one of 
the few early eQTL studies published based on a human tissue that was not 
LCL-based.  
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Our selection of brain tissue for this work was based on several factors. First, 
and primary of them was that our laboratory studies the genetic and etiologic 
basis of neurological disease; thus, this is our tissue of interest. Second, it has 
previously been shown that mRNA from post-mortem human brain can be 
utilized for the study of gene expression (Gilbert et al. 1981). Third, it has 
previously been shown that disease associated loci, including those related to 
neurological disease such as APOE and MAPT, are subject to distortions in 
allelic expression (Lambert et al. 1997; Bray et al. 2004; Myers et al. 2007b). 
At the time of inception of this work, we had begun investing considerable 
resources in identifying the genetic basis of complex disease using genome-
wide genotyping. It was clear from early work that the disease-linked variants 
identified would not be amenable to traditional cell biology and modelling 
approaches, and likely that much of the immediate biologic effect of these 
alleles would be mediated through changes in expression. It has previously 
been shown that heritability of gene expression appears to affect between 40 
and 90% of genes, with median estimates of between 15 and 35% (Monks et 
al. 2004; Dixon et al. 2007; Göring et al. 2007). Thus, we thought it was 
critical to produce a dataset that would allow us to mine the effects of genetic 
risk variants in a disease-relevant tissue.  
 
Based on these priorities and rationale we embarked on the initial work 
described in this chapter. Using human brain samples from approximately 200 
neuropathologically normal individuals, we assayed each sample at 
approximately 500,000 SNPs and 24,000 mRNA transcripts and carried out 
an association-based analysis between genotype and gene expression to 
determine if eQTL could be detected within human cortical tissue.  
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2.2:  Materials and Methods 
2.2.1:  Subjects, National Cell Repository for Alzheimer’s Disease 
(NCRAD) cohort 
(Coordination of tissue collection was performed by Myers AJ and Hardy J.) 
 
We wrote to all the National Institute on Aging Alzheimer Centres and the 
Miami Brain Bank requesting samples. We requested 1 gram of frozen human 
cortex, from neurologically-normal brain, and the following sample 
information: gender, race, age at death, consensus diagnosis, 
neuropathological diagnosis, Consortium to Establish a Registry for 
Alzheimer's Disease (CERAD) scores (Mack et al. 1992; Galasko et al. 1995: 
199), Braak and Braak staging (Braak and Braak 1991), and cortical tissue 
region. We received 279 samples, which met the following criteria: first, they 
were self-defined as ethnically of European descent; second, they had no 
clinical history of stroke, cerebrovascular disease, Lewy bodies, or co-
morbidity with any other known neurological disease; third, the donor had 
been assessed by a board certified neurologist and where available had a 
Braak and Braak score < 3 (43% of controls used for this study assessed) or 
a CERAD score indicating either sparse or no neuritic plaques (34% of the 
controls used for this study assessed); and fourth, they had an age at death 
greater than 65 years. Of the received samples, 201 were successfully 
assayed for genotype and expression data. After excluding samples that were 
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ethnic outliers and samples that were possibly related 193, samples were 
used for analysis.  
 
2.2.2: Assays 
2.2.2.1: Genotyping 
(Genotyping of the samples was coordinated or performed by: Webster JA, 
Craig DW, Pearson JV, Zismann VL, Joshipura K, Huentelman MJ, Hu-Lince 
D, and Coon KD. As this cohort is made up of controls used as part of a 
genome-wide association study of Alzheimer’s Disease, the genotypes were 
assayed as described in that GWAS study (Coon et al. 2007).) 
 
Sample DNA isolated from brain tissue was hybridized to the Affymetrix 
GeneChip Human Mapping 500K Array Set according to the manufacturer’s 
protocols. Allele calls were determined using Affymetrix BRLMM Analysis 
Tool. The BRLMM algorithm is a modification, from Affymetrix, of the robust 
linear model of Mahalanobis distance (RLMM) algorithm developed for calling 
genotypes assayed on the Affymetrix array set. The BRLMM method includes 
a Bayesian step, which improves the estimates of clusters and variances for 
calling genotypes, and was developed for use with the Affymetrix 100K and 
500K chips. The algorithm makes use of data from multiple chips and SNPs to 
train a classifier for calling genotypes. This RLMM algorithm was proposed to 
replace Affymetrix’s initial Dynamic Model calling algorithm. For evaluation of 
the RLMM algorithm, the authors applied it to Affymetrix 100K SNP array data 
and compared the results to the existing Affymetrix Dynamic Model algorithm 
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using genotypes from The HapMap Project for comparison (Di et al. 2005; 
Rabbee and Speed 2006).  
 
The Affymetrix GeneChip 500K set is composed of two arrays each capturing 
approximately 250,000 SNPs. One array uses the Nsp I restriction enzyme 
and the other uses Sty1 to capture 262,000 and 238,000 SNPs respectively. 
Each SNP is represented on the array by a set of 24 or 40 different 25-mer 
oligonucleotides. Each SNP is interrogated by a 6- or 10-probe quartet, and 
each probe quartet is made up of a perfect match and mismatch probe per 
allele. Based on the array’s design and optimization criteria the arrays include 
a SNP every 5.8 kilobases, on average, providing ~65% coverage of genetic 
variation within the HapMap II CEU population, the SNP selection was not 
based on haplotype tagging variants (Barrett and Cardon 2006). The 
Affymetrix GeneChip genotyping arrays are a microarray-based platform for 
assaying genotypes based on hybridization (Figure 2.1). Matsuzaki et al., 
described the chip platform in 2004, based on the 100K array set. The 100K 
array simultaneously assays approximately 116,000 SNP on an 
oligonucleotide array. They achieved call rates of 99% and reproducibility 
rates of 99.97%. Based on an analysis of trios, from the HapMap Project, the 
authors claim an accuracy of 99.7% in the resulting genotypes. The 100K 
array’s design is based on including a marker approximately every 24 Kb in 
the genome, and almost 105,000 markers were common SNPs with a minor 
allele frequency greater than 5% (Matsuzaki et al. 2004).  
	   96	  
Figure 2.1: Cartoon of the Affymetrix GeneChip protocol. Total genomic DNA from a 
sample is digested with a restriction enzyme (Nsp I or Sty I; Nsp I is shown). The 
digested fragments are ligated to adaptors. The adaptor-ligated DNA fragments are 
then amplified, fragmented, labelled, and hybridized to the chip. This figure is 
reproduced from Affymetrix product literature. 
 
2.2.2.2: mRNA Expression 
(Generation of mRNA expression data was coordinated or performed by; 
Myers AJ, Rohrer K, Zhao A, Marlowe L, Kaleem M, Leung D, Bryden L, and 
Nath P.) 
 
Sample RNA was reverse transcribed into complementary RNA (cRNA) and 
biotin-UTP labelled using the Illumina® TotalPrep™ RNA Amplification Kit 
from Ambion, Inc. (catalogue # L-1755), based on the Eberwine technique 
(Van Gelder et al. 1990). The cRNA was quantified by three replicate 
measurements using a Nanodrop spectrophotometer (Thermo Scientific, 
Wilmington, Delaware, USA). The cRNA was then hybridized to Illumina 
HumanRef-8 version 1 Expression BeadChips using standard protocols. Six 
to eight chips (24-32 control samples) were run in parallel for each 
 
 
 
Figure removed. 
Third party copyright permission could not be obtained. 	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hybridization batch. Average detection scores across each expression chip 
were greater than 0.99.  
 
The Illumina Sentrix HumanRef-8 v1.0 Expression BeadChip assays the 
expression levels of approximately 24,000 human Refseq transcripts. The 
Illumina Sentrix BeadChip arrays use 50-mer sequence probes designed to 
capture, through hybridization, specific transcripts based on the transcript’s 
Refseq sequence. The Illumina expression arrays are a single colour system 
where hybridized transcripts are stained with streptavidin-Cy3 and 
quantitatively detected fluorescence emission. Each gene-specific probe 
contains an additional 29-mer address sequence for probe identification 
purposes and is then attached to a bead, this combination of bead and gene-
specific oligonucleotide is refered to as a bead-type (Figure 2.2). Each bead 
on the array will have hundreds of thousands of these gene-specific probe 
and address oligomers attached and then the beads are assembled onto the 
array platform. The beads assemble spontaneously into more than 1.6 million 
etched microwell pits, allowing each bead-type to have more than 30-fold 
redundancy on the array on average. After the beads are assembled onto the 
array, a hybridization procedure is performed to map the array using the 
address portion of the bead-type, which also validates the hybridization 
performance of every bead on the array. Each Illumina BeadChip includes 
multiple separate arrays on the chip, where an individual sample is hybridized 
to an array and multiple samples are run per BeadChip, one per array. The 
Illumina HumanRef-8 BeadChip contains eight arrays allowing eight samples 
to be assayed per chip. Based on Illumina’s technical documentation the 
arrays have a less than 0.017% false positive rate for differential expression 
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between technical replicates. Illumina also suggests that the BeadChip 
expression measures correlate well with gene expression measured by 
quantitative real-time PCR. For comparison with quantitative real-time PCR 
measures, Illumina measured ratios of 20 genes from two human tissues and 
found a strong correlation (R2 = 0.9328) between the measures from the 
Illumina BeadChip and quantitative PCR. 
Figure 2.2: Cartoon of an Illumina expression bead-type. Each transcript is captured by 
a transcript-specific probe; this probe is a 50-mer sequence designed to match a 
unique portion of the transcript’s reference sequence. The 50-mer probe is attached to 
a 29-mer address sequence so the probe can be identified. The probe and address 
oligonucleotide is then covalently attached to a bead. While this cartoon shows a 
single oligonucleotide attached to the bead, for simplicity, actually each bead has 
hundreds of thousands of these same gene-specific oligonucleotides attached. This 
figure is reproduced from Illumina product literature. 
 
2.2.3: Data Analysis 
2.2.3.1: Genotype Data 
The following minimum genotype cut-off values were used during analysis: 
per sample call rate of at least 90%, per SNP call rate of at least 90%, per 
SNP minor allele frequency of at least 1% and non-significant (p-value > 0.05) 
for Hardy Weinberg Equilibrium test. The resulting sample genotyping call-
rate had a mean of 97% and range 90%- 99%. Prior to analysis of the 
 
 
 
Figure removed. 
Third party copyright permission could not be obtained. 	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366,140 SNPs the chromosome physical positions for each SNP were re-
annotated from National Center for Biotechnology Information (NCBI) dbSNP 
based on Genome Build 36. Information about the ethnic structure of our 
cohort was obtained using the program Structure (Pritchard, Stephens and 
Donnelly 2000; Falush, Stephens and Pritchard 2003), and three ethnic 
outliers were removed (Figure 2.3). Structure was run using genotype data 
based on seven cohorts to examine ethnic bias within our series. The cohorts 
consisted of the control subjects used in this study, US Alzheimer’s cases, US 
controls from the Coriell Cell Line Repository and samples from the four 
HapMap populations. All of these cohorts were run on either the Affymetrix 
500K or the Illumina 550K genotyping platforms. Of the SNPs that overlapped 
between the Affymetrix and Illumina platforms, 2,035 were used in the 
analysis, where these variants were greater than 1 megabase apart, had a 
call rate greater than 98%, and a minor allele frequency greater than 10%. 
The SNPs were filtered on this basis to break up any LD that may exist 
between the remaining variants so the results would not be biased. The 
linkage model that Structure uses to detect population structure can be biased 
to overestimate divergence between ancestral populations and infer artificial 
admixture if SNPs in strong LD are included in the analysis (Falush, Stephens 
and Pritchard 2003). There were three ethnic outliers within the population 
used for this study. Two were of possible Asian descent (WGACON-185 and 
WGACON-194) and one of likely African descent (WGACON-66). We next 
examined the degree of relatedness among the samples within our cohort by 
using the pairwise identity-by-state (IBS) and identity-by-descent (IBD) 
analysis available in the PLINK analysis toolset (Purcell et al. 2007). The 
IBS/IBD analysis, using PLINK, estimates a genome-wide IBD measure 
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between each pair of samples. This estimate, based on the sharing of alleles 
between each pair of samples, can identify individuals that appear more 
similar to each other than expected by chance (i.e. relatedness). Five samples 
were excluded based on having a high degree of relatedness to another 
subject in the cohort, likely subjects from the same family. Subjects removed 
based on being likely related to another subject with the cohort were: 
WGACON-2, WGACON-107, WGACON-149, WGACON-216 and WGACON-
101. 
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2.2.3.2: mRNA expression data 
All expression profiles were extracted and rank-invariant normalized (Schadt 
et al. 2001; Tseng et al. 2001; Workman et al. 2002) using the Illumina 
BeadStudio software. In rank invariant normalization, a subset of gene probes 
are identified and used to set the parameters for normalization. This subset of 
gene probes is selected based on whether or not the probe’s rank changes 
across the samples, i.e. rank invariant. A gene’s probe is rank invariant if the 
probe’s expression intensity relative to other genes (rank) within a sample 
maintains the same relation across all samples. Prior to analysis of the mRNA 
transcripts, chromosome physical positions for each transcript’s probes were 
re-annotated from NCBI’s Entrez Gene based on Genome Build 36. Rank-
invariant normalized expression data were log10 transformed and missing 
data was encoded as missing, not as a zero level of expression.  
 
2.2.3.3: Selection of traits for analysis 
Transcripts that were detected in less than 5% of the sample series were 
excluded from analysis, based on subjects that passed all genotype-based 
quality filters. Based on this detection criterion 14,078 mRNA transcripts were 
selected for expression quantitative trait loci analysis. 
 
2.2.3.4: Expression Quantitative Trait Loci Analysis 
For the eQTL analysis, the PLINK analysis toolset was used to perform a 1 
degree of freedom allelic test of association. Briefly, the expression level of 
each transcript per sample was regressed on the number of minor alleles (0, 1 
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or 2) for the 366,140 SNPs that met the cut-off criteria to compute the effects 
of allele dosage on expression level. The analysis results were then 
separated into cis and trans associated SNP/transcript pair sets based on 
annotations. Cis SNPs were defined as those located within the genomic 
region that includes the gene encoding the transcript. The boundaries of the 
cis-genomic region were defined as 1 megabase (Mb) from the 5’ end of the 
transcript and 1 Mb from the 3’ end of the transcript. To account for missing 
expression data, results where there were not at least three expression data 
points for the minor homozygotes (BB genotype) were removed. 
 
2.2.3.5: Corrections for multiple tests 
(Webster JA and Holmans P were involved in the design and execution of the 
multiple test correction.) 
 
The frequentist significance testing approach is one of the most common 
employed in genetics and most genetic researchers use p-values to show 
statistical significance within their results (Sham and Purcell 2014). Many 
variants are typically tested in genetic analyses leading to a higher test 
burden, especially under a genome-wide study. A significance threshold of a 
p-value less than 0.05 is typically used, resulting in a 5% chance of a false-
positive result. However, with many tests being performed, assuming 
independence of tests, each test using this threshold still carries this 5% 
chance of a false positives so performing many tests increases the number of 
possible false positives. The traditional approach to correct for the multiple 
tests being performed is a Bonferroni correction. The Bonferroni correction 
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adjusts the threshold of significance based on the number of independent 
tests being performed while maintaining a target family-wise error rate, 
typically 5%. However, for tests performed based on genetic variants many of 
these variants do not represent independent tests, as many of the variants are 
correlated through linkage disequilibrium. Another common approach for 
multiple test correction is to computationally generate an empirical distribution 
of smallest p-values based on repeated random swaps of the data. Random 
swapping breaks the trait and genotype relationship and then by comparing 
the p-value from the real data to the generated distribution an empirically 
adjusted p-value can be calculated (North, Curtis and Sham 2002).  
 
To correct for the multiple tests performed in this study, an empirical 
distribution was created by randomly permuting the subject identifiers within 
the transcript expression data. One thousand of these permuted datasets 
were generated, the subject identifiers where swapped simultaneously for all 
transcripts within the dataset. These permuted dataset were then analysed in 
the same way as the actual data. For each dataset, the minimum p-value for 
each transcript/SNP association was recorded. A transcript-specific genome-
wide empirical p-value was obtained for each transcript/SNP association by 
counting the number of simulated minimum p-values for that transcript, which 
were lower than the observed p-value and dividing by 1000. Transcript-
specific genome-wide empirical p-values < 0.05 were considered significant 
for the transcript/SNP association. This provides an estimate of genome-wide 
significance that is robust to non-normality of transcript expression data and 
inter-SNP linkage disequilibrium because the repeated random swapping 
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generates an empirical distribution as well as breaking the trait and genotype 
relationship.  
 
Additionally, a study-wide correction for the number of transcripts tested in 
addition to the number of SNPs tested per transcript was performed. This 
additional correction was performed in two steps for those transcripts where 
an empirical transcript-specific genome-wide significant eQTL was identified. 
This correction was performed in two steps and only for a subset of the 
potentially significant eQTL because of the computational burden of running 
the increasing number of simulations. An additional round of the permutation 
procedure was repeated using 100,000 replicates, in order to obtain a more 
accurate estimate of the empirical p-value. Then one million permutations 
were performed to achieve a distribution sufficient to apply a Sidak correction 
to the transcript-specific genome-wide corrected empirical p-values. The 
Sidak single step p-value adjustment is given by the formula αcorr = 1 - (1 - 
α)C where α corr is the corrected p-value, α is the uncorrected p-value and C 
is the number of tests. This test is slightly less conservative than the 
commonly used Bonferroni correction. In our analysis the number of transcript 
tests was 14,078 such that a αcorr = 0.05 is approximately α = 3.64x10-6. 
Because of computational limitations, transcripts were selected for this test by 
the following criteria: significant transcript-specific empirical p-values less than 
0.00001 and more than 15 associated SNPs. The four transcripts that met 
these criteria were: KIF1B (19 SNPs with transcript specific empirical p-values 
=0), ZNF266 (18 SNPs), RPL14 (17 SNPs), and IPP (27 SNPs). 
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2.2.3.6: Filtering for known Biological and Methodological 
Covariates 
SNP and transcript-associated pairs that had a methodological covariate or 
biological covariate effect were removed from the result set. The 
methodological covariates included: day of expression hybridization, institute 
source of sample, post-mortem interval, and a covariate based on the total 
number of transcripts detected in each sample. The biological covariates 
included: gender, age at death, and cortical region. For the assessment of 
covariate effects we used a conservative approach. In the regression model, if 
any covariate term had an uncorrected p-value of less than 0.05 for a SNP-
transcript pair, that SNP-transcript pair was excluded. This filtering step 
removed 52.2% and 23% of the cis and trans results respectively. 
 
2.2.3.7: Polymorphism(s) in Assay Probes 
To account for any potential confounding effect of SNPs located within the 
transcript hybridization probes on the expression chips, any significant result 
where there was a variant in the transcript probe was removed. In order to do 
this we needed to determine whether known SNPs mapped to the transcript 
probes, thus creating a possible false positive through non-biologically 
relevant differential hybridization. We used the Hapmap II CEU genotyped 
data for this purpose. Hapmap II SNPs that were polymorphic in the CEU 
population were mapped with respect to the transcript probes. R-squared 
values between the significant SNP, within our screen, and the SNP within the 
probe from the HapMap II CEU dataset were then annotated within our 
results. For the transcript probes with a SNP located within the 50-mer 
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hybridization probe it is presumed that a significant correlation between the 
probe’s expression level and a cis-SNP is a false positive as a result of 
hybridization bias when the correlated SNP and the SNP in the probe are in 
LD. This filtering step removed 12.8% of the cis results. The potential 
confounds of polymorphisms within assay probe designs had previously been 
brought to light and we implemented a scan to remove the potential false 
positives from the study. In the concurrent period of this work, Alberts et al. 
published a study of this confound and its potential impact on eQTL studies. 
Their study showed that many mapped local eQTL in genetical genomics 
experiments do not reflect actual expression differences caused by sequence 
polymorphisms in cis-acting factors changing mRNA levels. Instead, they 
indicate hybridization differences caused by sequence polymorphisms in the 
mRNA region that is targeted by the microarray probes. Many such 
polymorphisms can be detected by a sensitive and novel statistical approach 
that takes the individual probe signals into account. Applying this approach to 
mouse and human eQTL data, they found that many local eQTL are falsely 
reported as "cis-acting" or "cis" and can be successfully detected and 
eliminated with this approach (Alberts et al. 2007). 
 
2.2.4: Data and Biomaterial Access 
Expression data and sample information have been deposited in NCBIs Gene 
Expression Omnibus (Edgar, Domrachev and Lash 2002) and are accessible 
through GEO Series accession number GSE8919 (Figures 9.1, Appendix). 
DNA from the samples, employed in this screen, is available upon request 
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through the National Cell Repository for Alzheimer’s Disease (NCRAD), 
Indiana University, USA. 
 
2.3:  Results 
After quality control filtering 193 samples, 366,140 SNPs, and 14,078 mRNA 
transcripts were selected for the eQTL analysis. The analysis was performed 
by treating the expression profile of each transcript as the phenotype, i.e. a 
quantitative trait. A quantitative trait analysis was then performed on the 
genotype and expression data by linear regression to correlate allele dosage 
with expression. In addition, we corrected, by filtering, for several biological 
covariates and methodological covariates (Table 2.1).  
 
Table 2.1: Summary of sample characteristics, which were used as covariates in the 
eQTL analysis. Table adapted from (Myers et al. 2007a). 
 
Correlations between 366,140 SNPs and the expression of the 14,078 
detected transcripts were assessed. In this analysis, after using a permutation 
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based test correction and excluding results with a possible covariate effect, 
852 transcripts were significantly correlated with genetic variation. An 
empirical p-value < 0.05, based on 1000 permutations, was used as a cut-off 
for a per trait significance of the SNP and transcript correlations, an eQTL. 
These significant association results were divided into cis-eQTL and trans-
eQTL based on updated annotations. For this study, cis was defined as those 
associations that involved SNPs that are within the gene or within 1Mb 
flanking either the 5’ or 3’ end of the gene. The trans set are all the correlated 
SNP and transcript pairs that did not meet the cis criteria. Trans results are 
correlated pairs where the SNP and transcript were on different chromosomes 
or the SNP was greater than 1Mb from the transcript on the same 
chromosome. Of the 852 transcripts significantly correlated with genetic 
variants, 73 of these were correlated with one or more cis SNPs and 791 were 
correlated with one or more trans SNPs. While the total number of transcripts 
correlated in trans was greater than those in cis, calculating the proportions of 
significant possible cis and trans ratios revealed a significant enrichment for 
cis associations, with peak enrichment at approximately 20 Kb. The average 
distance, for cis-eQTL, between the SNP and the transcript is 55.4 Kb. On 
average the genetic variation accounts for 18.5% (cis mean is 22% and trans 
mean is 18.1%) of the expression variation for these 852 transcripts. Table 
2.2 shows the results for the top eight transcripts with a cis eQTL.  
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An analysis of the distances of SNPs correlated in cis with transcripts relative 
to the transcription start site (TSS) revealed a relatively symmetric distribution 
(Figure 2.4). This symmetry about the TSS is consistent with results shown for 
cis-eQTL in the HapMap lymphoblastoid cell line (LCL) samples (Stranger et 
al. 2007).  
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Figure 2.4: Distribution of cis-eQTL SNPs relative to the transcription start site (TSS). 
 
It has previously been shown that MAPT expression is affected by the MAPT 
haplotype (Myers et al. 2007b). The cis-eQTL for MAPT in our results is 
consistent with this previous finding, alleles that occur on the major haplotype 
of MAPT (H1) are associated with higher MAPT transcript expression. It 
should be noted that a subset of the subjects included in our eQTL study were 
also used in the MAPT expression haplotype study. This provided an internal 
positive control that based on a genome- and transcriptome-wide analysis we 
can find effects that were previously seen in a candidate gene analysis of 
these samples, where that study was based on real-time PCR expression 
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measures. It has also been shown that the tau (MAPT) protein expression 
levels in cerebrospinal fluid (CSF) vary with genetic variation at this locus 
(Figure 2.5) (Laws et al. 2007). In the Laws et al. study, their approach was to 
attempt to fine map the association of genetic variation on the H1c haplotype 
in the MAPT region with Alzheimer’s disease (AD). Their approach made use 
of associating variants in this region with changes in tau protein levels in CSF, 
in subjects from Germany. Neurofibrillary tangles are present in AD pathology, 
which suggests a role for microtubule-associated protein tau (MAPT) in AD. 
Their analysis suggested that the AD locus could be narrowed to a region in 
close proximity of the SNP, rs242557, as this variant is correlated with CSF 
tau levels. The SNP, rs242557, is a haplotype tagging SNP for the H1/H2 
haplotypes in the MAPT region and more specifically can be used to tag a 
sub-haplotype in the region, H1c, associated with AD (Laws et al. 2007). 
 
Figure 2.5: Plot showing the linear relationship between the genotypes of rs252557 and 
protein levels of tau in CSF. CSF levels per individual are shown according to the 
individual’s genotype. Mean CSF levels and standard deviation of show next to the 
genotype groups. Linear regression of the allele dose with CSF levels results in a 
significant positive correlation with the A allele. Figure reproduced from (Laws et al. 
2007). 
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While the MAPT locus did not contain the strongest eQTL found in this 
analysis, it is of importance because of its link to many neurodegenerative 
diseases, including tauopathies and Parkinson’s disease (Simón-Sánchez et 
al. 2009; Höglinger et al. 2011). Also, as discussed in the introduction to my 
thesis, this region of the genome contains a large block of LD resulting from 
the presence of a genomic inversion that limits the recombination between the 
H1 and H2 haplotypes in the region. As such, we should see many cis SNPs 
correlated with the MAPT transcript; however, our initial analysis did not 
reveal this expected pattern of association. Upon further investigation of the 
cis signal it is apparent that there is association signal for the eQTL over the 
extended region of LD; however, much of the signal is just below the p-value 
cut-off threshold used and thus excluded from our significant results set 
(Figure 2.6). 
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Figure 2.6: Manhattan plot showing this region’s eQTL p-values for an mRNA transcript 
for the gene MAPT. Each point represents the p-value for a specific SNP along 
chromosome 17 that is cis to the MAPT transcript. Also included in the plot are the 
recombination rates (right axis) as a dark grey continuous line based on HapMap data. 
Threshold for significance is denoted by horizontal dashed line. The relative position 
of the gene is the labelled arrow centred near the bottom of the plot. The direction of 
the arrow is the gene’s strand. 
 
Another gene with an eQTL, that has been previously reported in population 
based eQTL studies in human lymphoblastoid cell lines, is ribosomal protein 
S26 (RPS26) (Cheung et al. 2005; Stranger et al. 2005). This gene is also 
found to have an eQTL in our analysis (Figure 2.7). 
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Figure 2.7: Shown is an eQTL for RPS26 present in brain and also previously identified 
in eQTL analyses in LCLs. (a,b) Cheung et al. reported a significant association with 
the variant, rs2271194, which is in complete LD with two out of the six associated 
SNPs from our eQTL analysis in brain, including rs11171739, which was the SNP that 
gave the strongest association in brain. (a). Boxplot shows the linear relationship 
between genotype (x-axis is genotype allele dose), for rs11171739, and RPS26 
expression (y-axis is log10 normalized expression intensity) in brain. The boxplot 
shows expression summaries for the three genotype groups where top bar is 
maximum observation, lower bar is minimum observation, top of box is upper or third 
quartile, bottom of box is lower or first quartile, middle bar is median value. (b) LD plot, 
using the CEPH HapMap data, shows that the variants, significantly correlated with 
RPS26 expression, rs11171739 in brain and rs2271194 (circled) in LCLs, are in 
complete LD. Complete LD between the two variants suggests it is likely that both 
screens are picking up the same association for RPS26 expression. Haplotype block 
plots were created using Haploview (Barrett et al. 2005). Black boxes with no numbers 
indicate r2 = 1. For r2 values < 1, the r2 value is shown as a percentage in white text in 
the box. Figure reproduced from (Myers et al. 2007a). 
 
2.4: Discussion 
In this study, we found that eQTL are detectable on a genome-wide scale in 
human brain tissues. Of cortically-expressed transcripts, the eQTL analysis 
performed suggests that 6% may have expression profiles that correlate with 
genotype. On average, genetic variation accounted for 18.5% of a gene 
expression variation for transcripts with a significant eQTL in brain. In 2007, 
Dixon et al. also published a large, for the time, eQTL study based on LCLs 
from 400 subjects. Their eQTL analysis included genotypes for 408,273 SNPs 
and 54,675 transcripts (from 20,599 genes). They first estimated the 
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heritability of expression and found that 15,084 (28%) of the transcripts 
showed narrow-sense heritability. For these heritable transcripts, they 
performed an eQTL analysis and found that the peak SNP for each heritable 
expression trait on average accounted for 18% of the heritability. However, 
the more heritable the expression trait the more of the heritability was 
accounted for by the peak SNP from the eQTL analysis (Dixon et al. 2007). 
For the significant cis-eQTL identified, in our study of brain, on average the 
variant was located 55.4 Kb from the transcript. While these types of eQTL 
analysis have previously been performed in LCLs and for select genes in 
primary tissues, including brain, this was one of the first whole-genome eQTL 
studies in a human primary tissue. We found that while numerically more 
trans were detected in the analysis that the eQTL results are enriched for cis. 
Like previous studies, the cis-eQTL we identified are distributed symmetrically 
about the transcription start sites and the eQTL signals are generally larger 
closer to transcript start sites. This pattern likely reflects the LD present 
proximal to the gene and its regulatory regions and the decrease in LD with 
distance. In 2007, Stranger et al. published a study considering eQTL within 
and between populations from The HapMap Project. Their study was done 
using expression from LCLs including all 270 subjects from the HapMap 
Consortium. Their analysis included 2.2 million common SNPs, where 
variants were considered common if the MAF was at least 5% per population. 
They found 1,348 genes with a cis-eQTL and 180 with a trans-eQTL. 
Replication between at least two populations was found for 37% of the cis 
associations and 15% of the trans associations. Their results support an 
enrichment of functional cis-regulatory variants in the human genome 
(Stranger et al. 2007). In 2007, Bergen et al. published an eQTL study for 
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genes commonly studied in cancer research in LCLs. They attempted to 
estimate how many genes may be affected by cis-variation using three 
separate analysis approaches. Their gene expression set included 697 genes 
from 30 LCLs combined with resequencing data from 552 genes, which 
resulted in 30 candidate genes with appropriate variation for a cis-eQTL 
analysis. They found significant cis-eQTL for eight of the genes tested. When 
they compared their results for 14 genes both with and without cis-eQTL 
signal to other literature sources they found 80% of genes with a cis-eQTL 
and 85% of genes without a cis-eQTL were concordant with previous studies. 
Based on their results and previous studies, they estimated that 
approximately 25% of genes have a significant cis-eQTL and that the eQTL 
signal accounts for approximately 30% of the gene’s expression variation 
(Bergen et al. 2007). Based on these studies, there are some similarities in 
their findings when compared to the results from our study of eQTL in brain. 
The similarities include: distribution of cis-eQTL around the transcription start 
site, enrichment for cis- over trans-eQTL, and the average amount of 
expression variation, for transcripts with a significant eQTL, accounted for by 
the associated genetic variation. However, there are also some dissimilarities 
related to the proportion of genes identified with an eQTL and the rate of 
replication with other studies for the eQTL identified. For these dissimilarities, 
in our study of brain, we identified fewer transcripts proportionally than these 
other studies and fewer eQTL that have also been identified by other studies. 
These differences are likely related to the conservative approach we took in 
regards to excluding any result where a covariate had any indication of an 
effect on expression, and this study was one of the first to be performed 
genome-wide in a human primary tissue as opposed to LCLs. 
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This study does replicate an eQTL previously seen in gene specific studies on 
the expression of MAPT, a gene central to several neurodegenerative 
diseases. One of these studies, showing an eQTL for MAPT was performed in 
a subset of the samples included in this cohort (Myers et al. 2007b). This 
eQTL has also been seen previously for MAPT in a study related to 
progressive supranuclear palsy (Rademakers et al. 2005). Protein level 
changes of tau (MAPT) in relation to genotype, a protein QTL (pQTL), have 
also been previously reported in cerebrospinal fluid (Laws et al. 2007). 
Additionally the gene, RPS26, for which we have identified an eQTL, has also 
been reported in two other eQTL studies based on HapMap LCLs (Cheung et 
al. 2005; Stranger et al. 2005).  
 
There are inherent limitations of this study. First, we used more than one brain 
region for the source of tissue; this means that the eQTL detected here may 
well be generalizable across brain tissues, and indeed across cell types, but 
that we may be missing other cell- or region-specific eQTL. Additionally, it is 
unlikely that including multiple brain tissues created false positives related to 
known variation in gene expression between brain tissues, given our 
conservative handling of covariates. It is instead likely that the approach taken 
to deal with covariate effects, and including the tissue region as a covariate, 
resulted in an increase of false negatives. For example, if a transcript did have 
a significant eQTL, where the genetic variation accounted for large amount of 
the expression variation, but at the same time the tissue region covariate had 
a very small but detectable effect for this eQTL, it would be excluded from our 
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significant result set. In 2007, Hovatta et al. published an eQTL study based in 
inbred mice for region-specific brain expression. Their study design was to 
focus on specific brain regions whereas previous studies in mice typically 
used whole brain homogenates of large regions. However, the brain is 
heterogeneous and expression profiles do differ between regions. Their study 
included five brain regions from six inbred mouse strains. They did not find a 
large number of strain-specific genes based on gene expression but did find a 
large number of genes that showed region-specific expression profiles. 
However, for genes showing strain-specific expression profiles these were 
constant across brain regions. Based on an eQTL analysis, they found an 
enrichment of cis-regulators for strain-specific genes but for region-specific 
genes the enrichment was for trans elements. Their results suggest that many 
regulatory networks are tissue-specific and that this suggests that it is 
important to perform eQTL studies in tissues that are relevant to the 
phenotype of interest (Hovatta et al. 2007). A second limitation in our study 
was that the genotyping assay used was an early technology, and while it 
represented a significant advance over previous methods, the coverage of 
known common genetic variation was low compared to more recent 
genotyping platforms. More recent genotyping platforms typically base their 
design on variants that tag HapMap haplotypes thereby increasing the 
coverage of known genetic variability in the human genome captured during 
genotyping. Thirdly, this type of work captures expression in a cross-sectional 
manner, in post-mortem tissue; therefore, it is difficult to address other types 
of expression that may be influenced by genotype, such as (for example) 
induced expression, or sub-cellular localization of transcripts. Another 
limitation was the detection threshold selected in determining whether a 
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transcript was well detected in our study and therefore suitable for eQTL 
analysis. In this study we defined a transcript as well detected if it was present 
in at least 5% of the samples. However, at the same time as part of the 
analysis, in identifying significant eQTL, a filter was applied post hoc requiring 
that all significant eQTL have at least three expression measurements for the 
minor homozygote to ensure that the allele dosage regression was not based 
on incomplete data. This means that many transcripts with a low detection 
rate were tested for an eQTL that would never be considered significant in our 
analysis design. This resulted in an unnecessary increase in our multiple test 
burden as well as computation time. Lastly, as with other eQTL methods of 
the time, this work relies on array-based expression analysis, and this method 
does not capture splicing events as effectively as (for example) sequence-
based methods. These limitations notwithstanding, we believe this study 
provides an initial resource of eQTL in human cortical tissues that is of use for 
researchers investigating loci and gene models related to neurological 
disease. It is likely that further study of eQTL in primary tissues will add to our 
functional understanding of the effect of genetic variation in the human 
genome and serve as a resource in the study of complex traits associated 
with this variation.  
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3:  Identifying eQTL in Distinct Human Brain Regions 
(Gibbs et al. 2010) 
Statement of Contribution to this Research: 
I was involved in the conception and design of this study, including choice of 
genotyping platform, expression platform, and selection of tissue. I performed 
data quality control, data analysis, and data interpretation. I co-drafted and 
edited the manuscript. Cookson MR, Singleton AB, van der Brug MP, 
Hernandez DG, Traynor BJ, and Longo DL were also involved in the 
conception, design, choice of platform, and tissue selection. Cookson MR, 
Singleton AB, and I drafted and edited the manuscript. Nalls MA and 
Singleton AB contributed to the data analysis. I was not involved in the 
collection of the tissue samples or the generation of the genotype and mRNA 
expression data. Coordination and collection of the tissue was performed by: 
Traynor BJ, Troncoso J, Johnson R, Zielke HR, Lai SL, and Ferrucci L. 
Genotyping of the samples was coordinated or performed by: Hernandez DG, 
Traynor BJ, Arepalli S, Rafferty IP, and Lai SL. Generation of mRNA 
expression data was coordinated or performed by: van der Brug MP, Dillman 
A, and Cookson MR. 
 
3.1:  Introduction 
Because of our interest in genomic regulation of expression and neurological 
disorders we embarked upon a series of experiments to provide a brain 
region-specific contextual framework for genetic regulation of gene 
expression. Based on the previous work (Chapter 2) it was apparent that a 
systematic analysis of eQTL in brain tissue was feasible. We embarked upon 
	   122	  
a set of integrated experiments designed to extend this previous work. 
  
We obtained frozen brain tissue from the cerebellum (CRBLM), cerebral 
frontal cortex (FCTX), caudal pons (PONS), and cerebral temporal cortex 
(TCTX) from 150 subjects (a total of 600 tissue samples). We undertook two 
separate assays across this series, genome-wide genotyping more than 
500,000 SNPs and mRNA expression profiling more than 24,000 transcripts in 
all four brain regions. Here I will discuss the results of these experiments, 
particularly in the context of integrated datasets to define expression 
quantitative trait loci (eQTL) and detailing differences and similarities across 
brain regions.  
 
Based on the successful completion and publication of the preceding, ‘pilot’, 
study (Chapter 2) we were able to initiate a second study of eQTL within 
human brain tissues with an expanded study and refined analysis design. The 
expanded study design included collecting and assaying multiple brain tissues 
from each individual, making use of newer and improved assay types and 
applying lessons learned in the ‘pilot’ study to improve analysis design and 
efficiencies. We employed dense tagging-based, whole-genome, SNP 
genotyping thereby improving coverage of genetic variability, within the 
human genome, for cohorts of central European descent. Additionally, we 
used newer versions of gene expression arrays that capture mRNA 
transcripts for known human transcripts based on more recent RefSeq 
information. Improved analysis design and efficiency over the previous work 
were attained in three primary areas: improved covariates, the implementation 
of imputation, and exclusion of inappropriate tests. For covariates we had 
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previously established that biological and technical covariates could have 
significant effects, and thus adjusted expression profiles for covariate 
information prior to eQTL analysis instead of filtering out possible significant 
eQTL where a covariate effect also exists. Using imputation to increase the 
density of genetic markers that are available for testing increases the power 
and ability to fine map the associations. Excluding transcripts that are not 
appropriate for inclusion, prior to eQTL analysis instead of after, reduced both 
the computational and multiple test burden. 
 
This chapter describes this effort and the observations we made relating to 
improved analytical approaches, the improvement in results imparted by 
denser genotype coverage, and the comparison across distinct brain tissues 
from the same individuals. 
 
3.2:  Materials and Methods 
3.2.1:  Subjects, North American Brain Expression Consortium 
(NABEC) 
(Coordination and collection of the tissue was performed by: Traynor BJ, 
Troncoso J, Johnson R, Zielke HR, Lai SL, and Ferrucci L.) 
 
Frozen tissue samples from the cerebral frontal cortex, cerebral temporal 
cortex, cerebellum, and caudal pons were obtained from 150 subjects who 
had donated their brains for medical research. Approximately 100-200 mg 
aliquots of frozen tissue were sub-dissected from each of the 600 samples 
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(150 brains x four regions) resting on dry ice to avoid thawing. Separate 
pieces were cut for DNA extraction to be used in SNP genotyping assays and 
RNA extraction for expression assays. Genomic DNA for genotyping was 
extracted using the DNeasy Blood and Tissue Kit as per the manufacturer’s 
instructions (Qiagen Inc., Valencia, California, USA). Total RNA was prepared 
using TRIzol (Invitrogen, Carlsbad, California, USA). 
 
3.2.1.1:  Subject Characteristics  
One hundred and fourteen brains were sampled from the University of 
Maryland Brain Bank, Baltimore, Maryland, USA. Thirty-six brains were 
sampled from the Department of Neuropathology, Johns Hopkins University, 
Baltimore, either as routine autopsy cases (n = 10), or as part of the National 
Institute on Aging-sponsored Baltimore Longitudinal Study of Aging (BLSA, n 
= 26). All individuals were of non-Hispanic, Caucasian ethnicity, and none had 
a clinical history of neurological or cerebrovascular disease, or a diagnosis of 
cognitive impairment during life.  
 
Summary statistics of the sample characteristics are shown in Table 3.1. The 
most common cause of death was accidental injury (n = 55 cases), followed 
by cardiovascular disease (n = 31), drug intoxication (n = 12), and pulmonary 
embolism (n = 3). Other causes of death included drowning (n = 3), 
respiratory disease (n = 2), compressional asphyxia (n = 1), suicide by 
hanging (n = 1), choking (n = 1), lightning strike (n = 1), liver disease (n = 1), 
mitral valve prolapse (n = 1), myocarditis (n = 1) and diabetic coma (n = 1). 
Cause of death was not available for the remaining 36 autopsies.  
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Table 3.1: Summary statistics of the subject characteristics 	  
3.2.1.2:  Sample Preparation  
(Sample preparation from the tissue was performed by: Traynor BJ, Lai SL, 
Hernandez DG, and van der Brug MP.) 
 
For each of the six hundred samples (150 brains x four regions), 
approximately 5 grams of frozen tissue was sub-dissected at either the 
University of Maryland Brain Bank or at the Department of Neuropathology, 
Johns Hopkins University, and sent on dry ice to the Laboratory of 
Neurogenetics (LNG), NIA. At LNG, 100-200mg aliquots of frozen tissue were 
sub-dissected from each sample. Samples were kept on dry ice to avoid 
thawing. Separate pieces were cut for DNA extraction to be used in SNP 
genotyping assays and RNA extraction for expression assays. Each tissue 
aliquot was stored at -80°C until use.  
 
Genomic DNA extraction for genotyping was performed using the DNeasy 
Blood and Tissue Kit as per the manufacturer’s instructions (Qiagen Inc., 
	   126	  
Valencia, California). DNA concentration was determined using a Nanodrop 
ND-1000 spectrophotometer (Thermo Scientific, Wilmington, Delaware), and 
DNA extraction was repeated using a new tissue aliquot for samples with 
DNA concentration less than 50 ng/uL, or for samples where the 
260nm/280nm wavelength absorption ratio was less than 1.7, indicative of 
significant protein contamination of the DNA sample.  
 
For each of the 600 brain samples, total RNA was prepared from 
approximately 100 mg of tissue using a glass-Teflon homogenizer and 1 mL 
TRIzol (Invitrogen, Carlsbad, California, USA) according to the manufacturer’s 
instructions. RNA samples were re-suspended in RNAse free water to a final 
concentration of > 500 ng/uL.  
  
3.2.2:  Assays 
3.2.2.1:  SNP Genotyping  
(Genotyping of the samples was coordinated or performed by: Hernandez 
DG, Traynor BJ, Arepalli S, Rafferty IP, and Lai SL.) 
 
Genotyping was performed using DNA extracted from cerebellar tissue. SNP 
genotypes were assayed using Illumina Infinium HumanHap550 version 3 
BeadChips (Illumina Inc., San Diego, California, USA) according to the 
manufacturer’s instructions. Genotype data was analysed using the 
Genotyping Analysis Module 3.2.32 within the BeadStudio software version 
3.1.4 (Illumina Inc.). All 150 brain samples had an average call rate of 99.86% 
(range 97.72% - 99.95%).  
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The Illumina HumanHap550 chip assays genotypes for 561,466 SNPs across 
the genome. The Illumina Infinium genotyping platforms are based on the 
Sentrix bead arrays. The Sentrix arrays are a single base-resolution platform, 
which helps avoid some of the sequence complexity that may arise from 
calling genotypes based on oligonucleotide probe arrays. This system is 
based on allele-specific primer extension and includes a two-colour readout, 
one colour for each allele tested (Figure 3.1). Based on the manufacturer’s 
comparisons to PCR-based genotyping assays the Illumina arrays had a call 
rate of 99.7%, reproducibility of 99.96%, and concordance rate of 99.97% 
(Gunderson et al. 2005). In a follow on paper describing the efficiency, 
accuracy and scalability of the Illumina whole-genome genotyping platform 
the authors compared the genotype reproducibility rates based on HapMap 
samples and found that concordance was above 99% (Steemers et al. 2006). 
This array is based on haplotype tagging SNPs and provides 87% coverage 
of known genetic variation in HapMap II CEU population (Li, Li and Guan 
2008).  
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Figure 3.1:  Cartoon of genotyping 
using the Illumina Infinium Sentrix 
arrays. A) Each variant is represented 
by a bead-type where fragmented 
sample DNA binds to a 
complementary probe sequence 
stopping one base before the allele 
being assay. B) Single-base extension 
incorporates one of four labelled 
nucleotides conferring allele-
specificity, extending the probe with 
the correct base. C) Probes are laser 
excited causing the nucleotide label 
emits a colour signal for detection. 
Figure adapted from Illumina 
promotional material. 
 
3.2.2.2:  RNA Expression  
(Generation of mRNA expression data was coordinated or performed by: van 
der Brug MP, Dillman A, and Cookson MR.) 
 
Profiling of 22,184 mRNA transcripts was performed using HumanRef-8 
version 2 Expression BeadChips (Illumina Inc.) in accordance with the 
manufacturer’s protocol. Raw intensity values for each probe were 
transformed using the rank invariant normalization method (Workman et al., 
2002; Schadt et al., 2001; Tseng et al., 2001) using the Gene Expression 
Module 3.2.7 within Illumina’s BeadStudio software. The Illumina Sentrix 
 
 
 
Figure removed. 
Third party copyright permission 
could not be obtained. 	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HumanRef-8 v2.0 Expression BeadChip assays the expression levels of 
approximately 24,000 human Refseq transcripts using 50-mer probes. 
 
3.2.3:  Data analysis 
For each of the four brain regions, a regression analysis was performed on 
the expression intensities generated for mRNA transcript probes. Gender, 
age, post-mortem interval (PMI), tissue source, and hybridization batch were 
included as covariates in each of these analyses. Residuals from the 
regression analysis for each probe were then used as the quantitative trait for 
that probe in a genome-wide association analysis to identify quantitative trait 
loci. These analyses were performed using the assoc function within PLINK, 
which correlates allele dosage with change in the trait (Purcell et al., 2007). 
Each of the four tissue regions were analysed separately, and independent 
genome-wide association analyses were performed looking for quantitative 
trait loci associated with mRNA expression levels (expression QTL; eQTL). 
To correct for the large number of SNPs tested per trait, a genome-wide 
empirical p-value was computed for the asymptotic p-value for each SNP 
using 1,000 permutations of sample-label swapping. To correct for the 
number of traits being tested per tissue region, a false discovery rate (FDR) 
threshold was determined based on the empirical p-values using the fweR2fdr 
function of the multtest package in R (Pollard, Dudoit and van der Laan 2005). 
Empirical p-values were allowed to exceed this threshold if the linkage 
disequilibrium R2 was greater than or equal to 0.7 with a SNP with empirical 
values within the FDR threshold. Keeping SNPs with a sub-significant 
empirical p-value, if they are in strong LD with a SNP significantly correlated 
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with a transcript’s expression, does not alter whether or not a significant eQTL 
is detected for a transcript, but does allow for a broader detection of the edges 
of the locus. The sequences of transcript probes with significant eQTL were 
examined for the presence of polymorphisms, with a MAF > 1%, using CEU 
HapMap data, and if present that eQTL was removed from the result set. 
  
3.2.3.1:  Genotyping data  
The threshold call rate for inclusion of a sample in the analysis was 95%. Two 
samples initially had a call rate below this threshold, but were successfully re-
genotyped using fresh DNA aliquots. Thus, all 150 brain samples had a call 
rate greater than 95%, and were included in the subsequent analyses for 
quality control of the subjects based on their genotypes (average call rate was 
99.86%; range 97.72% - 99.95%, based on the missing procedure within the 
PLINK v1.04 software toolset (Purcell et al. 2007)). 
 
The gender of the samples reported by the brain banks was compared 
against their genotypic gender using PLINK 's check-sex algorithm. The 
check-sex function determines a sample’s genotypic gender based on 
heterozygosity across the X chromosome. Two samples with gender 
discrepancies were detected. One of these arose from a clerical error at the 
brain bank and was included in the analysis after correction of the clinical 
information, whereas the other sample (UMARY1496) was removed from 
subsequent analysis.  
 
To confirm the ethnicity of the samples, Identity-By-State (IBS) clustering, 
principal components (PCA), and multidimensional scaling (MDS) analyses 
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(Price et al. 2006) were performed within PLINK using the genotypes from the 
brain samples that had been merged with data from the four HapMap I 
(International HapMap Consortium 2005) populations (n = 32 Caucasian 
(CEU), 12 Han Chinese, 16 Japanese and 24 Yoruban non-trio samples 
previously genotyped by Illumina and assayed on the Infinium HumanHap500 
version genotyping chips). Outlier detection was based on a sample’s 
distance, for the first and second principal components, being more than three 
standard deviations (S.D.) from the mean of the reported population group for 
those components. Two samples were outliers based on population and were 
excluded from further analysis (UMARY4545, UMARY927) (Figure 3.2). MDS 
is a method for information visualization, particularly for distance metrics. 
MDS aims to place each item in N-dimensional space such that the between-
object distances are preserved as well as possible. PCA is a data 
transformation that converts possibly correlated variables into linearly 
uncorrelated components; where the first component accounts for largest 
variance, the second component the second most variance, and the Nth 
component the least amount of variance. Genotype data of the samples was 
compared to identify cryptic relatedness using the Identity-By-Descent (IBD) 
procedure within PLINK. No samples were found to be from related 
individuals. The IBS/IBD analysis, using PLINK, estimates a genome-wide 
IBD measure between each pair of samples. This estimate, based on the 
sharing of alleles between each pair of samples, can identify individuals that 
appear more similar, to each other, than expected by chance. 
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Figure 3.2: Population MDS plot based on genotype, from genome-wide IBS pairwise 
distances between the 150 samples used in this study (LNG, black circles) and 
HapMap samples (CEU, red diamonds; CHB, greens x’s; JPT, blue +’s, and YRI, purple 
triangles). The plot shows that of the 150 samples, from the study, reported to be 
Caucasian individuals from the United States, two samples are ethnic outliers relative 
to the rest of the study cohort and the CEU population from HapMap (indicated by 
Removed labels). Outlier detection was based on 3 S.D. from the mean for the reported 
population group. Figure reproduced from (Gibbs et al. 2010). 
 
Mach software version 1.0.16 (Li et al. 2009, 2010) and HapMap 2 CEU 
phase data (release 22) were used to impute genotypes for ~2.5 million 
SNPs. Imputed SNPs were excluded if the linkage disequilibrium r2 values 
between imputed and known genotypes were less than 0.3, and if their 
posterior probability averages were less than 0.8 for the most likely imputed 
genotype. For each of the four tissue regions, SNPs were also excluded if: (a) 
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the call rate was less than 95%, (b) Hardy-Weinberg equilibrium (HWE) p-
value was less than 0.001, and (c) the SNP had less than 3 minor 
homozygotes present. On average, for the four tissues groups, ~1.6 million 
SNPs passed these quality threshold checks and were appropriate for use in 
the eQTL analyses. The exact numbers of SNPs used per tissue group are 
shown in Table 3.2. 
 
 
Table 3.2 Summary counts of total subjects, mRNA transcript probes, and SNPs that 
were included for analysis per tissue region. Each column represents a tissue region: 
cerebellum (CRBLM), cerebral frontal cortex (FCTX), caudal pons (PONS), and cerebral 
temporal cortex (TCTX). Table adapted from (Gibbs et al. 2010). 	  
3.2.3.2:  RNA expression data  
Raw intensity values for each probe were transformed using the rank invariant 
normalization method (Schadt et al. 2001; Tseng et al. 2001; Workman et al. 
2002) for mRNA analysis. Individual samples that had an average detection 
score less than 0.99 were either discarded or re-run from a separate 
preparation. The following mRNA samples were excluded based on this 
metric: UMARY1668 (CRBLM), UMARY1909 (FCTX), UMARY4543 (PONS) 
and UMARY4782 (PONS). The following individuals were not run on mRNA 
expression arrays for any tissue region: BLSA1672, JHU1344 and JHU1361.  
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3.2.3.3:  Clustering of Samples by Brain Region 
Performing a Hierarchical Clustering (HCL) (Eisen et al. 1998) of the sample 
expression profiles using the TM4 MeV version 4.1.01 tool (Saeed et al. 
2003), ‘Average Linkage clustering’ resulted in the samples separating by 
brain tissue region. Separation of samples into four distinct clusters matching 
the brain tissue region was clear (Figure 3.6A). For clustering all detected 
transcripts were used. The HCL samples trees were saved as Newick tree 
files and plotted again using the HyperTree tool 
(http://hypertree.sourceforge.net/). The Newick format is a standard format for 
representing visual data trees in a computer-readable format. 
 
3.2.3.4:  Selection of traits for analysis 
Traits were excluded from analysis if they were detected in less than 95% of 
samples for each tissue region. For each tissue region and trait type the 95% 
threshold was determined using total number of analysable samples, for this 
pairing of region and trait. Only probes that were detected in 95% of all 
samples within a tissue type were used for further analysis. In total, 10,326 
mRNA transcripts were analysed within at least one brain tissue region; 8,076 
(78%) mRNA transcripts were analysed within all four brain tissue regions 
(Figure 3.3).  
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Figure 3.3: Stylized Venn diagrams showing the frequency overlap, between the four 
brain tissues, of the number of transcript probes that were detected in 95% of samples. 
The rectangles with different orientations and border, shown on the left legend 
represent the different tissue and the different squares represent overlapping 
frequencies between different tissues. The colour coded squares represent the number 
of tissues overlapping, where the central blue square in the diagram represent the 
number of probes reliably detected in all four tissues. Hence, the blue square in the 
diagram indicates that 78.2% of transcript probes were detected in all four tissue 
regions. Figure adapted from (Gibbs et al. 2010). 	  
Using a 95% detection threshold, in the tissue sample series, is a more 
appropriate cut-off for inclusion in the eQTL analysis as it makes more 
appropriate use of the power of the series and reduces the number of traits 
analysed, which will then likely be discarded by multiple test correction and 
other trait selection criteria. In my previous thesis study, many initially 
suggestive trans-eQTL and some cis were false positives related to low 
detection rate of the transcript (Figure 3.4). These, in most instances, were 
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filtered from the published result sets with additional test correction and 
filtering steps. 
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Figure 3.4: Plot showing transcript detection rate based on all subjects and suggestive 
or better eQTL signal from the mix cortical tissue eQTL analysis study (Chapter 2). In 
that study a transcript had to be detected in 5% of subjects to be included for analysis. 
In the later two studies this was increased to 95%. As the plot clearly demonstrates 
much of the trans signal (red) and some of the cis signal (blue) were for transcripts 
that were not well detected in the series. Even though many of these were removed by 
other corrections and filters, prior to publication for that study, it still dramatically 
increased computation time and test burden for transcripts that should not have been 
included for analysis.	  
 
3.2.3.5:  Polymorphism(s) in Assay Probes 
Sequence variants within the sequence of the probe used to assay individual 
traits may cause differential hybridization and inaccurate expression 
measurements. To exclude this confound, the sequences of probes with 
significant correlation to a trait were examined for the presence of known 
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polymorphisms, with a MAF > 1%, using CEU HapMap data, and if present, 
that QTL was removed from the result set. Removal of eQTL, where the 
transcript’s probe sequence contained a known polymorphism excluded 36 
(10.1%) of transcripts from the CRBLM, 35 (9.5%) from FCTX, 30 (9.7%) from 
PONS, and 44 (10.1%) from TCTX. Of the above set of transcripts, excluded 
from the analysis results, seven were present in all four tissue regions results. 
 
3.2.3.6:  Correction for known Biological and Methodological 
Covariates 
Prior to quantitative trait loci analysis, each trait was adjusted using the 
available biological and methodological covariates in an attempt to remove 
the influence of these potentially confounding affects.  In R, each trait was 
regressed using the following model: 
Y=β0 + β1X1+… βnXn + ε 
 
In this model, Y is the trait profile (log2 normalized mRNA expression 
intensities) and X1 … Xn represent the biological covariates Age and Gender 
and the methodological covariates post-mortem interval (PMI), which Brain 
Bank the samples was from, and which preparation / hybridization batch the 
sample was processed in. Within this model gender, tissue bank, and batch 
were treated as categorical covariates. After fitting each trait to the model the 
residuals from the model are kept and represent the trait in eQTL analyses.  
Thus, the expression variation attributable to gender, age, post-mortem 
interval, tissue bank and hybridization batch are removed prior to eQTL 
analysis. Histograms showing the proportion of mRNA traits that are 
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potentially impacted by these covariates are shown in Figure 3.5. Covariates 
for hybridization batch and Brain Bank tissue source had the largest effect, 
but were also very colinear. Gender and post-mortem interval (PMI) 
covariates had the smallest effects. It is unknown whether the cause of death 
was confounding effect within our subject cohort. A cause of death covariate 
was not included in the covariate adjustment as the information was not 
complete for 24% of the subjects in the cohort. It has previously been shown 
that agonal state for conditions such as hypoxia and coma affect gene 
expression in post-mortem brain more than age, gender, and post-mortem 
interval, which are covariates that were available for analysis within our 
subjects (Tomita et al. 2004). It has also previously been reported by Li et al. 
that tissue pH (measure of acidity or basicity) from post-mortem human brain 
is indicative of agonal state. They found that subjects with a prolonged agonal 
state had a lower pH than subjects with brief deaths. Additionally, they found 
that samples with lower pH showed an increase in expression of transcription 
factors and genes encoding stress-response proteins, and decreased 
expression for energy metabolism and proteolytic activity related genes. The 
authors suggest that the functional specificity of these gene expression 
changes reflect a coordinated biological response in living cells and not 
random RNA degradation (Li et al. 2004).  
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3.2.3.7:  Quantitative trait loci analysis  
For each of the four brain regions, a regression analysis was performed on 
the residuals described in the preceding section for mRNA transcript 
expression levels. The trait residuals were then used as the quantitative 
phenotype for that probe in genome-wide association analysis looking for 
quantitative trait loci. These analyses were performed using the assoc 
function within PLINK, which correlates allele dosage with change in the trait. 
Each of the four tissue regions was analysed separately, and independent 
genome-wide association analyses were performed to identify expression 
quantitative trait loci (eQTL). The PLINK toolset quantitative trait association 
analysis fits data to the following model:  
Y=β0 + β1ADD+ ε 
In this model, Y is the quantitative trait and ADD represent genotypes 
encoded as allele dosage.  
 
3.2.3.8:  Correction for multiple tests 
To correct for the large number of SNPs tested per trait, a genome-wide 
empirical p-value was computed (North, Curtis and Sham 2002) for the 
asymptotic p-value for each SNP by using 1,000 permutations of swapping 
the sample labels of the traits, using the maxT permutation functionality 
provided within PLINK. A permutation based method using label-swapping of 
the traits is an appropriate method of test correction (Churchill and Doerge 
1994) for these analyses as it is not dependent on these quantitative traits 
having a normal distribution and also allows the linkage disequilibrium of the 
genomic regions being tested against the traits to be maintained. 
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To correct for the number of traits being tested per tissue region, a false 
discovery rate (FDR) threshold was determined based on the empirical p-
values using the fwer2fdr, family wise error rate to false discovery rate, 
function of the multtest package in R (Pollard, Dudoit and van der Laan 2005). 
The multtest package is an R library providing multiple methods for use to 
correct for multiple hypothesis testing. The FDR method finds the largest p-
value that is substantially smaller than expected, based on the desired false 
discovery rate level, where this largest p-value and all p-values less than it 
can then be considered significant (Benjamini and Hochberg 1995). Empirical 
p-values were allowed to exceed this threshold if their linkage disequilibrium r2 
was greater than or equal to 0.7 with a SNP with empirical values within the 
FDR threshold.  
 
3.2.3.9:  Replicated eQTL  
To identify eQTL that have previously been reported, we considered the 
results from studies within the Pritchard Lab eQTL Browser 
(http://eqtl.uchicago.edu/). Of our 282 mRNA transcripts with a cis-eQTL 
detected in at least one tissue, 149 (53%) of these may have also been seen 
in at least one or more previous eQTL studies. To avoid incomplete 
annotation information when comparing between studies, the search for 
overlap in the studies was based on the transcript’s gene symbol. Searching 
based on gene symbol means that the 53% possible overlap with other 
studies is applicable for stating that a gene with an eQTL was shared between 
studies, but this does not imply that the same eQTL was seen in multiple 
studies. For instance different transcripts for the same gene or a different 
region of genetic variation may have been identified between the studies. For 
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the 53 mRNA transcripts with a cis-eQTL that we detected in all four of brain 
regions, 37 of these have been identified in at least one or more eQTL 
studies. Overlap with findings in LCL HapMap samples (Stranger et al. 2007) 
is 76 transcripts, in cortical samples (Myers et al. 2007a) the overlap is 19 
transcripts, and in liver (Schadt et al. 2008) the overlap is 108 transcripts. 
While it may be discouraging that the overlap with findings from the Myers et 
al. cortical samples is not larger, we believe that this is a function of the 
coverage of genetic variation included in the analysis and changes to the 
analysis design, such as adjusting for covariates prior to analysis instead of 
removing all results with a potential covariate effect. The current study 
includes genotypes from 550K (~1.65 million after imputation and selection) 
SNPs whereas the Myers et al. study included 366,140 SNPs; the Schadt 
study used 782,476 SNPs; and the Stranger study used ~2.2 million SNPs. 
So ~53% of our transcripts with a cis-eQTL may have also been seen in at 
least one other study; this does not take into consideration differences in the 
tissues, assay platforms, analysis methods and annotations used in these 
studies.  
 
3.2.4:  Data Access 
The genotype and expression data are publicly available as NCBI dbGaP 
study accession phs000249.v1.p1 and NCBI GEO series accession 
GSE15745 (Edgar, Domrachev and Lash 2002; Barrett et al. 2007; Mailman 
et al. 2007) (Figures 9.2 and 9.3, Appendix). 
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3.3:  Results 
3.3.1: mRNA transcript levels differ between brain regions  
To assess whether differences in mRNA expression were consistently 
different between brain regions a global comparison of these measures 
across tissues was performed. Unsupervised cluster analysis using these 
data demonstrated that the four brain regions have different expression 
profiles (Figure 3.6A). Expression pattern differences were most distinct 
between cerebellum, pons and cerebral cortical tissue, with frontal and 
temporal cortices clearly separating within the dataset. These data show that 
mRNA expression levels vary measurably and markedly between brain 
regions. 
 
The next analysis was limited to the mRNA dataset of those probes where 
sufficient detection was observed in 95% of samples analysed in each tissue 
region. This provided data on a total of 10,326 probes against individual 
mRNA transcripts. The distribution of observed transcript abundance was 
plotted as a histogram for each tissue (Figure 3.6B). We next compared 
mRNA expression levels at individual loci directly between each possible pair 
of tissue regions (Figure 3.6B). In general levels of expression were quite 
similar between tissues. Measures within frontal and temporal cortices were 
consistently the most alike whereas cerebellar tissue provided the most 
distinct profile of the four regions.  
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Figure 3.6: Analysis of mRNA measures across four human brain regions. (A), 
unsupervised cluster analysis of mRNA expression levels. Cluster branches from each 
brain region are colour coded accordingly and demonstrate consistent separation of 
cerebellum, pons and cerebral cortical samples; with separation of frontal and 
temporal cortex samples using mRNA transcript levels. (B) Tissue based pairwise 
comparisons of mRNA expression. The analyses in these figures used only transcripts 
that were well detected in each pairing of tissues compared. Histograms show the 
distribution of mRNA expression levels for each tissue, axes are log2 normalized 
expression intensities and the % of transcripts at that expression level. Scatter plots 
are direct comparison of the level of each detected transcript in each tissue pair; axes 
are the log2 normalized expression intensities. Notably frontal cortex (FCTX) and 
temporal cortex (TCTX) show the most similar patterns of expression; conversely, all 
comparisons against cerebellar (CRBLM) tissue show this tissue to have the most 
distinct patterns for all measures. Figure was adapted from (Gibbs et al. 2010). 	  
3.3.2:  Genotype influences mRNA expression 
A primary aim underlying these experiments was to examine the extent of 
genetic control of expression within brain tissues. To investigate this process, 
we undertook a series of eQTL analyses. From the 537,411 genotyped SNPs 
that passed quality control filtering we imputed 2,545,178 SNPs. After 
additional quality and analysis specifications filtering 1,629,853 SNPs 
(average) were used for analysis. With these data, we then performed 
regression of allele dosage against each measure using expression of mRNA 
transcripts as the dependent variable and genotype as the independent 
variable and treating each tissue as a separate analysis. We corrected for 
number of tests per trait by permutation and for the number of traits using an 
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FDR-like measure. This yielded a necessarily conservative threshold for 
significance (Churchill and Doerge, 1994). Prior to analysis, each trait was 
adjusted using available biological and methodological covariates in an 
attempt to reduce the influence of systematic confounding effects. Post hoc 
we annotated significant eQTL as cis if the SNP was within 1 megabase (Mb) 
of the transcript being tested; all other SNP-dependent variable tests were 
designated as trans. Notably, because the designation of cis- and trans-eQTL 
tests was performed post hoc, there was no distinction in terms of level of 
statistical correction between these groups. 
 
There were a large number of significant correlations detected between 
genetic variation and variation in the expression of mRNA transcripts, with 
significant eQTL detected in each of the four brain regions; ranging from 280 
(3.2%) in the pons to 391 (4.2%) in the temporal cortex (Table 3.3). These 
eQTL accounted for between 18% and 77%, of corrected expression levels, of 
associated transcripts between individuals. On average the eQTL accounted 
for 28% of the expression variation of the associated transcript (cis-eQTL 
mean is 30% and trans-eQTL mean is 22%). 
 
Table 3.3: Counts of significant eQTL by brain region; cerebellum (CRBLM), cerebral 
frontal cortex (FCTX), caudal pons (PONS), and cerebral temporal cortex (TCTX). 
Counts include total, cis and trans numbers for correlated pairs of mRNA transcripts 
and SNPs as well as unique number of mRNA transcript probes and SNPs. Table 
adapted from (Gibbs et al. 2010). 
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To assess the enrichment of detected cis-eQTL relative to those in trans we 
calculated the number of observed and possible cis- and trans-eQTL for 
mRNA expression levels. Based on a definition of cis at 1Mb, these data 
showed an enrichment of cis-eQTL relative to trans. The peak enrichment of 
cis-eQTL was observed at ~68 Kb for mRNA transcripts.  	  
The abundance of cis-eQTL for mRNA expression prompted us to examine 
the distribution of cis-eQTL (Figure 3.7A-D). This revealed that both the 
number of significant eQTL and the strength of association between SNP and 
mRNA expression level were inversely correlated with physical distance 
between the genetic variation and the transcript start site (TSS) of the mRNA 
transcript in question. The average distance, for cis-eQTL, between the SNP 
and the transcript is 70 Kb. The most significant cis-eQTL tended to be 
present in all four tissues tested (Figure 3.7E). Of the transcripts with cis-
eQTL that were significantly detected in at least one brain region, 53% have 
been previously reported, when intersecting by gene names instead of 
individual gene mRNA transcripts or assay probe IDs. This number increased 
to 70% when analysis is limited to those cis-eQTL detected in all four tissues 
(Myers et al., 2007a; Schadt et al., 2008; Stranger et al., 2007). Table 3.4 lists 
the top ten cis-eQTL transcripts found in this study. 
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Figure 3.7: (A-D) Significant cis-eQTL p-values per tissue region relative to the 
transcription start site (TSS). (E) Average p-values for cis-eQTL across regions. The 
more significant cis-QTL tended to be both closer to the transcription start site and 
common across tissue regions tested. Figure adapted from (Gibbs et al. 2010). 
 
3.3.3:  Detected eQTL are consistent across brain regions 
In order to compare detected eQTL between tissues, we selected every SNP-
transcript pair that passed the defined threshold for significance in at least one 
tissue. We then compared R2 values for each eQTL across tissues using 
ternary plots (Figure 3.8). The majority of significant cis-eQTL were shared 
across the four brain regions, while trans signals shared across tissues are 
almost complete absent. 
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Figure 3.8: Comparison of eQTL across tissue regions. Any eQTL that passed our 
threshold for significance in at least one tissue was included in the Ternary plots. The 
colour of the points in the ternary plots reflects the cumulative R2 value, from the 
correlations, for all tissues tested within each plot. Points toward the centre indicate 
an equal R2 value across the three regions under investigation. Points toward the 
corner of a plot indicate a high R2 in one of the three tissues; points toward the edges 
of the plot indicate a high R2 in two of the three tissues. (A-H) Comparing eQTL in 
every three-way combination of the four tissues for cis (A-D) and trans (E-H). Notably 
the cumulative R2 is generally higher for cis compared to trans loci. Green circles 
highlight a cluster of relatively high cumulative R2 values driven primarily by the 
observed R2 within cerebellar tissue. These points were revealed to be a cis-eQTL 
involving 20 SNPs and two neighbouring transcripts, PPAPDC1A and C10orf85. (Q-T) 
Boxplots show expression level plotted against genotype for one of these eQTL SNP-
transcript pairs (SNP rs2182513 and PPAPDC1A) and illustrates that this is a tissue-
specific eQTL limited to the cerebellum. C10orf85 follows the same pattern with an 
eQTL present in cerebellum but not in the other three tissue. Figure adapted from 
(Gibbs et al. 2010). 
 
 
These plots illustrate that the great majority of cis-eQTL with strong effect 
sizes were consistent across these tissues. We found tissue-specific eQTL to 
be less common for large effect sizes, but there were observable events. 
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However, for individual significant SNP and trait correlations, tissue-specific 
correlations were detectable (Figure 3.9). For example, while strong eQTL 
were found for churchill domain containing 1 (CHURC1) in all tissues and as 
reported previously in liver (Schadt et al. 2008), several cis-eQTL for 
phosphatidic acid phosphatase type 2 domain containing 1A (PPAPDC1A) 
were restricted to the cerebellum, despite reliable detection of the transcript in 
all four brain regions (Figures 3.10 and 3.11). 
 
Figure 3.9: Stylized Venn diagrams showing the frequency overlap of the number of 
significant SNP and transcript correlations that are detected in the four brain tissues. 
The rectangles with different orientations and border, shown on the left legend 
represent the different tissue and the different squares represent overlapping 
frequencies between different tissues. The colour coded squares represent the number 
of tissues overlapping, where the central blue square in each Venn diagram represent 
the proportion of significant correlations detected in all four tissues. Hence, the blue 
square in the cis diagram indicates that 18.6% of the significant SNP and transcript 
correlations detected were present in all four of the tissue regions. Whereas the green 
squares show the proportion of significant SNP and transcript correlations only 
detected in that region of the brain.  
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Figure 3.10: Manhattan plots, one for each brain tissue region, show the p-values from 
the correlations between SNPs and mRNA transcripts in a 500Kb region centred on 
CHURC1. A cis-eQTL for CHURC1 in this genomic region is present in all four brain 
tissues. A cis-QTL for CHURC1 has also been reported within liver (Schadt et al. 2008). 
Within each plot the X-axis is the physical position along this region of the 
chromosome and the Y-axis is the –log10(asymptotic p-values) for the correlations.  
The p-values are colour coded and numbered to match the annotated transcripts 
labelled in the top portion of the plots. Thus in cerebellum (CRBLM), cerebral frontal 
cortex (FCTX), caudal (PONS), and cerebral temporal cortex (TCTX) the dark blue ‘5’s 
are p-values, for individual SNPs, correlated with expression levels of CHURC1. mRNA 
transcript annotations shown in grey are those where a probe is present on the 
expression platform but not detected in 95% of the tissues. Figure reproduced from 
(Gibbs et al. 2010). 
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Figure 3.11: Manhattan plots show an example of a cis-eQTL for an mRNA that appears 
to be tissue-specific. The plots, one for each brain tissue region, show the p-values of 
correlations between SNPs and mRNA transcripts in a 1Mb region centred on 
PPAPDC1. Within each plot the X-axis is the physical position along this region of the 
chromosome and the Y-axis is the –log10(asymptotic p-values) for the SNP and 
transcript correlations. The p-values are colour coded and numbered to match the 
annotated transcripts labelled in the top portion of the plots. Thus in cerebellum 
(CRBLM) the red ‘2’s are p-values for SNPs correlated with the expression levels of 
PPAPDC1A.  Also present at this same genomic locus is another tissue specific eQTL 
for the mRNA transcript C10orf85, shown as green ‘3’s. Figure reproduced from (Gibbs 
et al. 2010). 	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3.4: Discussion 
The work I have described here and the public release of the data resulting 
from this effort, aim to facilitate an understanding of the initial consequences 
of common genetic variation on gene expression in brain. These data show 
clearly that, as expected, patterns of expression are measurably different 
across brain tissues. eQTL analyses reveal an abundance of significant eQTL 
that are predominantly cis in nature. Previous eQTL results, from the human 
cerebral cortex (Myers et al. 2007a), as well as eQTL results from HapMap 
lymphoblastoid cell lines (LCL) (Veyrieras et al., 2008) have suggested that 
SNPs proximal to genes, including SNPs upstream of the transcription start 
site (TSS), within the gene, and downstream of the transcription end site 
(TES) have a greater influence on gene expression than those further away. 
This is presumably because genetic variation around promoter elements, 
splice sites, and 3' UTRs affects transcription, splicing, and mRNA stability 
(Kwan et al. 2008) that results in an enrichment of cis- over trans-eQTL. The 
power to detect the signal in a local cis-variant is likely a direct effect whereas 
trans, if detectable, are likely indirect and underpowered for accurate 
detection in series of these sizes (Pastinen, Ge and Hudson 2006). As the 
effect from trans-variation is likely to occur through an indirect effect, this 
means there is likely another unaccounted-for intermediate effect in between 
the genetic variation and the trait being measured, which decreases the 
power of detection (Schliekelman 2008).  
 
It is notable, particularly given the systematic differences in expression 
patterns among the four tissues, that many of the significant eQTL with the 
strongest signal were consistent across brain tissues. Tissue-specific eQTL 
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are also observable in the current data set, suggesting that there are genetic 
effects on expression that are dependent on the tissue type used irrespective 
of expression levels of the mRNA. This emphasizes the importance of 
exploring eQTL in the context of a relevant tissue. The ability to analyse and 
compare both distinct and similar brain tissue regions, from the same 
subjects, in this study allowed for a more thorough comparison of eQTL in 
brain tissues. Whereas in the previous study, described in Chapter 2 of a 
single sample set based on a mix of cortical tissues, the only whole-genome 
eQTL results available for comparison were from HapMap lymphoblastoid cell 
lines (LCL), at that time. This study and data created the initial cohort that has 
since become known as the North American Brain Expression Consortium 
(NABEC). 
 
The use of LCLs in the discovery and understanding of eQTL has been quite 
useful; however, there may be potential problems with using LCLs as a proxy 
of other tissues and cell types in eQTL analysis. When using LCLs there may 
be potential artefacts in expression levels. Expression levels may correlate 
with Epstein–Barr virus (EBV) load and growth rates, some genes may exhibit 
monoallelic expression and LCLs are generated from a blood cell lineage 
(Choy et al. 2008; Plagnol et al. 2008). In a 2009, a report from Dimas et al. 
suggested that tissue specificity for eQTL is widespread with only 20 to 30% 
of eQTL replicating across tissues (Dimas et al. 2009). An interpretation of the 
Dima et al. results, suggests that eQTL shared across tissues are closer to 
the TSS and have a larger effect size while tissue-specific eQTL are more 
widely dispersed in cis and have a smaller effect sizes (Figure 3.12) (Dimas et 
al. 2009; Montgomery and Dermitzakis 2011). More generally it has also been 
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shown that eQTL shared across tissues typically falls somewhere between 
40% and 80% depending on tissue similarity and analysis methods (Heinzen 
et al. 2008; Ding et al. 2010). In 2008, Emilsson et al. published a large study 
of expression and obesity traits in an Icelandic population from blood and 
adipose tissue. Their results showed correlations between obesity traits and 
gene expression in both tissues, but the results were much stronger in 
adipose than in blood, 50% and 10% respectively. The stronger correlations in 
adipose tissue with obesity traits were likely expected as this tissue is 
primarily composed of adipocytes and obesity can be characterized by the 
increase in size of adipocytes. They also identified eQTL based on 
segregation and linkage analysis. Of the eQTL they identified, 50% were 
shared by both tissues and were strongly cis rather than trans (Emilsson et al. 
2008). In 2011, Innocenti et al. published a study considering the 
reproducibility of eQTL studies. This study based on human liver from 3 
cohorts found that ~30% of SNP-expression correlations failed to replicate. 
They suggest that other factors associated with the tissue were confounders 
for replication including: drug exposure, clinical descriptors, and tissue 
ascertainment. They reiterated that the array’s expression probe design can 
be a confounder, if polymorphisms within the assay probes are not accounted 
for. They found that controlling for these possible confounds increased the 
replication rate. They also found that the most replicable eQTL variants were 
those enriched at gene starts and stops. For 14 genes, they did additional 
validation and fine mapping confirming haplotype-specific in-vitro expression 
differences. Overall, their study potentially validated hundreds of eQTL in 
human liver. They suggest that many of these eQTL may be informative in 
indentifying and functionally characterizing the genetic contribrution to 
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diseases and complex traits (Innocenti et al. 2011). Innocenti et al. reference 
two examples of previously characterized mechanistic links to disease and 
complex traits that also intersected with replicated eQTL within their study: 
warfarin drug response and vitamin K epoxide reductase complex subunit 1 
(VKORC1) expression (Rieder et al. 2005), and sortilin 1 (SORT1) expression 
correlations with lipid levels and heart disease (Kathiresan et al. 2008). 
Additionally, Innocenti et al. suggest that their results may also support the 
hypotheses that NOD2 expression levels are linked to leprosy risk (Zhang et 
al. 2009), and that C2orf43 gene expression levels are linked to prostate 
cancer risk (Takata et al. 2010). 
 
	  
Figure 3.12: Cartoon from Montgomery and Dermitzakis review showing larger and 
shared effects for eQTL are closer to the transcription start site (TSS) and that weaker 
and tissue-specific effects tend to be further from the TSS and that trans effects may 
help to understand gene and regulatory networks. Figure reproduced from 
(Montgomery and Dermitzakis 2011). 
 
Other studies, performed during the late 2000s, also began to consider other 
forms of expression or regulatory traits and their association with genetic 
variation. In 2009, Wei Zhang et al. published a study examining alternative 
splicing (AS). This study made use of Affymetrix exon expression arrays in 
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176 LCLs from HapMap CEU and Yoruban subjects. They identified local and 
distant genetic variants associated with transcript isoform variation between 
the two populations and found a substantial fraction (8%) of transcripts with 
isoform variation were associated with genetic variation (Zhang et al. 2009b). 
In 2009, Kun Zhang et al. published a study of allele-specific expression 
(ASE), which was based on four cell lines from two subjects for the Personal 
Genome Project. They found that between 11% and 22% of heterozygous 
mRNA SNPs showed allele-specific expression per cell line, and that between 
4% and 8% of these were tissue-specific. When analyses were expanded to 
include two pairs of siblings, they found that ASE was more similar among the 
siblings than in the unrelated subjects. In their results, genetic variation 
accounted for more variation in allelic ratios of expression than tissue type or 
growth conditions. Based on expression of alleles by strand, they suggest that 
allelic ratios are primarily cis-regulated on the sense strand (Zhang et al. 
2009a). In 2010, Dandan Zhang et al. published a study of CpG site 
methylation QTL (methQTL) in human cerebellum from ~150 subjects. They 
found that 9% of CpG sites that displayed large variation between subjects 
were also correlated with cis genetic variants. They also found that ~1% of 
methQTL were also eQTL, where both DNA methylation and gene expression 
were also correlated (Zhang et al. 2010). It should be noted that DNA 
methylation at CpG sites has also been generated in all four tissues for the 
NABEC subjects described in this chapter. I have not included a description of 
this data, analysis, or results because this data is part of another student’s 
thesis on DNA methylation in human tissues. I will briefly describe the 
methylation results here, as they are similar to those found by the Zhang et al. 
study, which were also done using human cerebellar tissue. I identified 
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methQTL in the NABEC tissues following almost the exact same analysis as 
used for the identification of eQTL in this chapter. For methQTL, we found 
between 4% and 5% of CpG sites methylation levels were significantly 
correlated with genetic variation. The genetic variants, for the methQTL, 
accounted for between 18% and 88% of the CpG methylation level, at 
individual CpG sites. I then performed an analysis of the intersection of eQTL 
and methQTL to determine if these traits were independent of each other. I 
found that while 4.8% of the genetic loci intersected (2.6% of methQTL and 
8.2% of eQTL) their effects on gene expression levels were independent. 
 
While we were able to detect tissue-specific eQTL in the four brain tissues, 
the majority of the eQTL detected appear to have a high degree of sharing 
between the tissues. Even though we selected tissues that are both diverse 
and similar, where cerebellum was the most distinct and the cerebral cortical 
regions were similar, these tissues are heterogeneous in cellular composition. 
This heterogeneous cellular composition makes it difficult to determine if the 
degree of eQTL sharing we see between brain regions is a result of eQTL 
being similar between different types of neurons or different types of glia, or 
do they appear shared because specific neuronal and glia cell types have 
cell-specific eQTL but the presence of enough of these cells in bulk tissue 
regions is allowing us to detect the majority of the cell-specific signal but 
without a way to deconvolute the signal. The possibility may also exist that 
with glia and granule cells being a common class of cell types in the brain that 
the eQTL we are detecting represent shared eQTL among glial cell types and 
shared eQTL among granule cell types. With this in mind we undertook the 
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next study in my thesis, identifying eQTL in samples enriched for a specific 
neuronal cell type. 
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4:  Identifying eQTL in a specific Human Neuronal cell 
type 
Statement of Contribution to this Research: 
I was involved in the conception and design of this study, including choice of 
genotyping platform, expression platform, and selection of tissue. I performed 
data quality control, data analysis, and data interpretation. Cookson MR and 
Singleton AB were also involved in the conception, design, choice of platform, 
and tissue and cell type selection. I was not involved in the collection of the 
tissue samples or the generation of the genotype and mRNA expression data. 
Coordination and collection of the tissue was performed by Traynor BJ. 
Genotyping of the samples was coordinated or performed by: Hernandez DG, 
Traynor BJ, Arepalli S, Rafferty IP, and Lai SL. Laser capture microdissection 
was performed by: Kumar A, Beilina A, and Kumaran R. Generation of mRNA 
expression data was performed by: Dillman A, Kumaran R, and Kumar A. 
 
4.1:  Introduction 
As shown in the previous two chapters, genetic diversity contributes to 
variation in gene expression in human brain. However, one difficulty with 
examining gene expression in tissues with heterogeneous cellular 
composition is that different cells have different gene expression patterns. For 
example, in the brain there are many types of neurons as well as different glia 
and other cell types. In my previously described eQTL studies, the tissue 
samples were based on human brain regions that contain a heterogeneous 
cell mix. The heterogeneity of the tissues adds a degree of ambiguity in 
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characterizing the eQTL identified. In 2011, Price et al. published a study of 
cis and trans heritability of gene expression based on 722 familial Icelandic 
subjects from blood and adipose tissue. They found that the heritability of 
gene expression for 37% of transcripts in blood and 24% transcripts in 
adipose was attributable to cis-regulatory variants. They also found that gene 
expression correlations between the tissues were also due to heritability of 
cis-regulatory loci, but this was not the case for trans-regulation for the two 
tissues. They repeated a similar analysis in unrelated individuals and found 
similar results. They suggest this means that tissues with heterogeneous cell 
types will be more effected by cis-regulation than tissues of homogenous cell 
types (Price et al. 2011). In order to understand whether changes in the 
cellular composition of the brain influenced the previous observations, we 
repeated the analyses in neurons isolated by laser capture microdissection 
(LCM). In 1999, Luo et al. published a study using LCM and microarrays to 
examine differential expression between adjacent large and small neurons 
from dorsal root ganglia (DRG) in rats. They found that they could cleanly 
capture adjacent large and small neurons and identified 40 transcripts 
differentially expressed, where 26 were preferentially expressed in small 
neurons and 14 in large neurons (Luo et al. 1999). In 2012, Friedrich et al. 
published a study of gene expression in Purkinje cells from mice examining 
Polyglutamine (PolyQ) diseases: spinocerebellar ataxia type 7 (SCA7) and 
Huntington's disease (HD). These diseases share a cerebellar degenerative 
phenotype of progressive selective cell loss and formation of protein 
aggregates. In this study, they used laser capture microdissection (LCM) to 
compare gene expression in Purkinje cells from transgenic PolyQ mouse 
models using microarrays. They used real-time PCR for validation of their 
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results. They found a similar reduced expression of mRNA in their mouse 
models where decreases in aldolase C and phospholipase C beta3 increased 
the vulnerability of Purkinje cells to excitotoxic events. Additionally, they found 
that the decrease in mRNA expression, in their mouse models, was facilitated 
by the Pcp2 promoter (Friedrich et al. 2012). The Purkinje cell is also the 
specific neuronal cell chosen for our study. This cell type was chosen 
because Purkinje cells are a large and distinctive neuronal cell type found in 
the cerebellar cortex, a tissue already collected for the NABEC cohort. 
Additionally, while the dendrites of Purkinje cells branch very profusely they 
do so in a flattened almost two-dimensional layer. These aspects of the 
Purkinje cells make them easily identifiable, using simple rapid staining in 
frozen sections, and their flattened structure makes them amenable for 
capture with LCM. Thus we performed a cis-eQTL analysis in a subset (N = 
85) of the North American Brain Expression Consortium (NABEC) subjects, 
where laser capture microdissection was used to isolate Purkinje neurons 
from the cerebellum. Additionally, for this subset of NABEC subjects, eQTL 
analysis was repeated using data from the bulk cerebellum and cerebral 
frontal cortex samples. 
 
4.2:  Materials and Methods 
4.2.1:  Subjects 
(Coordination and collection of the tissue was performed by Traynor BJ.) 
This study was composed of 100 neurologically normal Caucasian subjects 
from the United States; these subjects are from the North American Brain 
Expression Consortium (NABEC). Tissue from the cerebellum and cerebral 
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frontal cortex were previously obtained for all subjects. After filtering subjects 
based on quality control steps, based on data from all assays for the cell and 
tissue groups, 85 subjects remained and were used in the analysis. 
 
Frozen tissue samples of the cerebral frontal cortex and cerebellum were 
obtained from each of 388 subjects who had donated their brains for medical 
research, making up the current NABEC cohort. Of these, 100 subjects were 
chosen from the University of Maryland Brain Bank and Baltimore 
Longitudinal Study of Aging collections within the NABEC cohort. All 
individuals were of non-Hispanic Caucasian ethnicity, none of the subjects 
had a clinical history of neurological or cerebrovascular disease, or a 
diagnosis of cognitive impairment during life. The average age at time of 
death was 38.6 years of age (range, 16 – 101 years). Of the 100 subjects, 
33% were female. The average post-mortem interval was 14.5 hours (range, 
4 – 28 hours). 
 
4.2.2: Assays 
4.2.2.1: SNP Genotyping 
(Genotyping of the samples was coordinated or performed by: Hernandez 
DG, Traynor BJ, Arepalli S, Rafferty IP, and Lai SL.) 
 
Genomic DNA extraction for genotyping was performed using the DNeasy 
Blood and Tissue Kit as per the manufacturer’s instructions (Qiagen Inc., 
Valencia, California, USA). DNA concentration was determined using a 
Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE), 
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and DNA extraction was repeated using a new tissue aliquot for samples with 
DNA concentration less than 50ng/ul, or where the 260nm/280nm wavelength 
absorption ratio was less than 1.7, indicative of significant protein 
contamination of the DNA sample. SNP genotyping was performed using 
DNA extracted from cerebellar tissue for each subject using Infinium 
HumanHap550 version 3 BeadChips (Illumina Inc., San Diego, California, 
USA) according to the manufacturer’s instructions. Genotype data was 
analysed using the Genotyping Analysis Module 3.2.32 within the BeadStudio 
software version 3.1.4 (Illumina Inc.).  
 
4.2.2.2: mRNA Expression 
(Laser capture microdissection was performed by Kumar A, Beilina A, and 
Kumaran R. Generation of mRNA expression data was performed by Dillman 
A, Kumaran R, and Kumar A (Kumar et al. 2013).) 
 
Laser capture microdissection (LCM) is a sample extraction technique that 
allows for specific sub-selection of a tissue sample to be dissected out (Figure 
4.1). Typically, this sub-selection is for extracting a particular cell or group of 
cells from a tissue sample in order to obtain a pure population of cells to 
assay. Emmert-Buck et al. described a LCM method, in 1996. Their method 
starts with a transparent film being placed over a tissue sample. The sample 
is then microscopically viewed and the region or cells of interest are then 
selected (Figure 4.2A). An infrared laser then applies a short duration focus 
pulse that thermally adheres the transfer film to the selected region of the 
tissue (Figure 4.2B). The film, with the selected tissue, can then be extracted 
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from the larger tissue section (Figure 4.2C) (Emmert-Buck et al. 1996). This 
LCM method offered advantages of other microdissection techniques of the 
time. These advantages included: no manual microdissection, one step 
transfers, the transferred tissue on film retains original morphology, laser 
focus size allows for targeting of single cell. A possible drawback is that the 
localized heating of the film has some direct absorption by the underlying 
tissue, as enough energy must be applied to the film to raise the temperature 
to fusion point (Emmert-Buck et al. 1996). 
	  
Figure 4.1: Example of LCM extraction of Alzheimer’s disease plaques from a section 
of frontal cortex. E) Image of the frontal cortex section with the LCM selected regions 
already removed; the white circular shapes one of which is indicated by the black 
arrow. F) Image of the extracted regions, selected from the larger tissue sample, on the 
transfer film. The extracted regions are the darker circular shapes one of which is 
highlighted by a black arrow. Since the extracted tissue is still on the transfer film the 
pattern of extracted tissue aligns to their removal points on the previous image. G) A 
zoomed image (scale bar, 50 µm) of one of the extracted plaques, where the 
neurofibrillary tangle is the darker staining. The figure images are adapted and 
reproduced from (Emmert-Buck et al. 1996). 
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Figure	  4.2:	  A	  cartoon	  of	  LCM	  extraction	  process.	  a)	  The	  transfer	  film	  is	  placed	  over	  the	  
tissue	  and	  a	  sub-­‐section	  is	  selected.	  b)	  A	  laser	  pulse	  thermally	  bounds	  the	  selected	  sub-­‐
section	  of	  tissue	  to	  the	  transfer	  file.	  c)	  The	  sub-­‐selection	  tissue	  can	  then	  be	  extracted	  fro	  
the	  larger	  tissue	  section.	  This	  figure	  is	  reproduced	  from	  (Liotta	  and	  Petricoin	  2000).	  
 
For bulk tissue, total RNA was extracted using Trizol, biotinylated and 
amplified using the Illumina® TotalPrep-96 RNA Amplification Kit. For laser-
capture microdissection (LCM) tissue was immersed in Shandon M-1 
embedding matrix (Thermo Electron Corporation, Rockford, IL) and stored at -
80°C until use. Cryostat sections (7–8 µm thick) were cut and stained with 
Cresyl Violet (Ambion, Austin, TX). Laser capture microdissection was 
performed with ArcturusXT microdissection system (Arcturus, Mountain View, 
CA). The cell bodies of between 70 and 150 Purkinje cells were captured per 
subject. The excised cells were selected from the slide surface and captured 
on LCM Macro Caps. High-quality cellular total RNA was recovered from the 
collected cells using PicoPureTM RNA isolation kit (Arcturus) and treated with 
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RNase-free DNase (Qiagen, Valencia, California, USA). The quality of the 
RNA was analysed using an Agilent 2100 bioanalyzer (Agilent, Foster City, 
California, USA). Two rounds of amplification were carried out with the 
Ambion MessageAmp II aRNA kit. It should be noted that the LCM prepared 
samples underwent two rounds of amplification whereas the bulk tissue 
samples underwent one round of amplification, and this may introduce some 
bias to the expression measurements. However, it is unlikely that this bias, if 
present, would affect the type of primary analyses being performed in this 
study since the analyses are within tissue and then results compared across 
tissues. Amplified RNA from either bulk tissue extracts or LCM Purkinje cells 
were hybridized onto Illumina HumanHT-12 v3 Expression BeadChip 
(Illumina). The Illumina HumanHT-12 v3 Expression BeadChips assay the 
expression levels of approximately 49,000 human Refseq transcripts using 
50-mer probes. The Illumina HumanHT-12 v3 Expression BeadChip is 
constructed based on the Illumina Sentrix bead arrays, like the HumanRef-8 
v1.0 and v2.0 assays described in Chapters 2.2.2.2 and 3.2.2.2 respectively. 
However, the HumanHT-12 platform contains more arrays per chip, where 12 
samples can be processed per chip and contains more bead-types per array 
assaying 49,000 RNA transcripts. 
	  
4.2.3:  Data Analysis 
4.2.3.1: Genotype data 
Genotype based filtering included subject and SNP filtering based on call rate, 
expected subject gender, relatedness among subjects and population outliers 
when combined with HapMap3 genotypes. Genotype-based metrics for 
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filtering were acquired using the PLINK toolset (Purcell et al. 2007) and R (R 
Core Team 2012).  
 
The threshold call rate for inclusion of the sample in analysis was 95%. The 
SNP call rate was computed using the missing command within the PLINK 
v1.07 software toolset. The gender of the samples reported to NABEC by the 
brain banks was compared against their genotypic gender using PLINK 's 
check-sex algorithm. The check-sex algorithm determines a sample’s 
genotypic gender based on heterozygosity across the X chromosome. 
Genotype data of the samples were compared for cryptic relatedness using 
the Identity-By-Descent (IBD) procedure within PLINK. No subjects were 
excluded based on call rate, gender or relatedness. 
 
To confirm the ethnicity of the samples, Identity-By-State (IBS) clustering and 
multidimensional scaling analyses were performed within PLINK. The ethnicity 
check was run using the genotypes from the NABEC samples and genotypes 
from the HapMap3 populations. Outlier detection was based on a sample’s 
distance in the first and second principal components being more than three 
standard deviations (S.D.) from the mean of the study cohort for those 
components. Three subjects were identified as outliers based on population 
and excluded from further analysis. Population structure for the first two 
principal components after excluding NABEC population outliers is shown in 
Figure 4.3. 
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Figure 4.3: Population MDS plot, based on genotype, from genome wide Identity-By-
State pairwise distances between the subjects used in this study (LNG, black +’s) and 
HapMap III population samples.  The plot shows that all of the post quality control 
screened subjects used in this study match their reported population ethnicity of 
Caucasians of European decent. Outlier detection was based on 3 S.D. from the mean 
for the reported population group. There are no population outliers as this plot was re-
generated post removal of outlier subjects. 
 
A two-step imputation process was performed excluding genotyped SNPs 
where SNP and subject call rate was less than 95%, MAF was less than 1% 
and Hardy-Weinberg equilibrium (HWE) p-value was less than 0.000001.  
Mach (Li et al. 2010; Howie et al. 2012) and MiniMac (Howie et al. 2012)  
were used to impute genotypes for ~38.9 million autosomal SNPs based on 
European reference haplotypes from the 1000 Genomes Phase1 
v2.20101123 data (1000 Genomes Project Consortium et al. 2012). Imputed 
SNPs were excluded if their MAF was less than 0.035 or the r2 was less than 
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0.3 between known and imputed genotypes. This process resulted in ~6.4 
million autosomal SNPs available for eQTL analysis.  The MAF threshold of 
0.035 is an estimate that establishes a lower bound for the smallest allele 
frequency testable in this sample series for eQTL analysis. This lower bound 
was determined based on the MAF cutoff at which it becomes less likely that 
the imputed allele dosages would have at least 3 minor homozygotes present 
in this study. 
 
4.2.3.2: mRNA expression data 
Transcript expression data was cubic spline normalized (Workman et al. 
2002) and exported using the Illumina GenomeStudio Gene Expression 
module. Cubic spline normalization removes curvature that may exist in the 
data as a result of non-linear relationships between samples or groups of 
samples. The Illumina HumanHT-12 probes were re-annotated using the 
ReMOAT tool (Barbosa-Morais et al. 2010) to identify probes that may have 
design issues. The ReMOAT annotation tool performs a re-alignment of the 
Illumina probes then re-annotates the probes based on multiple public 
genomic and transcriptome resources and then scores the probes quality. I 
excluded all probes that were annotated as ‘Bad’ or ‘No Match’ by the 
ReMOAT tool. Probes are labelled as bad if the probe aligns to repeat 
sequences, intergenic or intronic regions, more than one transcript from 
different genes, or contains more than three mismatches to target sequence. 
Probes are labelled as no match if they do not align to any transcript or 
genomic region. Filtering based on the ReMOAT quality score fields resulted 
in 14067 of the 48803 probes being excluded from analysis. Expression-
based filtering included removal of subjects if any of their sample expression 
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profiles were outliers based on their mean normalized intensity profile or their 
overall detection rate in any of the sample groups. A subject’s overall 
detection rate was computed per sample type as the fraction of detected 
(expressed) probes from the total probe set that passed the ReMOAT probe 
quality filter. Outlier detection was based on a sample’s distance for their 
mean expression profile and transcript detection rate being more than three 
standard deviations (S.D.) from the mean of the study cohort for those 
measures. Four subjects where excluded as outliers based on their average 
expression level and detection rate; two were Purkinje cell samples (Figure 
4.4), one that was an outlier in both cerebellum and frontal cortex, and an 
additional one that was also an outlier in cerebellum. Additionally, eight of the 
subjects were not assayed for either cerebellum or cerebral frontal cortex. 
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Figure 4.4: Scatterplot visualizing the quality control step applied for detecting poor 
quality mRNA samples based on their overall profile being identified as an outlier. Here 
the data for the Purkinje cell samples is shown. The two metrics tested for outlier 
detection are the subjects overall detection rate (fraction of expressed probes), based 
on all QCed probes, and the average intensity over on all QCed probes. Outlier 
detection was based on 3 S.D. from the mean of the expression intensity or detection 
rate for the study cohort. As shown above two subjects were found to be outliers and 
excluded from the eQTL analysis in all groups.  	  
4.2.3.3: Polymorphism(s) in Assay Probes 
Sequence variants within the sequence interval of the probe design used to 
assay individual transcripts may cause differential hybridization and 
inaccurate expression measurement. To correct for potential hybridization 
bias resulting from polymorphisms within the mRNA 50-mer probe, I identified 
all probes where this artefact may affect the analysis and excluded these 
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probes. A probe containing a polymorphism was only considered to have an 
effect and therefore excluded if it contained a variant that had a MAF greater 
than or equal to 0.03529. This MAF is the same estimated lower bound 
appropriate for eQTL analysis in a cohort of this size. We used variants and 
their frequencies based on the European subjects from the 1000 Genomes 
Phase1 v2.20101123 (1000 Genomes Project Consortium et al. 2012) data to 
identify the probe set for exclusion from further analysis. This removed 1,938 
probes from the overall chip content in addition to those previously identified 
with design issues by the ReMOAT tool. 
 
4.2.3.4: Selection of traits for analysis 
Expression probes were considered reliably detected within an individual 
sample if the Illumina Detection p-value was <= 0.01. An expression probe 
was selected for eQTL analysis if the probe was reliably detected for 95% of 
the QC filtered subjects within a tissue sample group and free from probe 
design issues. In total 10,850 mRNA transcripts were analysed within at least 
one sample group: 7,044 mRNA transcripts were present within all three 
groups; 8,025 in Purkinje cell, 9,869 in cerebellum, and 9,983 in cerebral 
frontal cortex. 
 
4.2.3.5: Correction for known Biological and Methodological 
Covariates 
The selected probe expression profiles were then adjusted using known 
covariates for subject age, gender, post-mortem interval, principal 
components 1 through 12 based on identity-by-state pairwise distance
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this cohort and the HapMap3 populations representing any possible 
population substructure in the cohort (Price et al. 2006), and the mRNA 
sample preparation/hybridization batch. The expression profiles were then 
log2 transformed and covariates were stepwise fitted in R (R Core Team 
2012) against the following model: 
€ 
Y = β 0 + β1X1+ ...+ βnXn + ε  
In this model, β0 … βn represent the continuous and categorical covariates.  
The residuals of this model fit for each probe were then standardized to a z-
score and used as the quantitative trait for the eQTL analysis. A z-score (or 
standard score) is a measure of how many standard deviations a data point is 
from the mean of the data set. 
 
4.2.3.6: Expression quantitative trait loci analysis 
eQTL analysis was then performed using the standardized residuals for every 
selected and adjusted trait in both brain tissue regions and Purkinje cells 
using mach2qtl (Li et al. 2009) to regress the trait with the allele dosage 
probabilities. For each trait analysed, only SNPs that are cis to the trait and 
passed our imputation quality control and SNP MAF threshold were 
considered in the analysis. For these analyses, cis is defined as the genomic 
region that contains the trait (the gene encoding the transcript), where the 
boundaries of the genomic region are +/- 1Mb from the mRNA transcript start 
or end site. 
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4.2.3.7: Correction for multiple tests 
To correct for the large number of tests performed in the eQTL analysis of 
these three sample groups I applied a Bonferroni correction based on the total 
number of estimated independent tests performed per sample group. The 
approximate number of independent tests being performed can accurately be 
estimated by considering the number of LD blocks and inter block variants 
being tested (Duggal et al. 2008). To estimate the number of independent 
variants I reduced the (1000 Genomes Project Consortium et al. 2012) 
European subjects genotype data to the SNP set that was included in the 
eQTL analysis for our cohort. This genotype set was then LD pruned to 
estimate the number of SNPs representing the amount of independent genetic 
variation represented within the imputed genotype set used in the analysis 
(Nicodemus et al. 2005). Then for each eQTL analysis group, the total 
number of tests performed was computed by summing all cis tests per mRNA 
transcript probe. Each independent SNP may be tested in cis against multiple 
transcript probes and each of these is a separate test included in the sum of 
cis tests. Based on the total approximate independent test counts per analysis 
group a Bonferroni cut-off was determined. The number of approximate 
independent tests performed per analysis group differs based on the number 
of transcript probes that were reliably detected and selected for analysis 
within that group (as discussed in Section 4.2.3.4).  For the Purkinje cell 
samples a total of 2,758,709 independent tests (36,710,361 total actual) were 
performed and the threshold for significance was a p-value <= 1.81x10-8. In 
the cerebellar tissue samples a total of 3,375,842 independent tests 
(45,054,510 total actual) were performed with a threshold of significance of p-
value <= 1.48x10-8. In the cerebral frontal cortex tissue samples a total of 
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3,436,351 independent tests (45,853,437 total actual) were performed with a 
threshold of significance of p-value <= 1.46x10-8. 
 
To estimate a threshold of suggestive eQTL signal a Benjamini & Hochberg 
(1995) false discovery rate was computed (Benjamini and Hochberg 1995). 
This cut-off was computed based on all cis tests performed per analysis group 
regardless of independence of the SNPs. For the Purkinje cell group this 
threshold for suggestive eQTL signal is a p-value <= 1.52x10-6, in cerebellum 
p-value <= 1.88x10-5 and in cerebral frontal cortex the threshold is a p-value 
<= 1.55X10-5. 
 
4.2.3.8: Data Access 
The genotype and expression data for this study is publically available as 
NCBI’s dbGaP study accession phs000249.v1.p1 and NCBI’s GEO series 
accession GSE37205 (Edgar, Domrachev and Lash 2002; Barrett et al. 2007; 
Mailman et al. 2007) (Figures 9.2 and 9.4, Appendix). 
 
4.3: Results 
4.3.1: Expression in single and heterogeneous neuronal cell type 
populations  
Prior to eQTL analysis a general comparison of expression levels between 
Purkinje cells, cerebellum and cerebral frontal cortex was performed. Within 
Purkinje cells 8,025 mRNA transcript probes were well detected while 9,869 
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and 9,983 mRNA transcripts were well detected in cerebellum and cerebral 
frontal cortex respectively. Here well detected is defined as detected within at 
least 95% of the post quality control screened samples. In total 10,850 mRNA 
transcripts are well detected in at least one group and 65% of these are well 
detected in all three groups (groups are Purkinje cell, cerebellum and cerebral 
frontal cortex sample sets). Of this total population of detectable mRNA 
transcripts, 74% were well detected in Purkinje cells while 91% and 92% of 
this total transcript population were well detected in cerebellum and cerebral 
frontal cortex respectively (Figure 4.5). It is plausible that the significant 
decrease in well-detected transcripts within the Purkinje cell group may be 
expected, as it is a single neuronal cell type whereas the other two groups 
comprise tissues of mixed cell types. It is important to note however that the 
Purkinje cell group was isolated by laser capture micro-dissection, thus it may 
be possible that some portion of this decrease in well detected mRNA 
transcript probes is an artefact of the sample isolation and preparation 
method. The use of LCM is labour intensive and involves a time sensitive 
protocol. It has been shown that RNA quality can be affected during LCM 
primarily by humidity or the presence of water but also by cell count and 
tissue staining (Clément-Ziza et al. 2008; Ordway et al. 2009). 
 
Simply examining those transcripts detected in each tissue, I did not find an 
excess of the transcripts detected in Purkinje cells in cerebellar tissue (90%) 
when compared to those found in the frontal cortex (91%). This likely reflects 
the fact that Purkinje cells only represent a fraction of the total cell population 
in cerebellum and therefore transcripts that are exclusively Purkinje-specific 
would not constitute enough of a signal within the total cerebellum to be 
	   178	  
detected. Additionally for this study it was the cell body of the Purkinje cells 
that were captured for analysis, these cell bodies are located within the 
Purkinje cell layer of the cerebellar cortex, so not only do Purkinje cells 
represent a fraction of the total cell population in the cerebellum but also their 
cell bodies are not distributed throughtout the tissue. The Purkinje cell layer is 
a narrow region of the cerebellar cortex located between the molecular layer, 
which contains the dendrites of the Purkenje cells, and the granule cell layer. 
This observation, that cell-specific transcripts will likely not be well detected in 
whole tissue (and implicitly that the transcripts detected in whole tissue are 
therefore likely to be quite ubiquitously expressed in brain) is quite 
generalizable. This is reflected in the relatively small percentages of mRNA 
transcripts that are well detected only within a single tissue or cell type: 4.6% 
of transcripts were well detected in Purkinje cell only, 6.1% in cerebellum only, 
and 6.6% in frontal cortex only. As further reinforcement of this possibility, 
65% of the mRNA transcript probes are well detected in all three groups and 
an additional 18% are shared between the mixed cell type samples of 
cerebellum and frontal cortex (Figure 4.5). 
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Figure 4.5: Venn diagram showing set intersections for well-detected mRNA transcript 
probes between the two brain tissue regions and specific cell type. 
 
Next I assessed how similar the expression profiles of the mRNA transcripts 
are within the tissues. Considering the population of mRNA transcripts well 
detected in all three sample groups the overall expression profile of Purkinje 
cell was not significantly more similar to either of these two bulk tissue 
regions, the R2 was 0.55 and 0.57 when comparing with cerebellum and 
cerebral frontal cortex respectively. Additionally the Purkinje cell data are 
enriched for genes such as CALB1, PCP2 (also known as Purkinje cell-
specific protein L7) and GRID2. These genes are known to be specifically 
expressed by Purkinje cells (Figure 4.6) (Oberdick, Levinthal and Levinthal 
1988; Zhang, Zhang and Oberdick 2002; Rong, Wang and Morgan 2004). 
These three Purkinje specific markers are well detected in both the Purkinje 
cell and cerebellum samples but are not well detected in frontal cortex 
samples; where well detected means that transcript is present in 95% of the 
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samples. In considering the average expression levels of these Purkinje 
specific markers both CALB1 and PCP2 are more highly expressed in the 
Purkinje cell samples than in the cerebellum samples whereas GRID2 is 
similar in both (Figure 4.7). It should be noted that while LCM enriches for a 
specific cell type, and markers of Purkinje cells were more highly expressed in 
LCM compared to bulk tissue, the separation is imperfect and tightly 
associated cells such as glia and granule cells may also be captured with the 
Purkinje cell bodies and contribute some signal in the LCM Purkinje cell 
samples. Myelin basic protein (MBP) is a known oligodendroglial marker 
(Friedrich et al. 2012); there are three transcript probes for this gene on the 
Illumina platform that were detected in 92%, 6% and 36% of our Purkinje cell 
samples. Glial fibrillary acidic protein (GFAP) is a known astroglial marker 
(Friedrich et al. 2012); there is one transcript probe for this gene on the used 
expression platform, which was detected in all of our Purkinje cell samples. 
The expression of GFAP is likely an indication of Bergmann glial cells also 
being captured with the LCM samples as they are found in the Purkinje layer 
of the cerebellum and are known to express GFAP. Parvalbumin (PVALB) is 
another neuronal marker for Purkinje cells (Friedrich et al. 2012); the 
expression array includes one probe for this gene, which was detected in all 
of the Purkinje cell samples. 
	  
Figure 4.6: In situ hybridization showing the localization of L7 mRNA in Purkinje cell 
dendrites from A) mouse, B) rat, and C) human (bar in panel = 1.25 mm) This figure is 
reproduced from (Zhang, Zhang and Oberdick 2002). 
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Figure 4.7: Scatterplots showing comparisons between bulk tissue regions and 
specific neuronal cell type. Each point represents the average expression over all 
QCed subjects in a tissue region and cell type for all transcript probes that are well 
detected in at least one analysis group. As each transcript probe is not well detected in 
all groups the average expression level is scaled by the detection rate within the 
group. On the left is the comparison between cerebellum and Purkinje cell and the 
right plot is between the frontal cortex and Purkinje cell. In both plots some Purkinje 
specific gene markers are highlighted in red: GRID2, CALB1 and PCP2. Plot on the 
right shows that the Purkinje specific markers are close to zero for abundance in 
frontal cortex as they should be, as Purkinje cells are not present in that tissue region. 
In the plot on the left all three markers are detected, as Purkinje cells are present in the 
cerebellum; however, as should be expected the expression levels for PCP2 and 
CALB1 are higher in Purkinje cells. 	  
4.3.2: Genotype effects mRNA expression 
Much like our previous eQTL study in our larger four brain region study I was 
able to identify eQTL in Purkinje cells, cerebellum and cerebral frontal cortex 
samples even with the reduced sample size (~60% of previous subject cohort 
size). As with other eQTL studies the strength of the signal was evenly 
distributed around the transcription start site (Figure 4.8), with stronger signal 
typically closer to the TSS. The average distance between the transcript start 
site and the significantly correlated SNPs is 56 kilobases (Kb) and per 
analysis group: 36 Kb for Purkinje cell, 56 Kb for cerebellum, and 59 Kb for 
cerebral frontal cortex. It is unknown whether the tighter distribution for 
Purkinje cell is because this is a single cell type while the other two are 
heterogeneous tissues. For the heterogeneous tissues, it may be possible 
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that the distribution is broader because we are detecting more eQTL related 
to enhancers modulating expression for the multitude of neuronal and non-
neuronal cell types present in the bulk tissue. For instance, if many of the 
eQTL signals in the core promoters are shared across cell types and most of 
this signal is more proximal to the transcription start site (TSS), this will draw 
the average distance closer to the TSS with a more narrow distribution of 
distances. While if the eQTL signal found in cell-specific enhancers is located 
further from the TSS, both up and downstream of the TSS, this will elongate 
the average distance from the TSS. When detecting these eQTL for cell-
specific enhancer(s) in a single type of cell this will also broaden the tail of the 
distribution; however, in a bulk tissue of heterogeneous cell types if the 
signals from multiple cell-specific enhancers are detected this will broaden the 
overall distribution of the distances. Within the Purkinje cell group 10 (0.1%) 
traits (mRNA transcript probes) were found to have a significant correlation 
with cis SNPs, or 472 trait/SNP pairs. Significant cis-eQTL were also 
identified, as expected, in our heterogeneous tissue regions, 64 (0.6%) traits 
or 2,565 trait/SNP pairs in cerebellum and 61 traits (0.6%) or 2,090 trait/SNP 
pairs in cerebral frontal cortex. 
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Figure 4.8: Distribution of all significantly correlated SNPs relative to the transcription 
start site (adjusted for strand) of the mRNA transcript the SNP is correlated with. The 
X-axis is the physical distance between a SNP and the TSS of the transcript and the Y-
axis is –log10(p-value) from the regression test between the SNP’s allele dosage and 
the transcript’s expression levels. The analysis tissue groups are colour coded as 
follows, Purkinje cell (green), cerebellum (CRBLM, red), and cerebral frontal cortex 
(FCTX, blue). Results are concordant with previous eQTL studies being fairly evenly 
distributed about the transcription start site with the eQTL signal being stronger closer 
to the gene. 
 
4.3.3: Many eQTL appear to be cell- and tissue-region specific 
In contrast to our previous study, many of the significant eQTL detected 
appear to be cell-type and tissue-region specific. A large portion of this is 
likely accounted for by the previous study including two biologically and 
ultrastructurally related regions (cerebral frontal and temporal cortex). In that 
study, it was shown that both the cerebral frontal and temporal cortex had 
high similarity in their overall expression profile and their eQTL (Figures 3.6B 
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and 3.8D). Of the 10 mRNA expression probes or traits with a significant 
eQTL in the Purkinje cell analysis, five of these were only significant within the 
Purkinje cell and not significant in the cerebellum or cerebral frontal cortex 
samples (Figure 4.9). For the other five mRNA expression probes, with 
significant eQTL in Purkinje cell, four of these also had significant signal in 
both cerebellum and cerebral frontal cortex, and 1 was shared between only 
the Purkinje cell and cerebellum groups. Table 4.1 lists these 10 transcripts 
with their best eQTL p-value from the Purkinje cell analysis. The single mRNA 
transcript probe shared between Purkinje cell and cerebellum is for 
peroxisomal biogenesis factor 6 (PEX6). Mutations in PEX6 are linked to 
Zellweger syndrome, a severe neonatal neurodegenerative disorder with a 
hallmark of delayed cerebellar development (Volpe and Adams 1972). For the 
heterogeneous tissues the significant eQTL identified within the cerebellum 
and cerebral frontal cortex also appear to be specific to their tissue regions 
with 35 of 64 and 33 of 61 respectively significant only within their tissue 
region. As may be expected the heterogeneous tissue types shared more in 
their intersection than with the Purkinje cell group. 
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Figure 4.9: Venn diagram showing set intersections for mRNA transcript probes, with a 
significant eQTL, detected between the two brain tissue regions and Purkinje cells. As 
shown, between 50% and 55% of transcripts, with a significant eQTL, are cell or tissue 
specific. 
 
It is important to note that while based on significant eQTL results, the 
abundance of cell and region-specific eQTL signal does not mean that some 
suggestive signal is completely absent for the other cell and tissue groups. To 
further investigate the similarity in the eQTL signals I plotted the regression 
effect (correlation coefficient) for each of the two-way comparisons based on 
the union of all significant trait and SNP pairings (Figure 4.10). The effect 
sizes are computed by mach2qtl (Li et al. 2009), used to identify the 
correlations by regression between allele dose probabilities and expression 
levels. As shown in these plots, many trait and SNP signals are of similar 
effect size but not necessarily statistically significant within each of the 
analysis groups. However, there are very strong signals that are specific to 
the Purkinje cell type, or one of the other two tissue regions. 
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Figure 4.10: Scatter plots of the effect sizes compared between the different analysis 
groups for all SNP and traits pairs that were significant in one or both of the 
comparison tissue groups plotted. The effect sizes (regression correlation coefficients) 
were computed by mach2qtl (Li et al. 2009) to identify the correlations between allele 
dose and expression levels. If the SNP and trait pairing was significant in only one 
group it is colour coded by group: Purkinje cell (green), cerebellum (CRBLM, red) and 
cerebral frontal cortex (FCTX, blue). If the pairing was significant in both comparison 
groups it is colour coded black. As expected most significant signals follow positive or 
negative correlations in both comparison groups, i.e. signal should be in top right or 
bottom left quadrants of the plots. Also, completely vertical and horizontal lines of 
signal are primarily artificial in cases where a correlation is significant in one analysis 
group but was not tested in another analysis group because the transcript was not well 
detected in that analysis group, in these instances the effect size is set to zero for the 
missing correlation. 
 
To further elucidate the differences between group specific and shared eQTL 
signal I have included some of the mRNA transcript probe specific results 
using regional Manhattan plots to show the associated SNP’s position relative 
to the mRNA transcript the expression probe captures. Included are examples 
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of eQTL that appear to be cell-specific, but with suggestive signal in the other 
tissues, shared but borderline sub-significant in one of the tissues, and 
significant in all three groups. Of the five apparent Purkinje cell specific eQTL 
one of these is because the mRNA transcript was well detected in Purkinje 
cells but not in the cerebellum or cerebral frontal cortex samples, and 
therefore did not meet the quality control thresholds for inclusion in their 
analysis groups. This eQTL is for a transcript of CCZ1B, encoding CCZ1 
vacuolar protein trafficking and biogenesis associated homolog B. The 
regional Manhattan plot is shown in Figure 4.11.  
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Figure 4.11: Manhattan plot showing this region’s eQTL p-values for an mRNA 
transcript for the gene CCZ1B. Each point represents the p-value for a specific SNP, 
along chromosome 7, that is cis to the CCZ1B transcript. Here only the Purkinje cell 
eQTL is present and significant, there is no data for cerebellum and cerebral frontal 
cortex as this transcript is not well detected in those tissues, and so does not meet 
criteria for inclusion in analysis of those tissues. Also included in the plot are the 
recombination rates (right axis) as a dark grey continuous line based on HapMap III 
data. Threshold for significance is denoted by horizontal dashed line and the 
suggestive signal threshold is denoted by the horizontal dotted line. The relative 
position of the gene is the labelled arrow centred near the bottom of the plot. The 
direction of the arrow is the gene’s strand. 
 
An example of an mRNA transcript with a significant eQTL only within 
Purkinje cells but also with suggestive eQTL in cerebellum and cerebral 
frontal cortex is for a transcript of ALDH3A2, encoding aldehyde 
dehydrogenase 3 family member A2. As shown in the regional Manhattan plot 
for this eQTL while a significant signal is not seen intersecting with that of the 
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Purkinje cell signal, there is clearly a suggestive peak for this transcript in 
cerebellum and cerebral frontal cortex over the same genomic interval (Figure 
4.12). 
 
Figure 4.12: Manhattan plot showing this region’s eQTL p-values for an mRNA 
transcript for the gene ALDH3A2. Each point represents the p-value for a specific SNP, 
along chromosome 17, that is cis to the ALDH3A2 transcript. Here only the Purkinje 
cell eQTL is significant; however, there is some suggestive signal also present in both 
cerebellum (CRBLM, red) and cerebral frontal cortex (FCTX, blue). Also included in the 
plot are the recombination rates (right axis) as a dark grey continuous line based on 
HapMap III data. Threshold for significance is denoted by horizontal dashed line and 
the suggestive signal threshold is denoted by the horizontal dotted line. The relative 
position of the gene is the labelled arrow centred near the bottom of the plot. The 
direction of the arrow is the gene’s strand. 
 
As an example of an eQTL that has shared signal across analysis groups, but 
within one of the groups the signal was borderline sub-significant, is for a 
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transcript of PEX6. This transcript was mentioned earlier as the eQTL 
transcript probe that was found to be significant in both the Purkinje cell and 
cerebellum but not within the cerebral frontal cortex. Upon further inspection 
of the eQTL signal for this probe, while not reaching statistical significance 
within the current analysis, the signal is close to the predetermined threshold 
for significance. This is clearly shown in the regional Manhattan plot for PEX6 
(Figure 4.13). 
 
Figure 4.13: Manhattan plot showing this region’s eQTL p-values for an mRNA 
transcript for the gene PEX6. Each point represents the p-value for a specific SNP, 
along chromosome 6, that is cis to the PEX6 transcript. Here both the Purkinje cell 
(green) and cerebellum (CRBLM, red) eQTL are significant; however signal for cerebral 
frontal cortex (FCTX, blue) is also but borderline sub-significant. Also included in the 
plot are the recombination rates (right axis) as a dark grey continuous line based on 
HapMap III data. Threshold for significance is denoted by horizontal dashed line and 
the suggestive signal threshold is denoted by the horizontal dotted line. The relative 
position of the gene is the labelled arrow centred near the bottom of the plot. The 
direction of the arrow is the gene’s strand. 
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Lastly an example of an eQTL with a significant signal across Purkinje cells, 
cerebellum and frontal cortex is shown (Figure 4.14). This eQTL is for an 
mRNA transcript for CHURC1. This eQTL is also one of the strongest and 
most consistent eQTL detected across studies. The regional Manhattan plot 
for the CHURC1 eQTL from this analysis is shown below and is clearly 
significant in each of the three sample groups used in this analysis. 
Considering not just the CHURC1 transcript, with a significant eQTL, but all of 
the individual SNPs making up the eQTL there was very high overlap between 
the tissues suggesting this is the same eQTL in all three analysis groups. All 
of the SNPs identified, for the CHURC1 eQTL, from the Purkinje cell analysis 
were also significant in cerebellum and cerebral frontal cortex, and 98% of the 
significant SNPs from the cerebral frontal cortex eQTL were significant in 
cerebellum. In addition to the strong eQTL seen for CHURC1 in NABEC 
related studies previous studies have also identified eQTL for CHURC1 in 
lymphoblastoid cell lines from the HapMap populations (Stranger et al. 2007; 
Veyrieras et al. 2008) and in human liver (Schadt et al. 2008).  
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Figure 4.14: Manhattan plot showing this region’s eQTL p-values for an mRNA 
transcript for the gene CHURC1. Each point represents the p-value for a specific SNP, 
along chromosome 14, that is cis to the CHURC1 transcript. Here the eQTL is clearly 
significant in all groups: Purkinje cell (green), cerebellum (CRBLM, red) and cerebral 
frontal cortex (FCTX, blue). Also included in the plot are the recombination rates (right 
axis) as a dark grey continuous line based on HapMap III data. Threshold for 
significance is denoted by horizontal dashed line and the suggestive signal threshold 
is denoted by the horizontal dotted line. The relative position of the gene is the labelled 
arrow centred near the bottom of the plot. The direction of the arrow is the gene’s 
strand. 
 
To get a broader picture of the overlap of eQTL, I generated a larger pool of 
associated loci using a less restrictive correction, recognizing this will 
invariably increase the number of false positives. When considering 
suggestive or better eQTL, based on a FDR correction per group with a mean 
cut-off of p-value <= 1.19x10-5 (1.88x10-5 in Purkinje cells, 1.55x10-5 in 
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cerebellum, and 1.52x10-6 in cerebral frontal cortex) additional signal that is 
both shared and specific is possibly revealed. The proportion of shared and 
specific transcripts with an eQTL remains approximately 50% shared and 
50% specific for Purkinje cells, while the proportions of transcripts with a 
region-specific eQTL increases for the other two groups from 55% to 74% in 
cerebellum and from 54% to 68% for frontal cortex. It is important to note that 
using a less restrictive test correction results in increasing the sensitivity to 
detect an eQTL but also results in a decrease in a specificity of the detection. 
This means that more false negatives may be recovered but at the same time 
more false positives will be introduced, beyond the 5% originally allowed for. It 
is also important to clarify that these shared and non-shared counts of eQTL 
are based on set overlaps of the unique mRNA transcript probes with eQTL 
signal. However, many more of the genetic variants making up the eQTL may 
also be specific to Purkinje cells or the other two tissue regions. While this is 
difficult to assess on a whole-genome basis, it will likely be useful for 
individual loci of interest to perform finer scale analyses on the existing data, 
and likely additional functional characterization. 
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4.4: Discussion 
The current work shows that cell-type specific eQTL signals can be identified. 
This reinforces the idea that undertaking eQTL analysis in tissues and specific 
cell types relevant to biological, cellular and molecular function is important for 
understanding how particular mRNA transcripts vary with genetic variation 
within the context of a specific cell-type. Even with the modest sample size 
used within this study, both shared and tissue-specific eQTL could be 
identified and the resolution of these eQTL should improve with much larger 
subject cohorts. While performing eQTL analyses in heterogeneous tissue 
regions still remains relevant, the application of this work in specific cell types 
should elucidate much more of the effect of genetic variation on gene 
expression in a functionally specific context. This is apparent in these results 
in the set overlap between Purkinje cells and the cerebellum. While Purkinje 
cells are one of the largest and most distinct neurons in the brain and only 
found in the cerebellum it is the cerebellar granule cells that are the most 
numerous neurons in this tissue. The cerebellar granule cell is one of the 
smallest and most densely packed neurons in the brain. The cerebellum also 
contains other interneuron cell types such as Golgi cells, basket cells, stellate 
cell, and Bergman glial cells. It is possible that analysis of a large enough 
cohort of cerebellum samples would capture all the signal that is detectable 
with a smaller cohort of Purkinje cell samples; however, there are likely two 
limitations to this possibility: first, the signal may be too small to detect within 
the inherent noise of the assay; second, eQTL have been detected with 
contrasting directions of effect when comparing tissues, and presumably this 
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extends to cell types, thus a signal may be masked in a heterogeneous tissue 
sample.  Purkinje cells only represent a fraction of the total cell population in 
cerebellum and therefore transcripts that are exclusively Purkinje-specific 
would not constitute enough of a signal within the total cerebellum to be 
detected. Lastly, and perhaps more importantly the use of single cell types 
provides resolution as to which cell types are also contributing or possible 
reducing the relative signal between the functional neuronal cell type contexts. 
For example, consider a situation where a particular mRNA transcript has a 
significant eQTL that is found in both Purkinje cells and another cerebellar cell 
type such as granule cells. If in this instance separate portions of the loci, 
such as different haplotype blocks across the promoter, are more important in 
one cell context but not in the other, it may not be possible to observe the net 
eQTL signal identified using bulk tissue.  
 
In 2009, Lee et al. published a study of tissue-specific expression from 
fibroblasts, LCLs, induced pluripotent stem (iPS) cells, and differentiated iPS 
cells. They suggest that using iPS cells helps reduce in-vitro experimental 
noise that allows for the detection of tissue-specific cis-regulatory variants that 
effect gene expression. They also found that allele specific expression (ASE) 
is both genotype- and cell-dependent, but that the majority of genotype effects 
are detectable and consistent across cell types, except for genes on the X 
chromosome (Lee et al. 2009). Studies using multi-tissue samples often focus 
on across tissue replication so tissue-specific signals may be harder to 
account for especially across studies but also within studies by not accounting 
for differences in effect sizes, allelic direction, or additional effects from non-
linked variants on the same gene (Fu et al. 2012). In the 2011 Nica et al. 
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report, they performed an analysis based on twins from the MuTHER study 
and measured gene expression in LCLs, skin, and fat to identify cis-eQTL. In 
line with other studies, of the time, they found that 4.7% of genes have an 
eQTL. Based on method refinement for comparing across-tissue eQTL 
signals, they found that 30% of their eQTL are shared between all three 
tissues and that 29% are tissue-specific. However, for the shared eQTL 
between 10% and 20% have significant differences in magnitude of effect 
(Nica et al. 2011). In 2012, Fu et al. published a multi-tissue cis-eQTL study 
based on 85 subjects with gene expression from liver, two adipose tissues, 
and muscle that were compared to eQTL results from more than 1,200 blood 
samples. They examined the possible tissue-dependent eQTL based on four 
categories: specific regulation, alternative regulation, different effect size, and 
opposite direction of effect (Figure 4.15). The authors consider specific 
regulation as cis-regulatory genetic variation that correlates with gene 
expression but only in one tissue. Under specific regulation, SNP X is 
associated with gene A’s expression in Tissue 1 but not in Tissue 2; 33% of 
the eQTL variants they identified fit this category. They consider alternative 
regulation as cis-regulatory genetic variation that is correlated with gene 
expression in multiple tissues but that each independent variant (locus) is 
associated with a specific tissue. Under alternative regulation, SNP X is 
associated with gene A’s expression in Tissue 1 but not Tissue 2 while SNP Y 
is also associated with gene A’s expression but in Tissue 2 and not in Tissue 
1; 14% of the eQTL variants they identified fit this category. The authors also 
found that 48% of the eQTL variants they identified were correlated with gene 
expression in multiple tissues but the effect sizes were different in magnitude, 
but in the same direction, between the tissues. Additionally, they found that 
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4% of eQTL variants that were associated with gene expression in multiple 
tissues had an effect that was in the opposite direction for the same variant in 
different tissues (Fu et al. 2012). 
 
 
Figure 4.15: Representation of tissue specific eQTL differences found. The pie charts, 
left centre, show the proportion of concordant and disconcordant eQTL identified 
between tissues. The disconcordant portion is shown as another pie chart, centre of 
figure, showing the proportion of disconcordance by the four types considered: 
specific regulation (top left), alternative regulation (top right), different effect size 
(centre right), and opposite allele direction (bottom right). This figure is reproduced 
from (Fu et al. 2012).  
 
While identifying eQTL based on samples enriched for Purkinje cells was 
informative in the detection of cell-type specific eQTL there still remains much 
to be done in eQTL of brain tissues and cell-types. The comparison of 
Purkinje cells to heterogeneous brain tissues did identify both shared and cell-
specific eQTL but this is not as informative as comparing eQTL from multiple 
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specific cell types from the brain. For instance, being able to identify cell-
specific eQTL in Purkinje cells, cerebellar granule cells, and Bergmann glial 
cells for comparison with the cerebellum would be more informative in 
understanding cell specific eQTL in brain. Using LCM to extract these specific 
types of cells from whole tissue is probably not appropriate in order to perform 
this kind of analysis. Purkinje cells, cerebellar granule cells, and Bergmann 
glial are all found in close proximity in the same layer of the cerebellum. While 
it is likely that using LCM can enrich the extracted sample for a particular cell 
type, as we have done in this chapter, it is probably not sufficient when 
comparing between cell types found packed so closely together. Using LCM 
may be appropriate for comparison of larger neurons that are not found in 
within the same tissue regions, such as Purkinje cells from the cerebellum 
and pyramidal neurons from the cerebral cortex, although these samples 
would still contain some portion of the smaller cell types located in close 
proximity such as glia and granule cells. There are additional methods for 
isolating cell types, but these also have similar limitations to LCM, such as: 
Translating Ribosome Affinity Purification (TRAP), Immunopanning (PAN), 
and Fluorescence Activated Cell Sorting (FACS) (Okaty, Sugino and Nelson 
2011). In the future a more feasible approach for getting cell populations 
enriched for specific cell types for analysis may be to differentiate iPS cells 
into the cell type(s) of interest for study. However, currently there are many 
limitations in the protocols for differentiating iPS cells into the desired cell 
type, including heterogeneity of cell types, variability of iPS cell clones, 
consistently generating a large number of cells, and notably that the in vitro 
context may not be a true representation of the in vivo context (Santostefano 
et al. 2015). Even as protocols improve to overcome these iPS cell limitations 
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it may not be practical to generate enough of these iPS cells lines such that it 
is possible to adequately represent common genetic variation so that a 
transcriptome-wide analysis could be performed. Using iPS would still be 
appropriate in a candidate based approach where you would be able to 
determine the number of subjects and the genotypes such that you could pick 
the subjects that are representative of the genetic variation for the gene or the 
cis-regulatory region of interest.  
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5: Application to disease GWAS loci 
5.1: Introduction 
The integration of eQTL and genome-wide association study (GWAS) loci has 
become a more common occurrence, where the drive is to begin to formulate 
possible hypotheses on how these loci confer risk for disease when the loci 
intersect. In studies examining the intersection of eQTL and GWAS results it 
has been suggested that eQTL are enriched at GWAS loci (Verlaan et al. 
2009; Nica et al. 2010; Nicolae et al. 2010). Many studies suggesting how 
disease risk may arise from changes in expression associated with genetic 
variants have been published:  for Crohn’s disease (Libioulle et al. 2007), 
childhood asthma (Cantero-Recasens et al. 2010), lupus (Nica et al. 2010; 
Sakurai et al. 2013), Type 2 diabetes (Zhong et al. 2010), osteoarthritis 
(Syddall et al. 2013), and drug response for rheumatoid arthritis (Cui et al. 
2013). Of course the appropriate study, replication, and validation of these 
hypotheses must take place. In some instances these are just intersections 
between an expression quantitative trait and disease risk locus, such as the 
one from a replicated GWAS locus for Crohn’s disease. Examination of the 
Crohn’s disease locus, considered a 1.25 megabase gene desert (large 
region lacking in genes) on chromosome 5 where the risk variants are also 
part of a cis-eQTL, for the nearest gene in the region, prostaglandin receptor 
EP4 (PTGER4) (Libioulle et al. 2007). Other studies have made efforts to look 
beyond the intersection of disease risk loci and eQTL by integrating existing 
public annotations. In 2010, Zhong et al. published a study integrating eQTL 
(in liver, and two adipose tissues), GWAS variants and pathway information 
from the Kyoto Encyclopaedia of Genes and Genomes (KEGG) (Kanehisa 
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and Goto 2000). The inclusion of the KEGG information made it possible to 
elucidate which pathways may play a role in disease. Based on pathways 
enriched for eQTL genes whose variants also intersected disease associated 
risk variants they identified 16 pathways that may play a role in Type 2 
diabetes (Zhong et al. 2010). Other studies have considered how other 
expression related QTL might intersect with disease risk. In 2009, Fraiser and 
Xie published a study examining transcript isoform variation, which they 
labelled polymorphic transcript variation (PTV). This study was based on gene 
expression in human B cells from two populations. They found that tens of 
thousands of exons showed variation in expression levels that were heritable, 
and correlated with cis-variants (splicing QTL, sQTL). The cis-variants 
correlated with PTV were enriched for risk variants associated with four 
autoimmune diseases: Crohn's disease (CD), Type 1 diabetes (T1D), 
rheumatoid arthritis (RA), and ankylosing spondylitis (AS). B cells are known 
to have a role in autoimmune diseases. They suggest that for eight of the 
common risk variants of immune disease, that PTV may be the risk 
mechanism (Fraser and Xie 2009). In 2010, Nica et al. published a study on 
the integration eQTL and GWAS loci. They developed an algorithm for the 
integration of disease- and expression-associated loci that accounts for local 
LD structure in order to identify GWAS signals that may also be cis-eQTL, 
which they called Regulatory Trait Concordance (RTC). Applying their RTC 
method, they found an enrichment of cis-eQTL among GWAS SNPs. Their 
method confirmed prior eQTL disease mediated effects for ORMDL3 and 
asthma, C8orf13 and lupus, and SLC22A25 and Crohn’s disease (Nica et al. 
2010). 
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Beyond the intersection of eQTL and disease risk loci, other studies have 
begun to focus on possible mechanisms in identifying the risk variant and how 
the risk for disease is conferred through gene expression. In a follow-up of the 
ORMDL3 eQTL associated with childhood asthma (Moffatt et al. 2007), it was 
found that the changes in ORMDL3 expression result in a change of 
inflammatory response. This change in inflammatory response is by way of 
altered endoplasmic reticulum-mediated calcium signalling leading to an 
unfolded-protein response inducing inflammation (Cantero-Recasens et al. 
2010). In a 2013 study, by Syddal et al., of how osteoarthritis risk may be 
modulated by expression, the authors focused on a variant in the 5’ UTR of 
growth differentiation factor (GDF5), a gene that is associated with increased 
risk of osteoarthritis in Europeans and Asian populations. The risk 
susceptibility is through decreased expression of GDF5. They found four 
trans-acting factors binding to the 5’UTR of GDF5, three of which repress 
expression via the osteoarthritis risk allele for a cis-regulatory variant in the 
binding site (Figure 5.1) (Syddall et al. 2013).  
	  
Figure 5.1: Schematic showing the allele in the cis-regulatory variant that changes a 
binding site in the 5’ UTR of GDF5, for the factors Sp1, Sp3, DEAF-1, and P15 complex, 
which results in repressing GDF5 expression. This figure is reproduced from (Syddall 
et al. 2013).  
 
In 2013, Sakurai et al. published a study to identify the potential causal risk 
variant for Systemic lupus erythematosus (SLE). In patients with SLE both 
	   204	  
mRNA and protein levels of interleukin-10 (IL-10) are elevated in sera. SLE is 
associated with a risk variant 9.2 Kb upstream of IL10. They found that 
preferential binding of the transcription factor Elk-1, at the IL10 risk allele, 
increases expression of IL-10 in SLE patients for both mRNA and protein 
(Figure 5.2). Sera levels of IL-10 are elevated in SLE patients and correlated 
with disease activity. Expression levels of both phosphorylated Elk-1 and IL-
10 were elevated in SLE patient’s cells (Sakurai et al. 2013). 
	  
Figure 5.2: Correlation plots of IL-10 mRNA expression levels (A) and protein levels 
(B), for controls and SLE patients, by genotype at the SLE risk variant, rs3122605. The 
risk allele is correlated with increased mRNA expression (A) and protein levels (B), of 
IL-10, by allele dose for the G allele in both patients and controls. Figure reproduced 
from (Sakurai et al. 2013). 
 
In 2013, Cui et al. published a study of drug response for anti-TNF therapies 
(etanercept, infliximab and adalimumab) in patients with rheumatoid arthritis. 
The performed a meta-GWAS to identify a genetic basis for why some 
patients failed to have adequate drug response. It was found that a variant 
associated with change in disease activity, for etanercept patients but not the 
other two therapies, is predicted to disrupt a transcription factor binding-site in 
CD84, an immune-related gene. The allele associated with drug response 
also correlated with higher expression of CD84 in blood. CD84 expression 
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correlates with disease activity score. Additionally, in a replication analysis, 
which included multiple ethnicities, the drug response for etanercept was 
significant only for European ancestry patients (Cui et al. 2013). These 
studies provide examples for the formation of a disease aetiology hypothesis 
where disease risk loci and eQTL intersect and in some instances begin to 
provide evidence related to these hypotheses. 
 
5.2: Examples in Neurological diseases 
An important reason for the execution of the work presented in my thesis and 
the creation of this data resource is to allow us and others to understand how 
loci associated with neurological diseases, we work on, may have an effect on 
gene expression in human brain. To this end, we have referred to these 
NABEC eQTL data in the study of GWAS related to neurological diseases. 
These studies include Progressive Supranuclear Palsy (PSP) at loci near the 
SLC25A38/MOBP and the MAPT H1/H2 inversion polymorphism region 
(Höglinger et al. 2011) (Figure 5.3a-c). These data have also been used to 
investigate loci associated with Tourette’s Syndrome (Scharf et al. 2012), 
Obsessive-Compulsive Disorder (Stewart et al. 2012), amyotrophic lateral 
sclerosis (ALS) (Traynor et al. 2010), frontotemporal lobar degeneration 
(FTLD) (Carrasquillo et al. 2010) and Alzheimer’s disease (Guerreiro et al. 
2010; Holton et al. 2013). 
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Figure 5.3: Manhattan plots for PSP associated regions that also have significant 
eQTL. (a) eQTL results for the SLC25A38-MOBP region, on chromosome 3, shown are 
the eQTL p-values per SNP for three transcripts; MOBP is red, RPSA is blue, and 
SLC25A38 is green. (b) eQTL results for the H1/H2 inversion polymorphism region near 
MAPT, on chromosome 17; eQTL p-values colour coded by transcript probe provided 
in legend. (c) eQTL results for the for the H1/H2 inversion polymorphism region, on 
chromosome 17 near MAPT, controlling for H1/H2 by conditional analysis based on 
variant that tags the haplotypes. After controlling for the haplotype only an eQTL for 
ARL17A remains. Plots in panel (c) use the same colour legend as panel (b). Each plot 
in the left panel are results from the cerebellum and plots in the right panel are from 
cerebral frontal cortex. The colour of each data point is colour coded per transcript 
and represents the p-value for a SNP allele dose correlation with a transcript’s 
expression level. Each SNP is tested against multiple cis transcripts. This figure is 
reproduced from (Höglinger et al. 2011) 
 
While the proximity of an eQTL to a GWAS loci does not imply that the 
disease risk and expression effect are the same loci, in a few clear instances 
we have shown that the eQTL effect signal intersects with a GWAS signal, 
and at the very least is a potential candidate for the biologic effect. An 
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example of a significant eQTL overlapping with a significant locus is one from 
a meta-GWAS for Migraine (Anttila et al. 2013) that included eQTL data 
based on combined NABEC and UK Brain Expression Consortium (UKBEC) 
data in cerebellum and cerebral frontal cortex. In this study the eQTL 
overlapped with the GWAS loci with moderate LD between the eQTL and 
GWAS loci, but one locus was in perfect LD. The eQTL in perfect LD with the 
GWAS locus is for a transcript from the gene STAT6, signal transducer and 
activator of transcription 6, interleukin-4 induced. STAT6 phosphorylation has 
been shown to lead to prostaglandin release as a result of astrocyte response 
to oxidative stress (Park et al. 2012), and in macrophages has been shown 
that transcription factor activation signals are transduced by STAT family 
members (Lawrence and Natoli 2011). Additionally, we have made great use 
of the NABEC/UKBEC eQTL data within our GWAS studies of Parkinson’s 
disease (PD). Beginning with an early GWAS of PD (Simón-Sánchez et al. 
2009) we were able to intersect the signals of our disease risk alleles with 
those of an eQTL for a transcript of MAPT showing an increase in MAPT 
abundance with risk allele dosage (Figure 5.4).  
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Figure 5.4: Shown are boxplots for several SNPs associated with Parkinson’s Disease 
(Simón-Sánchez et al. 2009) that also are significant eQTL for a MAPT transcript in the 
cerebral frontal cortex. The figure shows an increase in the abundance of the MAPT 
transcript with dosage of the risk allele.  
 
It has since been shown that our original finding of an eQTL for the MAPT 
transcript is likely an artefact of a polymorphism within the Illumina 50-mer 
probe for this transcript. While I have consistently screened our probes for this 
type of artefact, I have done so using allele frequencies within populations of 
European descent, where available. Unfortunately, the variant within the 
mRNA probe design is for a 2 base pair InDel present on the H2 haplotype for 
this region. The earlier screenings performed for this type of artefact were 
based on HapMap SNP data for the European population and this InDel 
variant was not present in that dataset, at that time, with an allele frequency in 
the European population. This type of screening has vastly improved with the 
release of the 1000 Genomes genotypes (1000 Genomes Project Consortium 
et al. 2012) based on sequencing data, where it is now possible to screen 
from this resource, in the appropriate population, at the appropriate allele 
frequency that includes both single nucleotide and InDel variants.  
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In a more recent analysis of PD risk loci based on results from the 
International Parkinson’s Disease Genomics Consortium (IPDGC) we have 
continued to make use of the NABEC/UKBEC eQTL data showing overlap 
between disease risk and eQTL at multiple risk loci (Nalls et al. 2011, 2013, 
2014). Based on the most significant variants for the 26 loci associated with 
PD, from the most recent meta-GWAS (Nalls et al. 2014), the NABEC/UKBEC 
eQTL results from cerebellum and cerebral frontal cortex were scanned based 
on these PD risk variants to see if they were also part of eQTL. In performing 
the scan I limited the search space to just the cis possible eQTL tests that 
would involve these PD risk variants and only the transcripts well detected 
(detected in 95% of samples) in the NABEC/UKBEC series that were within 1 
Mb of these risk variants. Reducing the eQTL search space in this simple 
manner, only including eQTL tests which included the PD risk variants, also 
reduces the multiple test burden therefore increasing the sensitivity to detect 
signal, but of course this also reduces specificity. Using this PD risk and eQTL 
intersection search scheme results in approximately 360 independent eQTL 
tests per tissue, yielding a significance threshold of 1.4x10-4 based on a 
Bonferroni multiple test correction to maintain a 5% false positive rate. This 
search identified three PD risk loci that were also correlated with expression 
changes for five genes (six transcripts) in one or both brain tissues. Two of 
these eQTL are for pleckstrin homology domain containing family M (with 
RUN domain) member 1 (PLEKHM1) and leucine rich repeat containing 37, 
member A4 (pseudogene) (LRRC37A4) in the MAPT region of chromosome 
17. Both, PLEKHM1 and LRRC37A4, are correlated with the same PD risk 
variant rs17649553 and significant only in the cerebellum; these two eQTL 
were also correlated with the H1/H2 MAPT haplotype, denoting the large 
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inversion polymorphism present in that genomic region. Three other genes 
with an eQTL, present in human brain, intersect with two PD risk loci. The first 
of these risk loci is on chromosome 1, in the region of nuclear casein kinase 
and cyclin-dependent kinase substrate 1 (NUCKS1) and RAB7 member RAS 
oncogene family-like 1 (RAB7L1), where the most significant (p-value = 
1.36x10−13) risk variant from the PD meta-GWAS is rs823118 (Nalls et al. 
2014). This PD risk variant is located 1.35 Kb downstream of the 3’UTR of 
RAB7L1 and 4.2 Kb upstream of the 5’UTR of NUCKS1 and is correlated with 
expression changes in both genes. While the eQTL for NUCKS1 shows 
significant signal in both cerebellum and cerebral frontal cortex, the RAB7L1 
eQTL is only significant in cerebellum (Figure 5.5).  
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Figure 5.5: Manhattan plot of region, on chromosome 1, across the GWAS associated 
PD risk locus spanning NUCKS1 and RAB7L1. The plot shows association p-values 
representing the significance of correlation between a variant’s allele dosage and the 
transcript’s expression level. The points are colour coded by transcript and tissue 
region in red, blue, green, and purple while the grey data points represent the p-values 
from the meta-GWAS for PD. The plot also includes the recombination rates (right axis) 
as a dark grey continuous line based on HapMap III data. The threshold for 
significance is denoted by horizontal dotted line. The relative positions of the genes 
are the labelled arrows centred in the upper portion of the plot. The direction of the 
arrow is the gene’s strand. The most significant PD risk variant, rs823118, is labelled 
near the bottom of the plot, at its chromosomal position, and the vertical dashed line. 
 
It has recently been shown that the protein RAB7L1 interacts with the protein 
leucine-rich repeat kinase 2 (LRRK2) (MacLeod et al. 2013; Beilina et al. 
2014), LRRK2 is a gene harbouring Mendelian mutations that cause PD 
(Paisán-Ruíz et al. 2004; Nichols et al. 2005) as well as a risk locus 
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associated with sporadic PD (Nalls et al. 2014). LRRK2 encodes a 
multidomain protein with GTPase (enzymes that hydrolyze guanosine 
triphosphate) and kinase activities, and has been shown to be involved in 
macroautophagy-lysosomal protein degradation and Golgi apparatus integrity 
(MacLeod et al. 2006; Heo, Kim and Seol 2010; Dodson et al. 2012; Stafa et 
al. 2012). Current findings, from MacLeod et al., suggest that the retromer and 
lysosomal pathways are important in PD pathogenesis. They show that a 
deficiency of RAB7L1 gene expression, in rodent primary neurons and its 
ortholog in fly dopamine neurons, recapitulates some of the degenerative 
phenotype observed in expression models for a familial PD mutation in 
LRRK2. However, they also find that overexpression of RAB7L1 rescued the 
mutant LRRK2 phenotype. Additionally, both the RAB7L1 PD risk and LRRK2 
PD linked mutation resulted in endosomal and Golgi sorting defects; and 
affected the VPS35 component of the retromer complex. They suggest the 
potential causal risk variant may be a variant in LD with a PD risk variant that 
results in the alternative splicing of RAB7L1, where the risk allele leads to 
increased skipping of exon 2 (MacLeod et al. 2013). In another study, from 
Beilina et al., it was shown that RAB7L1 is a protein-binding partner of 
LRRK2. This binding interaction was identified using an unbiased screen from 
protein-protein interaction arrays. Additionally, the genes BCL2-associated 
athanogene 5 (BAG5) and cyclin G associated kinase (GAK) encode proteins 
that are also part of this protein complex; GAK is also a PD associated locus. 
These protein interactions were validated in cell lines and in mouse brain. The 
authors’ experiments suggest that the proteins encoded by LRRK2, RAB7L1, 
GAK, BAG5, and heat shock 70kDa protein 4 (Hsp70) form a single protein 
complex. Examining the cellular localization of these proteins the authors 
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found that both RAB7L1 and GAK are largely vesicular in neuron localization, 
which suggest that RAB7L1 directs Lrrk2 to trans-Golgi network derived 
vesicles. Based on these results, the authors suggest that these proteins form 
a complex that promotes clearance of Golgi-derived vesicles through the 
autophagy-lysosome system (Beilina et al. 2014). 
 
The second PD risk locus that intersects with an eQTL, in the brain, is on 
chromosome 7 and located in an intron of the glycoprotein transmembrane 
nmb gene (GPNMB), where the most significant (p-value = 2.37x10−12) risk 
variant from the PD meta-GWAS is rs199347 (Nalls et al. 2014). This PD risk 
variant is correlated with changes in gene expression for two transcripts of 
nucleoporin like 2 (NUPL2); rs199347 is located in the intron of GPNMB and 
is 53.1 Kb downstream of the 3’UTR of NUPL2. Both NUPL2 transcripts have 
a significant eQTL in both cerebellum and cerebral frontal cortex (Figure 5.6). 
Functionally, a hypothesis may be formed that the effects of an expression 
change in NUPL2 may have an affect on the LRRK2 protein binding complex 
described by Beilina et al., in reference to the RAB7L1 and LRRK2 protein-
protein interaction. NUPL2, previously known as hCG1, is part of the nuclear 
pore complex (NPC) and required for export of mRNA from the nucleus to the 
cytoplasm. Based on a previous finding, from Kendirgi et al., NUPL2 protein 
may be required for the export of Hsp70 mRNA from the nucleus to the 
cytoplasm. This finding was based on experiments using a small interfering 
RNA (siRNA) knockdown of hCG1 (NUPL2) mRNA that resulted in decreased 
Hsp70 protein levels, under heat shock conditions in HeLa cells. The 
decreased protein levels resulted from Hsp70 mRNA not being exported from 
the nucleus to the cytoplasm because of the reduction in NUPL2 protein 
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levels (Kendirgi et al. 2005). It is known that Hsp70 protein is important in 
removing clathrin from vesicles, including at the trans-Golgi. One way to 
connect NUPL2 and LRRK2, a known PD gene, and other gene candidates 
from PD GWAS: BAG3/5, Hsp70, GAK, and RAB7L1 is to assume that there 
is a simultaneous protein complex at the trans-Golgi that removes clathrin. 
Increasing protein levels of any one of these would promote protein complex 
formation and, hence, function. In this model, more NUPL2 protein would 
mean more cytosolic Hsp70 protein resulting in more LRRK2 protein complex 
function, exacerbated by stimulation. Of course, this hypothesis would require 
many experiments to support its claims but they are testable ideas. 
Knockdown of NUPL2 could diminish LRRK2 relocalization to the trans-Golgi. 
Additionally, this hypothesis requires a few assumptions, including that 
promoting the formation of the LRRK2 protein complex alters the removal of 
clathrin from vesicles or the clearance of Golgi-derived vesicles through the 
autophagy-lysosome pathway and that this alteration in function is deleterious 
and involved in the disease pathway of PD. (Note: Hypotheses of how NUPL2 
may be involved in PD through HSP70 and LRRK2 are based on personal 
communications with Mark Cookson and Andrew Singleton).  
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Figure 5.6: Manhattan plot of region, on chromosome 7, across the GWAS associated 
PD risk locus spanning NUPL2. The plot shows association p-values representing the 
significance of correlation between a variant’s allele dosage and the transcript’s 
expression level. The points are colour coded by transcript and tissue region in red, 
blue, green, and purple while the grey data points represent the p-values from the 
meta-GWAS for PD. The plot also includes the recombination rates (right axis) as a 
dark grey continuous line based on HapMap III data. The threshold for significance is 
denoted by horizontal dotted line. The relative positions of the gene are the labelled 
arrow centred in the upper portion of the plot. The direction of the arrow is the gene’s 
strand. The most significant PD risk variant, rs199347, is labelled near the bottom of 
the plot, at its chromosomal position, and by the vertical dotted line. 
 
5.2: Other GWAS loci 
To access the prevalence of other disease- and complex trait-associated 
variants with eQTL variants in brain, a search of variants from the NHGRI-EBI 
GWAS catalogue (Welter et al. 2014) was performed against the 
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NABEC/UKBEC eQTL results from cerebellum and cerebral frontal cortex. 
The NHGRI-EBI GWAS catalogue is a repository provided by the National 
Human Genome Research Institute (NHGRI) and the European 
Bioinformatics Institute (EMBL-EBI), which maintains a manually curated, and 
quality controlled collection of published genome-wide association studies. 
For this search, the catalogue was downloaded on 4 April 2015 and included 
15,653 variants for 1,276 diseases or traits from 2,140 published studies. 
Based on the cis-tested variants from the NABEC/UKBEC eQTL analysis, 
12,888 of the NHGRI-EBI GWAS catalogue variants were tested against one 
or more of 9,374 transcript expression probes in one or both brain tissues. 
This testable set results in approximately 119,000 independent eQTL tests 
per tissue yielding a significance threshold of 4.7x10-7 when applying 
Bonferroni based multiple test correction to maintain a 5% false positive rate. 
At this threshold of significance, 320 (2.5%) variants are associated with 189 
(2.0%) expression traits for 201 (15.8%) disease or complex traits from 247 
(11.5%) studies in the NHGRI-EBI GWAS catalogue. These variants were 
then annotated so the distribution of variant types relative to transcription, 
could be considered, based on the following annotations: exon, intron, UTR, 
intergenic, upstream, and downstream. Upstream and downstream regions 
included variants that lie within 5 Kb of the 5’ and 3’ UTR respectively for 
these annotation purposes. For the variants that were both GWAS risk 
variants and part of an eQTL, when compared to all GWAS risk variants that 
did not show a significant eQTL, there were shifts within the distributions of 
variant types. For the variants that were both GWAS risk and eQTL variants 
there are increases, when compared to GWAS risk variants that were not 
eQTL variants, in the percentage of variants located upstream (+7.2%), exon 
	   217	  
(+1.1%), 3’ UTR (+0.7%) and downstream (+8.8%) (Figure 5.7). Conversely, 
this same variant set also showed a decrease in the number of variants 
present in introns (-12.7%) and intergenic (-5.3%) regions while the 5’ UTR 
remained relatively unchanged. When considering which of these regions may 
be functionally active regulatory regions, the variants were annotated based 
on ENCODE DNase I hypersensitivity sites (DHS) and transcription factor 
binding site (TFBS) clusters (ENCODE Project Consortium 2012). These two 
annotations should denote most of the active sites where transcription factors 
bind based on the diverse set of cell and tissue types used in the generation 
of these data. The DHS annotation data includes ~2.9 million DHSs based on 
125 cell types including differentiated primary cells (56.8%), immortalized 
primary cells (12.8%), malignancy-derived cell lines (24.0%) and multipotent 
and pluripotent progenitor cells (6.4%) (Thurman et al. 2012). The TFBS 
annotation data is based on 161 transcription factors and 91 cell types 
(Gerstein et al. 2012; Wang et al. 2012). It is estimated that between 8.5% 
and 19.4% of the human genome is covered by a DHS footprint or TFBS motif 
and that 94.4% of transcription factor occupancy sites are within DHS 
footprints (ENCODE Project Consortium 2012; Thurman et al. 2012; Kellis et 
al. 2014). For GWAS risk variants that were also part of eQTL, these are 
enriched for both DHS and TFBS clusters with both having ~10% increases in 
regulatory active regions when compared to GWAS risk variants that do not 
show a significant eQTL signal (Figure 5.8). 
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Figure 5.7: Bar graphs showing the distribution of variants by their genomic location 
relative to transcription for all NHGRI-EBI GWAS risk variants that were tested with and 
without a significant a cis-eQTL in the combined NABEC and UKBEC analysis in 
cerebellum and cerebral frontal cortex. The left column (Risk) represents all risk 
variants tested and the right column (eQTL_Risk) represents all risk variants that are 
also significant as a cis-eQTL variant. 
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Figure 5.8: Bar graphs showing the distribution of variants by there genomic location 
relative to functionally active regulatory regions based on ENCODE v3 annotations for 
all NHGRI-EBI GWAS risk variants that were tested with and without a significant cis-
eQTL in the combined NABEC and UKBEC analysis of cerebellum and cerebral frontal 
cortex. In the bars for both DHS (DNase I hypersensitivity sites) and TFBS 
(transcription factor binding sites) the grey colour represents risk variants that are not 
significant as an cis-eQTL variant and the black colour represents all risk variants that 
are also significant as a cis-eQTL variant. 
 
5.3: Discussion 
In this chapter I have highlighted applications of eQTL to disease risk loci 
performed by others: Crohn’s disease (Libioulle et al. 2007; Nica et al. 2010), 
autoimmune diseases (Fraser and Xie 2009), Type 2 diabetes (Zhong et al. 
2010), asthma (Cantero-Recasens et al. 2010; Nica et al. 2010), and lupus 
(Nica et al. 2010). I have also highlighted a few studies where not only were 
eQTL being applied to disease risk variants but some work has been done to 
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begin to understand disease mechanisms: inflammatory response in 
childhood asthma (Cantero-Recasens et al. 2010), osteoarthritis risk altering a 
regulatory binding site (Syddall et al. 2013), Systemic lupus erythematosus 
and IL10 (Sakurai et al. 2013), and response to anti-TNF therapies (Sakurai et 
al. 2013). These studies have made use of eQTL information to begin to 
understand the underlying molecular mechanisms linking a genetic locus to 
disease or complex trait resulting from changes in expression. I have also 
highlighted several studies where we have made use of the NABEC and 
UKBEC brain eQTL data to investigate neurological diseases: Progressive 
Supranuclear Palsy (Höglinger et al. 2011), Tourette’s Syndrome (Scharf et 
al. 2012), Obsessive-Compulsive Disorder (Stewart et al. 2012), amyotrophic 
lateral sclerosis (ALS) (Traynor et al. 2010), frontotemporal lobar 
degeneration (FTLD) (Carrasquillo et al. 2010), Alzheimer’s disease 
(Guerreiro et al. 2010; Holton et al. 2013), Migraine (Anttila et al. 2013), and 
Parkinson’s disease (Simón-Sánchez et al. 2009; Nalls et al. 2011, 2014). 
Additionally, I have used the NABEC and UKBEC brain eQTL variants to 
investigate all disease risk variants maintained by the NHGRI-EBI GWAS 
catalogue. Scanning the brain eQTL results based on more than 15,000 risk 
variants for more that 1,200 diseases or traits, 15% of these diseases or 
complex traits had an associated risk variant that was also an eQTL variant. 
In evaluating the risk variants that were also eQTL variants compared to all 
risk variants considered, the variants that were both risk and eQTL variants 
show an increase for being located within 5 Kb up and downstream of a 
transcript, and a decrease in intronic and intergenic variants. Additionally, the 
variants that were both risk and eQTL variants showed an increase in being 
located in regions of DHS and TFBS occupancy compared to the variants that 
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were not significant as an eQTL. This enrichment of GWAS risk variants that 
are also eQTL variants in active regulatory elements may support the 
hypothesis that the functional effect of the risk is mediated through changes in 
expression. 
 
Many of the above applications of eQTL in the analysis of risk variants are 
fairly rudimentary, typically based on the actual risk variant being present in 
an eQTL variant set or in LD with a variant in the eQTL variant set. However, 
methods are being developed to integrate disease risk and eQTL variants 
beyond a simple intersection of the genetic loci. In 2014, Corradin et al. 
published a method for defining enhancer-gene interactions in relation to the 
multiple enhancer variant hypothesis for common traits. Under this hypothesis 
a set of variants in LD affects multiple enhancers resulting in a cooperative 
affect on gene expression. To provide evidence of this model they considered 
GWAS results from six common autoimmune disorders based on data from 
HapMap B lymphoblasts. They found some evidence to support this 
hypothesis, but the effects on gene expression were modest (Corradin et al. 
2014). In 2012, Schaub et al. published a method using ENCODE functional 
data to investigate disease associated variants. The method’s purpose was to 
identify a functional variant as the actual risk variant for the disease 
association signal. They found a significant enrichment of variants within 
regulatory elements that are also associated with diseases. The strength of 
this enrichment increases when multiple functional sources and higher 
confidence disease associated variants are used (Schaub et al. 2012). In 
2011, Lappalainen et al. published a study proposing a hypothesis suggesting 
that cis-eQTL may modulate the penetrance of deleterious protein coding 
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variants. The hypothesis is that heterozygous deleterious coding variants and 
heterozygous cis-regulatory variants have an epistatic interaction, where if the 
deleterious coding allele is on the higher expressing haplotype of the cis-
regulatory allele the penetrance of the coding variant increases. They 
analysed genotype and mRNA expression data generated from both 
sequencing and arrays from CEU and Yoruban subjects from the 1000 
Genomes project to begin to test this hypothesis. They found an 
underrepresentation of functional coding variants on the higher expressed 
regulatory haplotypes suggesting purifying selection against these deleterious 
coding alleles, through their regulatory backgrounds. They also found that the 
allele frequency distributions of the eQTL alleles might support their 
suggestion of purifying selection. They found that LD between eQTL variants 
and nonsynonymous coding variants was stronger than LD between eQTL 
variants and synonymous coding variants. Additionally, they found that eQTL 
signals that intersect with GWAS signals show an enrichment for this type of 
putative epistatic interaction, suggesting that rare coding variants may attain 
higher penetrance through cis-regulatory eQTL (Lappalainen et al. 2011). In 
2014, Pickrell published a report describing the integration of annotation 
information applied to GWAS data for 18 human traits. The model included 
450 genomic annotations to model if these elements are enriched or depleted 
for loci associated with GWAS traits. They found that between 2% and 20% of 
trait associated SNPs influence protein sequence. They also found that 
repressed chromatin was depleted for several traits and that cell-type specific 
DNase-I hypersensitive sites were enriched for several traits. The integration 
of their annotation model as weights into GWAS analysis increased the 
number of high-confidence associations by ~5% (Pickrell 2014). 
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It is important to re-iterate that when using eQTL data to inform on a possible 
disease mechanism, when these loci intersect, that this information is only 
sufficient for forming hypotheses about disease mechanism(s). The 
appropriate study designs still need to be formulated and carried out to test 
these hypotheses. It is also important to note that while the large effect cis-
eQTL typically replicate across many studies and tissue types, often many of 
these have not been validated using a different assay type to quantify the 
mRNA expression measures such as quantitative real-time PCR. The 
presence of the eQTL at a disease risk locus does not mean that the disease 
risk is conferred through expression changes in that transcript. Conversely the 
absence of an eQTL does not mean that the disease risk is not mediated 
through changes in gene expression. As eQTL can be tissue-specific, an 
eQTL may be present in one tissue while being absent in another that may be 
the disease relevant tissue. Additionally, it is not uncommon for multiple 
transcripts, from different genes, to be associated with the same cis genetic 
locus. Both of these instances occur at the PD risk locus near RAB7L1, one of 
the PD loci I discussed earlier in this chapter. At this PD locus there is a 
significant eQTL for RAB7L1 in cerebellum but a significant eQTL for this 
transcript is not present in cerebral frontal cortex. This PD locus also has a 
significant eQTL in both cerebellum and cerebral frontal cortex for a transcript 
of NUCKS1. It is highly suggestive that RAB7L1 may be the relevant gene for 
PD risk at this locus on the basis that RAB7L1 is a protein binding partner of 
LRRK2, a known Mendelian and risk gene for PD. The empirical evidence still 
needs to be gathered to link the genetic risk near RAB7L1 to the gene 
RAB7L1 and likewise evidence needs to be gathered to confirm the RAB7L1 
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eQTL in a disease relevant cell type, such as dopaminergic neurons, as well 
as evidence to evaluate whether or not the disease risk is mediated through 
changes in expression of this gene. 
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6:  Conclusions 
As I have shown in these studies that make up my thesis, eQTL are 
manifested in human brain tissues. I have also demonstrated how these eQTL 
can begin to be applied in our understanding of disease risk variants. Many of 
the eQTL signals I have identified are shared between distinct tissue regions 
and even with an individual cell type, however there are also many eQTL that 
appear to be distinct among tissue regions and cell types. I have shown an 
example of a gene, CHURC1, which displays very strong eQTL signal across 
multiple neuronal tissues as well as in studies on non-neuronal tissue 
performed by others. I have also provided examples of eQTL that appear to 
be specific to a human brain region (PPAPDC1A) or distinct to an individual 
neuronal cell type (CCZ1B). Given our understanding of the regulation of 
gene expression it is not unrealistic to expect that eQTL may be identifiable 
for many RNA transcripts in many cell types. The identification of these eQTL 
would require a cohort size with sufficient power so that both common and 
less common variants could be included in the eQTL analysis as well as 
expression measures from a diverse set of tissue and cell types. The genetic 
variation from these eQTL are likely have a direct cis-regulatory affect on 
mRNA expression by altering the promoters or enhancers, splice site 
enhancers or suppressors, or miRNA binding sites within the 3’ UTR. With a 
sufficient  increase in power it may also become possible to start reliably 
detecting trans effects. Trans-regulatory effects are biologically feasible 
through genetic variation that affects the expression of regulatory proteins, 
changes to the DNA binding domain within regulatory proteins affecting which 
promoters and enhancers they bind to, or genetic variation in a regulatory 
protein’s protein-protein interaction domain possibly affecting how or when 
	   226	  
regulatory proteins assemble at a gene’s promoter and enhancer regions. 
However, this does not imply that all identified eQTL would be of the same 
importance within each cellular context as the relative effect within individual 
cell types may be much stronger or weaker. A possible example of this is the 
significant eQTL I have identified for a mRNA transcript from the gene 
ALDH3A2, which has a much stronger signal within Purkinje cells than the 
suggestive signal observed in the heterogeneous cell populations from the 
cerebellum or cerebral frontal cortex. I have also shown a Purkinje cell-
specific example, CCZ1B, which has a significant eQTL in Purkinje cells but 
none at all within the bulk tissue regions. However, it is also the case that the 
same mRNA transcript may have significant eQTL in multiple cell types or 
tissue regions but that the regions of genetic variation exists in distinct or 
overlapping blocks of variation and therefore does not necessarily represent 
the same eQTL signal. It is feasible in this scenario that portions of this 
variation may be more impactful within certain specific cellular contexts than 
in others, and this in turn may reflect the cell-type specific expression of 
regulatory factors such as transcription binding factors. Some studies have 
made efforts at better resolving the variation within a locus that appears to be 
cell and tissue-dependent, but these studies have typically included highly 
differentiated tissue types such as blood and brain (Heinzen et al. 2008; 
Dimas et al. 2009; Kwan et al. 2009; Fu et al. 2012; Hernandez et al. 2012). 
This reinforces the importance of undertaking eQTL studies ultimately within 
individual cell types. Performing eQTL studies within specific cell types 
informs us as to the effect of genetic variation on gene expression within the 
context of that cell type.   
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My thesis shows that ultimately performing these types of studies in all 
individual cell types would provide a more granular resolution of eQTL. This 
does not discount the applicability of performing these types of studies in 
heterogeneous tissues as well, which is currently a more feasible approach. 
Each layer of functional knowledge we develop is informative to the next. This 
is not only important for our general knowledge and understanding of biology 
but creates a basis for hypothesis generation when applied to phenotypes 
affecting cellular and molecular processes related to human health and 
disease. As a researcher in the field of neurodegenerative disease and 
disorders, I have performed and continue to perform these types of analysis in 
human brain tissues so that we will have a functional foundation that provides 
clues into the aetiology of the diseases that we study. A large public 
consortium is currently underway to greatly add to the already public eQTL 
datasets and should open many more avenues for the discovery and 
characterization of eQTL as well as the application of this information in 
understanding disease. The Genotype-Tissue Expression (GTEx) project is a 
large public resource database established so that investigators can study the 
relationship between genetic variation and gene expression in many human 
tissues (GTEx Consortium 2013). The GTEx project aims to have genotype 
and expression data for 47 tissues from 900 subjects by the end of 2015. The 
four-tissue eQTL project described in Chapter 3 was an early dataset included 
in an early GTEx repository and browser for software pilot testing, which was 
available to access through the NCBI eQTL browser.  
 
In viewing this doctoral work, the efforts here reflect the evolution of the 
modern eQTL field. Our early work centred on the feasibility of eQTL in 
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human brain tissue, and showed clearly that there was much to discover in 
this regard. We moved on to more refined experiments, which attempted to 
look at varied tissues, in a larger set of samples, and aimed to answer 
questions regarding the importance of examining cell type specific QTL. While 
this work has mirrored the considerable progress of the field there is still much 
to be done. These projects have generated vast amounts of data in relation to 
expressed transcripts in human neurological tissues and will no doubt provide 
many data mining opportunities in the years to come. Not all of those mining 
analysis would be appropriate for inclusion within an individual graduate 
research thesis. As such I would consider the completion of my graduate 
thesis of expression quantitative traits in human neurological tissue to be 
logically complete after the detection and characterization of the eQTL in 
human brain. I believe the primary detection of these eQTL is fairly complete, 
in the existing cohort, and described in my thesis and that the bulk of the work 
still remaining is within the characterization of these eQTL. Additionally much 
work remains to be done in using more integrative approaches in applying 
eQTL, and other functional, information towards understanding disease risk 
variants. The work of characterization should contain much of the following 
future work. 
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7: Future Work  
Moving beyond the simple QTL analysis, there are several spaces where 
additional work would be useful. It is likely to be informative to expand 
analysis from genotypes to haplotypes. In addition to providing haplotype 
block-specific eQTL, this will allow further investigation of the regional 
structure of the cis eQTL signals along the lines of work performed by 
Veyrieras and colleagues in 2008. This has the benefit of providing greater 
resolution regarding the location of the probable quantitative trait 
nucleotide(s), and thus insight into the functional basis of the genotype trait 
relationship. It may also be more biologically appropriate to alter the local 
boundries defining the cis region for eQTL analysis from a fixed distance, 
typically +/- 1Mb proximal to the transcript, and instead define the cis 
boundries based on the topologically associating domain (TAD) that the 
transcript is found in. It would be informative to investigate whether these 
expression signals are recent targets of natural selection and if present are 
they enriched in genes based on cellular function. Signatures of selection 
should be expected for variants from eQTL based on previous studies that 
assessed selection in cis-regulatory regions, eQTL, and beneficial adaptive 
traits in humans conferred by eQTL. ENCODE analyses of primate-specific 
cis-regulatory elements found that these elements display evidence of 
negative selection (ENCODE Project Consortium 2012). It has also been 
suggested that cis-eQTL may modulate the penetrance of deleterious protein 
coding changes through purifying (negative) selection (Lappalainen et al. 
2011). While it has also been suggested that cis variants associated with 
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changes in expression are enriched for variants showing signatures of recent 
positive selection (Kudaravalli et al. 2009). Two well studied instances of 
recent beneficial adapations in humans are malaria resistance and lactose 
persistence both or which are eQTL and show signatures of recent positive 
selection (Hamblin and Di Rienzo 2000; Hamblin, Thompson and Di Rienzo 
2002; Olds and Sibley 2003; Bersaglieri et al. 2004; Tishkoff et al. 2007). In 
2009, Flint and Mackay published a review of comparing QTL of quantitative 
phenotypes in mice, flies, and humans. They reported the existence of eQTL 
for a large number of loci but with moderate effects in all three species. 
However, based on studies done to that point they found very few 
homologous QTL (Flint and Mackay 2009). One area that has been 
considerably challenging is the reliable detection of trans-eQTL: these have 
generally proven difficult to replicate and it may be necessary to take several 
approaches in this regard, likely including anchoring observations in 
biologically plausible events (Dimas et al. 2008). Such an effort may also 
require the integration of other reference data such as that generated by 
ENCODE from a diverse set of tissues and cell types (~125) while recognizing 
that these cell types, or the conditions from which they were generated such 
as cancer cell lines (24%), may not be appropriate proxies for complete 
information. While these approaches will be useful it is likely that trans 
analysis will remain difficult until cohort sizes are large enough such that 
sufficient power is attained to reliably detect signal for intermediate effects. 
For instance, Westra et al. published a meta-analysis of trans-eQTL in 
peripheral blood, with a discovery cohort that included 5,311 subjects and a 
replication cohort of 2,775 subjects, in which they were able to replicate trans-
eQTL for 103 loci. However, this analysis, while transcriptome-wide for gene 
	   231	  
expression measures, limited the genetic variation included for analysis to 
only 4,542 SNPs that had been previously implicated in complex traits or 
disease. The authors reported replication rates of 52% and 79% (based on 
individual SNPs not loci) when the replication was performed in two cohorts 
with gene expression measures also from blood samples. The replication 
rates were much smaller when when considering smaller eQTL cohorts from 
non-blood gene expression measures, between 2% and 7%. Additionally the 
authors note that 95% of the trans-eQTL identified in their discovery analysis 
accounted for less than 3% of the gene expression variance and that the 
replication cohorts they had access to lack sufficient power for replication of 
these particular loci (Westra et al. 2013). In the same vein as including 
external reference data, it will also be useful to expand our current models 
from pairwise Trait~Genotype to more integrative models Trait~Genotype (or 
Haplotype) with additional data resources such as miRNA expression and 
CpG methylation as covariates. Where DNA methylation measures for CpG 
sites that are cis-regulatory or miRNA expression levels for miRNA with 
putative binding sites within the mRNA 3’ UTR (or the entire transcript) could 
be used as covariates within the regression models (Zhang and Su 2008; 
Younger, Pertsemlidis and Corey 2009).  
 
Ultimately, it would of course be extremely informative to include protein 
levels, and protein modifications in this effort, as this is often the next most 
proximal readout, to (in the example of disease) clinical phenotype. In 2010, 
Garge et al. published a study identifying protein QTL (pQTL) based on 24 
LCLs from HapMap subjects for 544 proteins. They found 24 proteins (15 
genes) where genetic variation accounted for more than 50% of the variation 
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in protein abundance. Of the 24 proteins, 19 were associated with cis-
variation and 4 of these were nonsynonymous coding variants that resulted in 
altered migration patterns on 2D gels (Garge et al. 2010). In 2013, Wu et al. 
published results re-affirming that mRNA expression levels are not a perfect 
proxy measure of protein abundance. They suggest non-correlations of these 
levels may be because of post-translational processes. In studies of mRNA 
expression and protein abundance the correlation of these measures has 
typically been modest. This study was based on ~6000 genes from 95 LCLs 
from HapMap subjects with protein levels measured by quantitative mass 
spectrometry. They found that protein levels vary between individuals and 
populations and that protein levels are heritable. They identified cis-pQTL, 
some of which did not have a previously identified eQTL based on eQTL 
analysis of mRNA expression from the same HapMap LCLs. A pQTL without 
a corresponding eQTL, where genetic variation is correlated with variation in 
protein abundance but not variation in mRNA expression would suggest that 
the effect of the genetic variation is post-transcriptional. They also found that 
sets of proteins involved in similar biology processes are well correlated 
between individuals, suggesting that these processes are tightly regulated 
(Wu et al. 2013). In 2014, Hause et al. published a study of pQTL based on 
68 Yoruban Hapmap LCLs considering protein levels for 441 protein isoforms 
of transcription factors and signalling genes. They identified 12 cis-pQTL and 
160 trans-pQTL. Two thirds of the eQTL from the same cohort and transcript 
set were also pQTL but this study also found that many pQTL did not have a 
corresponding eQTL. They found a significant enrichment in 5’ and 3’ UTRs 
and depletion in introns for eQTL. They also found 5’ and 3’ UTR enrichment 
for pQTL variants, but also saw enrichment for coding variants. They suggest 
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that these pQTL variant enrichments may be involved in protein stability or 
miRNA-mediated regulation of mRNA translation. Their results also suggest 
there might be buffering of eQTL and that pQTL may contribute to phenotypic 
diversity (Hause et al. 2014). In 2015, Battle et al. published a study of eQTL, 
ribosomal occupancy QTL (rQTL), and pQTL based on 75 LCLs from HapMap 
Yoruban subjects. This study combined pre-existing genotype and RNAseq 
based expression measures with ribosomal profiling and protein abundance 
from quantitative high-resolution mass spectrometry. In general, they found 
consistencies between QTL types. They found that on average the expression 
variation identified for eQTL was attenuated or buffered at the protein level. 
They also identified pQTL where eQTL were not present. Additionally, they 
were able to identify expression- and protein-specific QTL (esQTL and 
psQTL). They found that when eQTL and pQTL are discordant that the 
ribosomal data typically tracked with the RNA. They suggest this means that 
psQTL are not capturing signal related to transcription or translation but 
possibly rates of protein degradation. They find that psQTL are enriched for 
UTR and coding variants, but the enrichment in coding variants is larger for 
nonsynonymous variants than other coding variants (Battle et al. 2015). 
 
Another particularly exciting extension of the current work lies in the 
application of sequence-based assays of gene expression (RNAseq) within 
brain tissues. While array based work has many positives, the application of 
high-throughput sequencing, particularly with the development of improving 
analytical approaches, offers more potential insight. RNAseq offers several 
advantages: first it provides absolute knowledge regarding genotype, 
capturing rare and common variants; second it removes probe-based design 
	   234	  
limitations of microarrays; third, it allows for detection and analysis of low 
abundance RNA species for analysis, such as LRRK2; fourth, it allows assay 
of exon usage; and fifth, it can also directly reveal expression differences, in 
the context of allele-specific expression, by allowing the observation of an 
imbalance of alleles expressed within any informative transcript. Removing 
the probe-based limitation will allow for analysis of all detectable splice forms 
and whether or not eQTL are more associated with general gene expression 
or expression of gene splice forms as well as to be able to more clearly 
identify allelic expression. A probe-free design also removes the artefact of 
polymorphisms within the probe. In addition to detecting low abundance 
mRNA, protocols are now available for more general sequencing of RNA, 
including strand-specific and total RNA sequencing. There are many hurdles 
to overcome in RNAseq work and the sample preparation and data analysis 
are more challenging than with array-based work. Our laboratory has 
performed some preliminary transcriptome sequencing on ~60 smallRNA 
tissue samples, ~75 mRNA tissue samples and now approximately 300 total 
RNA tissue samples, from the NABEC cohort described in this thesis, where 
these subjects also have targeted deep resequencing and exome sequencing 
data. This work remains in the early stages; however, it promises to reveal 
further understanding into the genetic basis of expression. In 2008, Sultan et 
al. published a very early deep sequencing based study of gene expression in 
human embryonic kidney and B cells. They found that 66% of polyA 
transcripts mapped to known genes and 34% to unannotated genomic 
regions. Their findings suggested that RNAseq based measures of gene 
expression can detect 25% more expressed genes than microarrays. 
Additionally, with RNAseq based methods splicing events are measureable 
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and they found that exon skipping is the most common form of alternative 
splicing within their analysis and results (Sultan et al. 2008). In 2009, Tang et 
al. published a study describing a single-cell digital expression assay for 
performing mRNAseq. They suggest their method allows the detection of 
more expression events than trying to do so with other protocols requiring 
more material from more cells. They ran their assay on a single mouse 
blastomere and detected the expression of 75% more genes, between 8% 
and 19% of the genes expressed multiple isoforms in the same cell. 
Additionally, they detected more than 1,700 novel splice junctions (Tang et al. 
2009). In 2010, Pickrell et al. published their RNAseq study based on 69 LCLs 
from HapMap Nigerians subjects. This study used a pooled RNAseq 
approach to survey the transcriptional landscape and found extensive use of 
unannotated UTRs as well as 100 new coding exons. For the genes, with 
these new exons, 4.6% also had a cis-eQTL. For 90% of the eQTL, they 
identified, they found that the variants affecting expression are within 15 Kb of 
the gene. They also found that 88% of eQTL have reads from the higher 
expressing haplotype suggesting that many eQTL are allele-specific and 
result from modulation of cis-regulatory elements. Of note, based on 
heterozygotes, the ratio of reads from the fraction of the higher expression 
haplotypes correlates with the strength of the eQTL. Additionally, they found 
that genetic variation correlated with splicing (sQTL) and these were enriched 
in or near consensus splice sites (Pickrell et al. 2010). In 2010, Montgomery 
et al. also published an RNAseq study based on 60 LCLs from HapMap CEU 
subjects. Their results suggest that sequencing allows for improved dynamic 
range and better quantification of alternative and high expression transcripts, 
which should allow for improved eQTL detection. They found more eQTL 
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using RNAseq than expression arrays, when comparing to results generated 
from the same samples previously. However, some of these differences were 
related to the array’s saturation at the higher end and splicing complexity that 
are not well captured by the array’s probe designs. The RNAseq based data 
also allowed for the detection of QTL for long noncoding RNAs as well as 
allele-specific expression (ASE). Their results suggest that rare ASE may be 
markers of rare eQTL variants. They also identified QTL for splicing (sQTL). 
For the sQTL identified, 41% of these were exon skipping, 17% alternative 
acceptor, 13% multiple exon skipping, 6% alternative donor, 5% exclusive 
exons, and 5% were for retained introns (Montgomery et al. 2010).  
 
Another area I would like to pursue in relation to eQTL work in human brain is 
working with specific cell types, as I discussed in chapter 4. Following a 
similar course as Lee et al. described, in 2009, in using iPS cells to generate 
samples enriched for specific cell types which should already represent that 
natural genetic variation present in the subjects (Lee et al. 2009). Using iPS 
cells may also allow for the analysis of eQTL in neuronal cells types from 
patients with neurodegenerative diseases. Although, this would be 
depenedent on being able to overcome some of the limitations that can occur 
in iPS cell work such as generating the desired cell type without heterogeneity 
or a method that can account for the heterogeneity in the cell population. 
Currently it is not informative, from a disease perspective, to work with brain 
tissues of patients who died from neurodegenerative diseases such as 
Parkinson’s and Alzheimer’s disease. For neurodegenerative disease there is 
considerable cell loss in the brain, so assaying gene expression in these 
disease tissues is not informative for understanding the disease process. The 
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ability to differentiate iPS cells into neuronal cells types and study them in a 
pre- or early-disease state would be informative. More recently, it has become 
possible to more easily edit genomic sequence using CRISPR-Cas9. 
Clustered regularly interspaced palindromic repeat and Cas9 (CRISPR-Cas9) 
allows targeted editing and manipulation of the genome using the Cas9 
enzyme mechanism with a bacterially RNA-guided system (Barrangou 2014; 
Doudna and Charpentier 2014). I could foresee using the iPS cell based work 
to more narrowly map eQTL of interest in cells types of interest, such as 
Dopaminergic neurons generated from controls and PD patients, and in 
combination with other functional data identify the putative cis-regulatory risk 
variants. Using CRISPR-Cas9 these putative variants could be manipulated to 
identify causal risk variants and understand their effect in the cells and tissues 
relevant to disease. Although, currently I believe that CRISPR-Cas9 may 
need more refinement, as it is my understanding that beyond the targeted 
edits that sometimes other off target edits, such as InDels, can also occur. 
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9. Appendix 
	  
	  
Figure	  9.1:	  Figure is a screen capture for the GEO study page for the ‘pilot’ study 
cohort used in the eQTL analysis of mixed cortical tissues described in Chapter 2. 
GEO (Gene Expression Omnibus) is a public repository at the National Institutes of 
Health in the USA that allows public access to gene expression data used in studies 
(Edgar, Domrachev and Lash 2002; Barrett et al. 2007). The is for series accession 
GSE8919. 
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Figure 9.2: Figure is a screen capture of the dbGaP study page for the initial NABEC 
cohort used in the eQTL analysis described in Chapter 3. dbGaP (data bases of 
Genotypes and Phenotyes) is a public repository at the National Institutes of Health in 
the USA that allows public access with appropriate approval to genotypes data used in 
studies (Mailman et al. 2007). This is for study accession phs000249.v1.p1. 
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Figure 9.3: Figure is a screen capture for the GEO study page for the initial NABEC 
cohort used in the eQTL analysis described in Chapter 3. GEO (Gene Expression 
Omnibus) is a public repository at the National Institutes of Health in the USA that 
allows public access to gene expression data used in studies (Edgar, Domrachev and 
Lash 2002; Barrett et al. 2007). This is for series accession GSE15745. 
 
 
Figure 9.4: Figure is a screen capture for the GEO study page for the Purkinje cell data 
from the NABEC cohort used in the eQTL analysis described in Chapter 4. GEO (Gene 
Expression Omnibus) is a public repository at the National Institutes of Health in the 
USA that allows public access to gene expression data used in studies (Edgar, 
Domrachev and Lash 2002; Barrett et al. 2007). This is for series accession GSE37205. 
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